New approaches to fluorescence-based diagnostics for human African trypanosomiasis by Giordani, Federica
 
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Giordani, Federica (2011) New approaches to fluorescence-based 
diagnostics for human African trypanosomiasis. PhD thesis. 
 
 
 
 
 
http://theses.gla.ac.uk/2454/ 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
  
 
New approaches to 
fluorescence-based diagnostics 
for human African trypanosomiasis 
 
 
 
 
Federica Giordani 
 
 
 
 
 
 
 
 
Thesis submitted in fulfilment of the requirements for 
the degree of Doctor of Philosophy 
 
 
 
 
Institute of Infection, Immunity & Inflammation 
College of Medical, Veterinary & Life Sciences 
University of Glasgow 
 
 
 
 
November 2010 
 ii 
Abstract 
In the absence of any vaccine, prophylactic drug and effective vector control, the fight 
against human African trypanosomiais (HAT) is based on the the combination of active 
case-finding and consequent drug treatment of identified positive cases. Unfortunately, low 
sensitivity and specificity of current diagnostic techniques often result in misdiagnosis, 
leaving infected patients without cure or exposing them to inappropriate chemotherapy 
protocols, which use dangerous and expensive drugs. The development of more efficient, 
simple, cheap and field-robust diagnostic tests is, therefore, urgently needed. 
In the field, direct observation by light microscopy of trypanosomes in human fluids 
(blood, lymph node aspirate, cerebrospinal fluid) is considered the ideal way of confirming 
HAT infection. However, in practice this approach is problematic, especially for the 
Gambian form of the disease, where patients may present with very low parasitaemia. 
Detection limits of parasitological techniques can be improved by adding a preliminary 
step of sample concentration, although this further increases the laboriousness of HAT 
diagnostic algorithm. 
Recent advances in fluorescence microscopy could be exploited to facilitate trypanosome 
detection. The introduction and implementation of fluorescence microscopy in HAT 
endemic countries would offer the advantages of an increased overall sensitivity of 
microscopical examination and a more rapid screening of the specimen. In contrast to 
traditional, expensive and fragile fluorescence microscopes, new LED-illuminated 
instruments are relatively cheap, very efficient and portable, lending themselves to 
utilisation in poorly equipped rural settings. In order to design a new diagnostic tool that 
exploits LED technology, however, selective and reliable fluorescent markers to label 
trypanosomes in human fluids are needed. 
The development of new tools to assist in the diagnosis of African trypanosomiasis by use 
of LED fluorescence microscopy was the overall objective of this project. The work was 
mainly focused on testing various fluorescent compounds for their ability to selectively 
stain trypanosomes. Fluorophores were otained from commercial and academic sources, or 
else directly synthesised during the project. An important requirement evaluated was the 
compounds’ compatibility with the currently available SMR LED Cytoscience 
fluorescence microscope, developed and kindly provided by our collaborator Prof. D. 
Jones (Philipps University, Marburg). iii 
The utility of a UV LED-driven microscope in performing the arsenical drug resistance test 
was also assessed. This assay, developed in our laboratory to detect trypanosome strains 
resistant to arsenical and diamidine compounds, could represent a useful tool for 
chemotherapeutic decision making in the field, where resistance to arsenical drugs is a 
rising problem. iv 
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1.1 Human African trypanosomiasis 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a deadly 
parasitic disease endemic to sub-Saharan Africa (Stich et al., 2002). HAT belongs to the 
so-called “neglected tropical diseases” (NTDs), a group of infections affecting the world’s 
poor that includes, among others, leishmaniasis, Chagas’ disease, dengue, leprosy, 
schistosomiasis and onchocerciasis. The World Health Organisation (WHO) estimates that 
one billion people (one sixth of the world's population) are affected by at least one of the 
NTDs (http://www.who.int/neglected_diseases/en/). Unfortunately, since these diseases 
persist almost exclusively in the most marginalised communities of undeveloped countries, 
very little resource is spent to lighten their tremendous social and economic burden. HAT 
represents a major public health threat in Africa and together with nagana, the animal form 
of African trypanosomiasis, is considered a main obstacle for development of rural regions 
of the continent (Simarro et al., 2008). Since 1997, WHO has been raising awareness of 
this most neglected disease, favouring the establishment of national control programs and 
the involvement of public and private partnerships (Stich et al., 2003). These efforts have 
significantly reduced the incidence of HAT in endemic countries by implementation of 
surveillance and drug availability. 
1.1.1 The aetiological agent 
The aetiological agent of HAT is a haemoflagellate protozoan belonging to the species 
Trypanosoma brucei (genus Trypanosoma, order Kinetoplastida) (Cox, 2004). Of the three 
subspecies of T. brucei only two are infectious to humans (T. b. gambiense and T. b. 
rhodesiense), while T. b. brucei causes infection in wild and domestic animals (Barrett et 
al., 2003). Sporadic cases of human infection with other trypanosome species have been 
reported (Truc et al., 1998c; Joshi et al., 2005), but, at least in one case, infection could be 
ascribed to a mutated apolipoprotein L1 found in the serum of the patient (Lun et al., 
2009), which is a component of the trypanolytic factor that normally protects humans from 
animal trypanosome infection (Pays and Vanhollebeke, 2008). Both T. b. gambiense and T. 
b. rhodesiense are transmitted to the human host by the bite of an infected tsetse fly (genus 
Glossina), which acts as vector of the disease. 
The two forms of HAT differ greatly (Welburn et al., 2001a). T. b. gambiense is 
responsible for more than 90% of reported cases of HAT and causes a chronic form of the 
illness, which can last for months or years before major symptoms arise. Checchi and Federica Giordani, 2010    Chapter 1, 3 
colleagues indirectly estimated the duration of the Gambian form to nearly three years in 
absence of treatment, equally split between the two stages (see Section 1.1.4) of the disease 
(Checchi et al., 2008a). On the other hand, T. b. rhodesiense causes an acute form that 
usually leads to the patient’s death within weeks or few months (Brun et al., 2009). 
However, exceptions to these rules, with acute Gambian disease and chronic Rhodesiense 
trypanosomiasis cases, are observed (Garcia et al., 2006). Moreover, despite most T. b. 
gambiense infections being fatal in absence of treatment, human trypano-tolerance, with 
self-resolving and asymptomatic chronic infections, has been postulated (Checchi et al., 
2008b). Other differences between the Rhodesiense and Gambiense forms lie in their 
clinical features and the chemotherapy protocols used, in their epidemiology and 
transmission and, therefore, in the control strategies applied (Fèvre et al., 2006). 
1.1.2 Disease burden 
HAT transmission is restricted to the African continent (Figure 1.1), but around 50 cases 
per year are diagnosed elsewhere in people who had travelled to affected regions (Sinha et 
al., 1999; Ripamonti et al., 2002; Lejon et al., 2003a). Endemic foci of the disease have a 
discrete distribution, correlated to the presence of the tsetse flies. There are nearly 300 
active foci identified, confined to an area that stretches south of the Sahara and north of the 
Kalahari desert (Barrett et al., 2003). T. b. gambiense infection is found in west and central 
Africa: Angola, Democratic Republic of the Congo and Sudan are the most affected 
countries by the Gambian form, with more than 1,500 new cases per year reported up to 
2004 (WHO, 2006b). T. b. rhodesiense is found in the eastern and southern part of the 
continent. The above mentioned study identified Malawi, Uganda and United Republic of 
Tanzania as the countries with the highest incidence of this HAT form (50–1,500 cases per 
year). Uganda is the only country in Africa known to be affected by both T. brucei 
subspecies, but the distribution of these parasites is, at least for the time being, separate 
(Picozzi et al., 2005). 
Compared to other parasitic diseases like malaria or worm infections, incidence of HAT is 
lower, but its potential to give rise to devastating epidemics as soon as active surveillance 
is abandoned makes this illness a major health priority in endemic countries (Cattand et al., 
2001). Systematic control programs established by European authorities resulted in 
efficacious intervention in the big epidemics that occurred between the end of the 19
th and 
the beginning of the 20
th century, bringing the disease to a nearly elimination by the 1960s 
(Pépin and Méda, 2001; Maudlin, 2006). After the colonial era, however, the number of  Federica Giordani, 2010    Chapter 1, 4 
 
Figure 1.1 – Map of Africa showing the geographical distribution of T. b. gambiense and T. 
b. rhodesiense. 
The epidemiological status of the endemic countries is indicated with different colours. 
(Reproduced from Simarro et al., 2008; doi:10.1371/journal.pmed.0050055.g003). 
cases increased rapidly, due to lack of surveillance and awareness from local government, 
but also to poverty, political instability, wars and displacement of populations (Smith et al., 
1998; Cattand, 2001; Brun et al., 2009). Today, a total of 60 million people in 36 African 
countries are continuously exposed to the risk of infection by one of the two forms of 
HAT, but only 3-4 million are under surveillance (Cattand et al., 2001). For this reason, 
accurate epidemiological data for sleeping sickness are difficult to collect and reported 
incidence of the illness is often considered an underestimate (Fèvre et al., 2008; Welburn 
et al., 2009). Despite this uncertainty, at the end of the 20
th century, WHO estimated an 
annual number of cases of at least 300,000 (40,000 – 50,000 deaths), of which only 13% 
were identified and treated (WHO, 2001). Fortunately, improvement in control policies and 
new international initiatives have led, during the last decade, to a steady decline of total 
cases, currently estimated to be 50,000 – 70,000 (WHO, 2006b; Barrett, 2006). 
1.1.3 Vector and transmission 
HAT is transmitted to humans through the bite of infected haematophagous arthropods 
belonging to the Glossina species. Gambian trypanosomiasis is typically acquired from Federica Giordani, 2010    Chapter 1, 5 
riverine tsetse flies of the G. papalis group, but also G. fuscipes, G. tachinoides and G. 
calliginea can act as vectors of T. b. gambiense (Cattand, 2001). The reservoir of this 
infection is considered exclusively human. Therefore, the cyclic transmission human-fly-
human is the main cause of the persistence of the disease. Nevertheless, natural infections 
with T. b. gambiense have been reported in domesticated animals (pigs, dogs and sheep) 
and may occur in wild fauna as well (Njiokou et al., 2006), although the epidemiological 
impact of this reservoir on humans remains as yet undetermined (Pépin and Méda, 2001; 
Brun and Balmer, 2006; Fèvre et al., 2006). T. b. rhodesiense, on the contrary, is a 
zoonotic parasite found in savannah habitats. Human infection with this species is 
sporadic, but when it occurs the disease is highly virulent and progresses very rapidly. 
Rhodesiense trypanosomiasis is transmitted by tsetse flies belonging to the G. morsitans 
group (and, at lesser extent, to G. pallidipes, G. swynnertoni and G. fuscipes) that have fed 
on infected domestic (cattle in particular) and wild (especially ungulates) animals, which, 
therefore, serve as the main reservoir of the parasite (Pépin and Méda, 2001; Welburn et 
al., 2001b). Tsetse flies are usually active during the day, but some species can bite at night 
and both sexes can transmit the infection (Fèvre et al., 2006). Interactions between vector 
and parasite are complex. Only a very small percentage of natural population of tsetse flies 
are infected by T. brucei species and this can explain the absence of correlation between 
insect concentration and incidence of the human disease (Pépin and Méda, 2001). Other 
possible routes of infection with trypanosomes are through blood transfusions, infected 
needles or congenitally (Barrett et al., 2003). 
1.1.4 Life cycle 
Trypanosomes are pleomorphic, single-celled parasites with a two-host life cycle: 
mammalian and arthropod (Chappuis et al., 2005; Brun et al., 2009). The cycle (Figure 
1.2) starts when an infected tsetse fly takes its blood meal on the mammalian host and it 
inoculates the metacyclic trypomastigote form of the parasite present in its saliva. 
Trypanosomes quickly transform into the long slender trypomastigotes and proliferate by 
binary fission at the site of the bite for a few days, leading to an inflammatory chancre. The 
parasites, then, spread to the draining lymph nodes and the bloodstream (first or early 
haemolymphatic stage of infection), through which they reach other organs such as the 
spleen, liver, heart and endocrine system. After a few weeks (T. b. rhodesiense) or several 
months (T. b. gambiense) trypanosomes cross the blood-brain barrier (BBB) to invade the 
central nervous system (CNS) through mechanisms that are still poorly understood 
(Enanga et al., 2002): the patient is, then, said to be in the meningoencephalitic, second (or  Federica Giordani, 2010    Chapter 1, 6 
 
Figure 1.2 – Schematic representation of the digenetic life cycle of Trypanosoma brucei in 
the mammalian host and in the tsetse fly vector. 
(Reproduced with permission from Blum et al., 2008). 
late) stage of infection. When parasitaemia in the host increases, long slender 
trypomastigotes transform into non-dividing, short-stumpy trypomastigotes, which are 
taken up by the tsetse fly (which remains infective for its entire life), where they complete 
their life cycle. In the insect’s midgut trypanosomes transform into the procyclic stage and 
after two or three weeks they migrate to the salivary glands. Here other transformations 
lead to their development into metacyclic forms, ready to be injected into a susceptible 
vertebrate host during the next blood meal. 
During their whole life cycle African trypanosomes remain exclusively extracellular, thus 
fully exposed to the host’s immune response. To survive complement-mediated lysis and 
specific immune attack, parasites shield invariant surface molecules with a thick coat made 
of variant surface glycoproteins (VSGs). Only one VSG is expressed at a time and, once 
neutralising specific antibodies have been produced from the host, trypanosomes switch to 
a different VSG, thus allowing the population to survive (Machado et al., 2006; Morrison 
et al., 2009). This antigenic variation process explains the intermittent parasitaemia and the 
long asymptomatic incubation period typical of T. b. gambiense infection and it makes the 
development of a vaccine remote (Cattand, 2001). Federica Giordani, 2010    Chapter 1, 7 
 
Figure 1.3 – Diagram of a bloodstream Trypanosoma brucei cell illustrating the major 
organelles. 
Glycosomes and acidocalcisomes are not drawn to scale. 
(Modified from ILRAD Reports vol. 7 (1), Jan. 1989; available online at the website 
http://www.ilri.org/InfoServ/Webpub/Fulldocs/Ilrad89/Trypano.htm). 
1.1.5 Cell morphology and cell compartments 
African trypanosomes are eukaryotic, unicellular organisms, with a spindle-shaped cell 18-
20 mm long and 3 mm thick (Field et al., 2004; Figure 1.3). These parasites move thanks to 
a single flagellum that, in the trypomastigotes, arises from the posterior end of the cell, 
runs the whole length of the cell body, to which it is attached by an undulating membrane, 
and extends beyond it at the anterior end. Tightly connected to the basal body of the 
flagellum is the kinetoplast, a complex network of mitochondrial DNA composed of 30-50 
DNA maxicircles (22 kb) and 5,000-10,000 minicircles (1 kb) interlocked together to form 
a disk-shaped structure (Chen et al., 1995; Liu et al., 2005). Minicircles encode for guide 
RNAs, which control editing specificity of maxicircle transcripts for rRNAs and subunits 
of respiratory complexes (Simpson and Shaw, 1989; Hong and Simpson, 2003). The 
kinetoplast is contained in the posterior part of the single trypanosome mitochondrion, an 
organelle that elongates longitudinally throughout the whole cell body. In slender 
trypomastigotes the mitochondrion shows only a few short cristae and little metabolic 
activity, due to the fact that this form of the parasite relies on glycolisis and not on 
oxidative phosphorylation for energy production (Schnaufer et al., 2002). When the cell 
enters mitosis, the kinetoplast DNA replicates and divides before the nuclear genome 
(Field et al., 2004). The flagellum emerges from an invagination of the plasma membrane 
called the flagellar pocket (Field and Carrington, 2009). This structure is involved in 
various cell activities including immune evasion, by continuous clearance of VSG-Federica Giordani, 2010    Chapter 1, 8 
immunoglobulin complexes, and cell trafficking, being the only site where endocytic and 
exocytic processes occur (Morgan et al., 2002). The organisation of the cell compartments 
from the flagellar pocket towards the anterior side is highly polarised. Associated to the 
pocket is the Golgi complex with its endocytic and secretory vesicles confined between 
kinetoplast and nucleus. The single lysosome is usually close to the nucleus, which is 
located at the midpoint of the cell (Field et al., 2004). The nuclear genome of T. brucei 
includes 11 diploid, megabase-sized chromosomes and various aneuploid, mini- and 
intermediate chromosomes (30-700 kb), which harbour VSGs sequences and expression 
sites similar to those present in the subtelomeres of the megabase chromosomes (Berriman 
et al., 2005). The endoplasmic reticulum is distributed in the whole cytoplasm as well as 
the acidocalcisomes, acidic electron-dense granules with a diameter of around 0.2 mm, 
important for the homeostasis of various elements including several cations, dications 
(Na
+, Ca
2+, Mg
2+, Zn
2+) and phosphate (Docampo and Moreno, 1999; Rodrigues et al., 
1999). Acidocalcisomes, which have no counterpart in mammalian cells, can be visualised 
inside different Trypanosoma species by their specific staining with acridine orange 
(Vercesi et al., 1994; Mendoza et al., 2002). Glycosomes are other membrane-bound 
organelles, homogeneous in size (0.27 mm diameter), present throughout the whole cell 
body of T. brucei. These structures, which are closely related to peroxisomes, contain 
glycolytic enzymes and are particularly abundant in bloodstream trypomastigotes (240 per 
cell) (Opperdoes, 1987). 
1.1.6 Control strategies 
All countries affected by HAT have national programs dedicated to surveillance of the 
disease (Simarro et al., 2008). Control is based on two approaches: the reduction of the 
reservoirs (human or animal) of the parasite and the reduction of the chance of contact 
between vector and human host by means of vector removal (Welburn et al., 2001a). For 
T. b. gambiense form, where humans represent the main reservoir, active case-finding (and 
therefore, correct diagnosis) and treatment of the infected patients are the strategies 
adopted to interrupt transmission (Simarro et al., 2006; Brun et al., 2009). For T. b. 
rhodesiense, instead, the control of infection in livestock (and, to a minor extent, in 
wildlife) through the use of curative or prophylactic trypanocides or application of 
insecticides to the animals plays a crucial role (Hutchinson et al., 2003; Fèvre et al., 2006; 
Simarro et al., 2008). For Rhodesian HAT, vector control can also be an efficient approach 
for containing the transmission of the disease (Welburn et al., 2009). The fight against 
tsetse flies involves the use of insecticides and the installation of traps or screens (Torr et Federica Giordani, 2010    Chapter 1, 9 
al., 2005; Lindh et al., 2009). A new technology available to decrease tsetse population 
consist in the release of sterilised tsetse males (sterile insect technique, SIT), but its cost-
effectiveness is disputed (Vreysen, 2001). 
1.1.7 Chemotherapy 
Since African trypanosomiasis is considered invariably fatal if untreated, chemotherapy is 
mandatory. Unfortunately, as for the other neglected tropical diseases, drug research and 
development for HAT is a minor activity due to lack of profit perspectives for 
pharmaceutical companies (Trouiller et al., 2002). Although today new initiatives, like the 
Drugs for Neglected Diseases Initiative, DNDi (http://www.dndi.org/index.php), are trying 
to face this problem, HAT treatment still relies on only four drugs (Figure 1.4), three of 
them introduced over 50 years ago (Ollivier and Legros, 2001). Recently, nifurtimox (an 
orally administered 5-nitrofuran licensed for the treatment of Chagas’ disease) for use in 
combination with eflornithine (see later), has been added to the list (Delespaux and de 
Koning, 2007; Figure 1.4). The production and availability of these drugs is in constant 
danger and continues only thanks to agreements between WHO and the suppliers 
(Etchegorry et al., 2001; Barrett et al., 2003). All of these four drugs are far from ideal, 
with problems associated to toxicity, route of administration, low efficacy and resistance 
(Legros et al., 2002; Fairlamb, 2003). HAT therapy is even more complicated during the 
second stage of the disease, since drugs have to reach the brain by crossing the blood-brain 
barrier, which otherwise protects parasites from compounds active in the haemolymphatic 
compartment (Enanga et al., 2002; Lejon and Büscher, 2005). 
Pentamidine and Suramin are the drugs used to treat the early stage of HAT. Pentamidine 
isethionate (Lomidine
®) was introduced in the early 1940s and, since then, it has been used 
for the treatment of T. b. gambiense infection without being associated with any significant 
resistance outbreak (Delespaux and de Koning, 2007). During the colonial era this 
compound was also widely used as mass chemoprophylactic agent (Ollivier and Legros, 
2001). Pentamidine is administered by intramuscular injection (7-10 doses of 4 mg/kg 
daily or every two days) and it is relatively well tolerated (Legros et al., 2002). Three 
transmembrane transporters responsible for the selective accumulation of pentamidine 
inside trypanosomes have been identified (de Koning, 2001a) and two more have recently 
being discovered (Ortiz et al., 2009), but the mechanism of action of this slow-acting 
diamidine is still unclear. Suramin sodium (Germanin
®) is a polyanionic sulfonated 
naphthylamine used as first line treatment for T. b. rhodesiense form of HAT since 1920. Federica Giordani, 2010    Chapter 1, 10 
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Figure 1.4 – Chemical structure of the drugs used for human African trypanosomiasis 
treatment. 
Nifurtimox, a drug licensed for Chagas’ disease, has recently been included in the Essential 
List of Medicines for HAT chemotherapy in association with eflornithine. 
It can also be used as second drug of choice for Gambian first stage trypanosomiasis. 
Suramin is administered intravenously (typically, five injections every 3-7 days over a four 
weeks period) and can have severe adverse reactions like anaphylactic shock, 
neurotoxicity, kidney damage and cutaneous reactions (Legros et al., 2002). As for 
pentamidine, the trypanocidal mechanism of suramin is poorly understood (Barrett et al., 
2007). This compound is known to inhibit many enzymes and a multiple mode of action is 
compatible with the absence of resistance cases observed in the field (Fairlamb, 2003), 
although resistant lines are easily selected in the laboratory (Scott et al., 1996). 
Melarsoprol and eflornithine are the two drugs used to treat late stage HAT. Melarsoprol 
(Arsobal
®, Mel B) was introduced in 1949 and is active on both forms of sleeping sickness. 
Treatment protocols with melarsoprol traditionally consists of various intravenous 
injections of the drug (3.6 mg/kg body weight, dissolved in propylene glycol) separated by 
periods of 7-10 days (Cattand, 2001). Only hypotheses exist on the mode in which this 
drug kills trypanosomes, the disruption of the parasite thiol-redox balance being one often Federica Giordani, 2010    Chapter 1, 11 
proposed (Fairlamb, 2003). Melarsoprol is an organo-arsenical compound extremely toxic 
to humans and it is responsible for the death of up to 5% of patients to whom it is 
administered, due to a post-treatment reactive encephalopathy. Furthermore, over the last 
decade, an increasing number of clinical failures (up to 30% in some areas), particularly in 
the treatment of T. b. gambiense, have been observed (Brun et al., 2001; Ollivier and 
Legros, 2001). Apart from poor treatment regimens, these failures have been associated, at 
least partially, to alterations or loss of the parasite’s P2 amino-purine transporter (Carter 
and Fairlamb, 1993; Matovu et al., 2001a), which is involved in the uptake of melarsoprol 
but also of diamidines like pentamidine and diminazene aceturate (a veterinary 
trypanocide), leading to worries about possible cross-resistance onset (Barrett and 
Fairlamb, 1999; de Koning 2008; Section 1.2.8). The alternative drug for treatment of 
melarsoprol-refractory late sage T. b. gambiense is eflornithine (Ornidyl
®, DFMO). 
Introduced in 1990, this drug is not active on T. b. rhodesiense, is expensive (five times 
more than melarsoprol) and requires a high dose treatment: 400 mg/kg daily subdivided 
into four intravenous infusions for 7 or 14 days (Burri and Brun, 2003). Treatment failures 
have been observed (Balasegaram et al., 2009), but it must be taken into consideration that 
the compound has a cytostatic effect that requires an active immune system to clear 
infection (Bitonti et al., 1986). Nevertheless, DFMO has a much lower toxicity than 
melarsoprol: side effects include seizures, gastrointestinal problems and myelosuppression 
(Priotto et al., 2006). Originally developed as a cancer treatment, the intracellular target of 
eflornithine is well known: the drug acts as a suicide inhibitor of the enzyme ornithine 
decarboxylase, disrupting the essential polyamine biosynthetic pathway of the parasite and 
leading to several downstream effects (Barrett et al., 2007; Delespaux and de Koning, 
2007). 
Since DFMO registration, the first new drug candidate for HAT therapy has been an oral 
diamidine designed for the early stage of the disease, DB289, but, despite its efficacy, the 
compound’s development was recently stopped due to toxicity issues (Thuita et al., 2008). 
Diamidines remain interesting drug leads against HAT and other compounds, more potent 
than DB289 and including blood-brain barrier permeant derivatives, have already been 
identified (Wenzler et al., 2009). Nitroimidazoles are another class of molecule active 
against trypanosomiasis (Denise and Barrett, 2001); among them, fexinidazole, developed 
by DNDi, is currently in Phase I trials (Torreele at al., 2009). Thanks to recent advances in 
the knowledge of parasite biology new drug targets may be validated in the future (Croft et 
al., 2005; Barrett et al., 2003 and 2007). Moreover, improved therapeutic protocols and 
combinations of existing drugs are under evaluation for the advantages they can offer (in Federica Giordani, 2010    Chapter 1, 12 
particular the limitation of side effects and delay of drug resistance development, but also 
the reduction of costs and treatment duration). A new, shorter 10-day protocol with 
melarsoprol (2.2 mg/kg daily intravenously) has already been introduced with success for 
Gambian trypanosomiasis: it does not eliminate toxicity, but it reduces hospitalisation 
period and costs (Schmid et al., 2005). Combination therapies of nifurtimox with either 
melarsoprol or DFMO have been tested for treatment of HAT second stage: the association 
of nifurtimox with eflornithine, in particular, has given encouraging results during early 
clinical trials (Bisser et al., 2007; Priotto et al., 2006 and 2009) and, recently, this drug 
combination has been included in the Essential List of Medicines for HAT treatment by 
WHO (http://www.who.int/neglected_diseases/en/). 
1.2 Diagnosis of T. b. gambiense infection 
Accurate diagnosis and staging of sleeping sickness infection is of the utmost importance 
for disease management and control (Louis et al., 2001). Early detection of the disease 
allows not only to treat the patients with the cheaper, less toxic drugs for the first stage of 
the disease, but also to reduce the human reservoir of the parasite in the case of T. b. 
gambiense infection (Fèvre et al., 2006). Unfortunately, diagnosis of HAT still represents a 
major problem, due to insensitivity and laboriousness of the techniques available especially 
in remote locations with limited facilities. Passive case-finding (self-reporting patients) is 
extremely inefficient, as infected individuals can manifest symptoms only after many 
months, and usually refer to local health centres when already in the second stage 
(Ekwanzala et al., 1996; Smith et al., 1998; Abel et al., 2004; Odiit et al., 2004). 
Therefore, more effective active case-finding programs have been established to screen the 
whole population at risk through the work of specialised mobile teams (Ruiz et al., 2002; 
Robays et al., 2004; Simarro et al., 2006). HAT is diagnosed using a combination of tests. 
Every endemic country has adopted a specific algorithm for detection of infected subjects, 
but all strategies comprise a sequence of screening and confirmation steps (Figure 1.5). 
Suspected HAT cases are identified using indirect diagnostic tools (clinical features, 
serological tests and, to a lesser extent, molecular tests) and must always be confirmed by 
direct microscopy. On infected individuals staging of the disease is carried out to decide on 
the treatment protocol to use. Stage determination requires an invasive lumbar puncture 
and is usually performed in local treatment centres. Direct and indirect diagnostic 
procedures must also be applied during follow-up periods to check for relapses, but also to 
monitor seropositive individuals not confirmed by parasitological techniques (Chappuis et 
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Figure 1.5 – General flow chart for T. b. gambiense diagnosis. 
Every endemic country utilises a specific algorithm that can slightly differentiate from the 
one illustrated here. Threshold values indicated for second stage determination are those 
recommended by the World Health Organisation (WHO, 1998). The diagnostic techniques 
indicated in the figure are described in Section 1.2. 
CATT-wb: card agglutination test for trypanosomiasis on whole blood; FBE: fresh blood 
examination; TBF: thick blood film; mAECT: miniature anion-exchange centrifugation 
technique; mHTC: microhaematocrit centrifugation technique; QBC: quantitative buffy coat; 
CSF: cerebrospinal fluid; WBC: white blood cells; Prot: protein; +: positive test result; 
-: negative test result. 
None of the various assays available today for HAT diagnosis is ideal: practicality, costs 
and low efficiency are the main drawbacks. A test’s diagnostic accuracy is usually 
quantified by means of its sensitivity and specificity, which are respectively defined as the 
proportion of true positives (true positives/true positives+false negatives) and of true 
negatives (true negatives/true negatives+false positives) that are correctly identified by the 
assay (Altman and Bland, 1994a; Akobeng, 2007). More useful to clinicians to decide 
about the probability of disease in patients are the positive and negative predictive values, 
which represent the proportion of people with a positive test result who actually have the 
disease (true positives/true positives+false positives), and the proportion of people with a 
negative test result who do not have the disease (true negatives/true negatives+false 
negatives), respectively (Altman and Bland 1994b; Banoo et al., 2007). Predictive values 
are dependent on the population and change if the prevalence of the disease changes, while 
specificity and sensitivity remain unvarying. Since sensitivity and specificity are usually Federica Giordani, 2010    Chapter 1, 14 
inversely related, the choice of an assay with a certain precision depends on the case under 
study: in situations where it is important to detect the highest number of affected patients 
(like mass screening programs), a highly sensitive test is preferable, while for case 
confirmation tests a high specificity is needed to avoid the risk of false positives (Empson, 
2001; Nendaz and Perrier, 2004). 
1.2.1 Clinical features 
HAT is difficult to diagnose at an early stage, when symptoms are largely variable and 
aspecific and the disease can be easily confused with other common tropical infections, 
especially malaria (Louis et al., 2001). Fever, general malaise, headache, facial oedema, 
anaemia, cutaneous lesions are all manifest during the haemolymphatic stage (Kennedy, 
2006a). The only specific features are a local inflammation at the site of the tsetse bite, 
called the chancre, and an enlarged posterior cervical lymphadenopathy (Winterbottom’s 
sign). The chancre generally occurs 5-15 days after the inoculation of the parasite, but it is 
seldom observed in Africans (Büscher and Lejon, 2004). Palpation of enlarged neck glands 
and microscopic examination of the aspirate in positive cases is generally used for HAT 
diagnosis (Lutumba et al., 2005; Section 1.2.3.2). The diffuse inability of the local primary 
healthcare facilities to promptly identify the disease results in considerable delays in 
diagnosis and treatment, with consequent increase of risk of unfavourable prognosis and of 
human suffering (Bukachi et al., 2009). HAT becomes more easily recognizable as the 
disease progresses. Later clinical features reflect the involvement of specific organs: 
gastro-intestinal problems, cardiovascular disturbances, endocrine dysfunction and, 
sometimes, eye involvement can occur (Kennedy, 2006a; Blum et al., 2008). When the 
infection reaches the meningoencephalitic stage, signs of nervous system disruption 
become evident and extensive in Gambian trypanosomiasis. Sleep-pattern disturbances, 
with dysregulation of the circadian rhythm, represent the most typical feature at this stage 
and lend HAT its common name “sleeping sickness”. Other neurological changes include 
painful peripheral sensory disturbances, tone and mobility disorders, mental changes and 
psychiatric disorders. If untreated, patients stop eating, lapse into a semi-coma and finally 
die (Kennedy, 2006a and 2006b). 
1.2.2 Serological tests 
Application of serological assays to obtain indirect indication of infection (by antibody 
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areas but, as for clinical features, these tests are just indicative of the presence of 
trypanosomes. Since immunological tests lack sensitivity and specificity, subsequent 
parasitological confirmation has to be performed on the positive cases identified for final 
diagnosis (Chappuis et al., 2005). In the field, however, mobile teams often face complex 
situations where patients with a positive serology are not confirmed by microscopy (a 
phenomenon called seropositivity) and the question of whether to provide treatment to 
these subjects is disputed (Koffi et al., 2006). The main cause of seropositivity is probably 
the low sensitivity of parasitological methods that gives rise to false negatives (Section 
1.2.3), but this phenomenon can also be explained by false serological positives generated 
by cross-reactivity with animal trypanosomes or other co-infecting parasites. Moreover, an 
efficient immune system response could allow some subjects to control the virulence of the 
infection and keep it under detection limits of current diagnostics (Garcia et al., 2000 and 
2006). The serological tests available are very useful, but they are not ideal, because of 
their use of not defined recombinant proteins against variable antigens. Therefore, new 
protein markers for HAT serodiagnosis are under study (Hutchinson et al., 2004). 
1.2.2.1  CATT/T. b. gambiense 
Since its introduction in 1978, the card agglutination test for trypanosomiasis (CATT/T. b. 
gambiense) has been the most widely used technique for mass population screening in the 
field (Chappuis et al., 2005). The test is a cheap, fast and simple agglutination assay able to 
detect specific antibodies to the T. b. gambiense variable antigen type (VAT) LiTat 1.3, 
common in the serum of patients infected with this subspecies. Recently, a thermostable 
format of the test has been developed (Hasker et al., 2010). To perform the assay, a drop of 
reagent, consisting of lyophilised, blue-stained bloodstream trypanosomes expressing the 
LiTat 1.3 antigen and resuspended in PBS, is mixed with a drop of fresh, heparinized, 
capillary blood on a white plastic card, which is then shaken for 5 minutes on a 12/220 V 
card rotator. The result is immediately read by the naked eye: in subjects previously 
exposed to T. b. gambiense the trypanosomes agglutinate and form a blue clot. The test 
sensitivity on undiluted whole blood (CATT-wb) varies from 87 to 98%, while specificity 
can reach 90-95% (Penchenier et al., 2003; Chappuis et al., 2005). Serial dilutions of 
blood, plasma or serum before applying the test improve its specificity. The use of end-
dilution titers have been suggested as a useful tool for therapeutical decision making for 
CATT-wb positive patients (Simarro et al., 1999; Chappuis et al., 2004), although this 
approach can be risky because of the poor positive predictive value of the test where 
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different confirmation algorithms showed that the use of parasitologic confirmatory tests 
by concentration methods without CATT titration had a better efficiency (Lutumba et al., 
2007). The CATT loses its efficacy on samples from patients infected with strains of 
trypanosomes that lack, or do not express, the LiTat 1.3 antigen, resulting in false 
negatives, but the distribution of these strains seems limited (Dukes et al., 1992). Similarly, 
false positives can occur in patients infected with other trypanosome species or parasitic 
diseases, which cross-react with non-variant epitopes on the surface of trypanosomes 
present in the reagent (Jamonneau et al., 2000; Inojosa et al., 2006). Furthermore, the 
agglutination can be inhibited by complement factors, a phenomenon called prozone, when 
the test is performed on undiluted, heparinized blood or serum with low dilutions (<1:4). In 
these cases, addition of EDTA to the dilution buffer eliminates the problem by increasing 
the sensitivity with only a minor loss of specificity (Pansaerts et al., 1998; Magus et al., 
2002). Other disadvantages of CATT are that it does not work on T. b. rhodesiense and it 
does not differentiate between past and current infections: this is the reason why this test 
can not be used to assess treatment efficacy during follow-up (Section 1.2.7), since 
circulating antibodies can persist for several years after cure (Paquet et al., 1992). 
Variations on the same theme of the CATT have been proposed as, for example, the micro-
CATT (micro-card agglutination test for trypanosomiasis). This test allows the collection 
and storage (at 4 ºC) of dried blood samples on a filter paper (Miézan et al., 1991). The 
micro-CATT showed the same specificity of the CATT-wb but a lower sensitivity in the 
field (Truc et al., 2002). Furthermore, although it requires smaller volumes of reagents, it 
is a more expensive method than the CATT-wb because more consumables are needed to 
perform the assay. 
1.2.2.2  LATEX/T. b. gambiense 
The LATEX/T. b. gambiense is an agglutination card test developed as a field alternative 
to the CATT-wb. The reagent is based on the combination of three purified variable 
surface antigens (LiTat 1.3, 1.5 and 1.6) absorbed on latex particles, in order to avoid non-
specific cross reactions frequent in complex antigen preparations (Büscher et al., 1991). 
The test follows a procedure similar to the CATT, but as it is usually performed on diluted 
blood (≥1:4) it is more laborious to perform (Jamonneau et al., 2000). The LATEX/T. b. 
gambiense showed a higher specificity (up to 99%) but a lower, or similar, sensitivity 
(form 84 to 100%) when compared to the CATT assay (Truc et al., 2002; Penchenier et al., 
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1.2.2.3   Immunofluorescent antibody test (IFAT) and enzyme-linked 
immunosorbent assay (ELISA) 
The enzyme-linked immunosorbent assay (ELISA) and the indirect immunofluorescent 
antibody test (IFAT) can detect specific host antibodies (IgM, IgG), related to the presence 
of parasites in blood, plasma, serum or cerebrospinal fluid, after 3-4 weeks of infection. 
Tests use purified trypanosomal glycoproteins or lysates of whole trypanosomes of 
selected antigen types (Büscher and Lejon, 2004). The immunofluorescent antibody test 
has been used with success for HAT control in different countries (Noireau et al., 1988; 
Simarro et al., 2006) due to its high sensitivity and specificity (evaluated as superior to the 
CATT test). The ELISA methods can be performed with serum, filter paper eluates or 
cerebrospinal fluid (Lejon et al., 1998), but they were also shown to be able to detect 
specific antibodies against T. b. gambiense VSGs in the saliva, with sensitivity and 
specificity above 90%, thus opening new perspectives for the development of a new, non-
invasive serological test (Lejon et al., 2006). The ELISA assay can also be used for 
detection of parasite antigens in patients’ sera (Liu et al., 1989). This approach has the 
advantage of demonstrating that the parasite is still, or has recently been, present in the 
host and does not rely on his immune response. Various antigen candidates are currently 
under evaluation, although their low concentration in circulation could represent a major 
limitation for the development of a test for African trypanosomiasis (Radwanska, 2010). 
Moreover, studies on animal infections raised doubts about the sensitivity and specificity 
of this approach (Rebeski et al., 1999). Due to the need of expensive and sophisticated 
equipment and trained personnel, the use of IFAT and ELISA is restricted to specialised 
laboratories (Chappuis et al., 2005). 
1.2.3 Parasitological methods 
Direct detection of parasites in human fluids (lymph node aspirate, blood or cerebrospinal 
fluid) through light microscopy has always represented the “gold standard” of HAT 
diagnosis (Büscher and Lejon, 2004; Chappuis et al., 2005). Due to risks related to 
available drugs, confirmation of infection by parasitological techniques for clinically or 
serologically diagnosed suspects should always be done before starting treatment (Louis et 
al., 2001). Microscopy has virtually 100% specificity, but suffers from a very low 
sensitivity, that significantly affects the overall efficacy of African trypanosomiasis 
diagnosis in the field, failing to confirm 20-30% of infections (Robays et al., 2004; 
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and fluctuating parasitaemia typical of T. b. gambiense infection: parasites seldom exceed 
10,000 trypanosomes/ml (a number easily detectable) but can be present at numbers lower 
than 100 trypanosomes/ml (below the detection limit of the most sensitive parasitological 
methods in use) (Chappuis et al., 2005). To decrease the number of false negatives, it is 
possible to examine various samples over consecutive days, or to follow-up seropositives 
at regular intervals, but these strategies are difficult to apply in rural settings. Processing 
samples with concentration techniques before viewing improves the sensitivity and 
increases the cost-effectiveness of confirmation algorithms (Lutumba et al., 2007), but it 
also makes parasitological methods more laborious and expensive, limiting their routine 
use (Lutumba et al., 2006). Despite all of these drawbacks, light microscopy is widely used 
in the field because of its simplicity, its immediate results and the lack of a valid 
alternative. 
1.2.3.1  Chancre aspirate 
Trypanosomes can be detected in the chancre several days earlier than in the blood 
(Chappuis et al., 2005), especially in the Rhodesian form (Louis et al., 2001), but a blood 
smear is more sensitive. The chancre aspirate can be viewed directly under the microscope 
or after fixation and Giemsa-staining. This procedure is seldom used in the field because 
most infections are detected when the chancre has already disappeared (Büscher and 
Lejon, 2004). 
1.2.3.2  Lymph node aspirate 
Due to its simplicity, cervical lymph node palpation is systematically done (often in 
association with CATT) for population screening in many endemic countries. Even if this 
test is considered less cost-effective than the agglutination assay (Lutumba et al., 2005), in 
some areas it appears to be the best method for early diagnosis of human African 
trypanosomiasis (Vanhecke et al., 2010). When enlarged lymph nodes (Winterbottom’s 
sign) are identified, they are punctured and the fresh aspirate is spread on a slide and 
covered with a coverslip. The wet preparation is then quickly examined (to avoid lysis of 
parasites in the sample) by light microscopy at ×400 total magnification for the presence of 
motile trypanosomes. The sensitivity of this method varies between 40 and 80%, 
depending on the parasite strain, the stage of the disease (sensitivity is higher during the 
first stage) and the prevalence of other infections causing lymphadenopathy (Louis et al., 
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1.2.3.3  Thin and thick blood films 
To prepare wet blood films, 5 or 10 ml of finger-prick blood are placed on a slide and 
examined microscopically under a coverslip at ×400 total magnification (Louis et al., 
2001). Trypanosomes are revealed by their moving between the erythrocytes. In spite of its 
very low sensitivity, with a detection limit as high as 10,000 trypanosomes/ml (1 
parasite/200 microscope fields) this method is still used in some centres (especially for T. 
b. rhodesiense) because it is very simple, cheap and offers immediate results (Büscher and 
Lejon, 2004). Fixed thin blood films stained with Giemsa or Field’s solutions have a 
similar low sensitivity (Chappuis et al., 2005). The preparation of a thick blood film is, 
therefore, preferred since it slightly improves the sensitivity to 5,000 trypanosomes/ml 
(Louis et al., 2001). To prepare a thick blood film, 20 ml of finger-prick blood is placed on 
a small area of the microscope slide and defibrinated by the use of the corner of another 
slide. The sample is then left to dry without being fixed, protected from direct sunlight, 
stained with Giemsa or Field’s solution and finally observed under the microscope at 
×1,000 total magnification (Büscher and Lejon, 2004). This technique is the most widely 
used in the absence of a centrifuge, even if examination of each slide can take 10 to 20 
minutes and must be carried out by an expert microscopist, since parasites are often 
deformed during sample preparation and are easily missed (Chappuis et al., 2005). 
1.2.3.4  Microhaematocrit centrifugation technique (mHCT) 
The blood concentration technique of microhaematocrit centrifugation (mHCT), also called 
the capillary tube centrifugation technique (CTC) or Woo test (Woo, 1970), is generally 
used during mass surveys to test CATT-positive suspects in whom the diagnosis could not 
be confirmed by classical methods (Chappuis et al., 2005). The mHCT is relatively easy to 
perform: it consists in filling three-quarters full heparinized capillary tubes with 50-60 ml 
of finger-prick blood. After being sealed at their end, the tubes are centrifuged at high 
speed for 6-8 minutes in a haematocrit centrifuge, in order to concentrate the trypanosomes 
present in the blood at the level of the buffy coat. The capillary tubes are then mounted on 
a special holder and can then be directly viewed at low magnification (×100 or ×200 total 
magnification) for mobile parasites (Louis et al., 2001; Chappuis et al., 2005). By 
examining more than one capillary tube (usually 6 or 8), the sensitivity of mHCT 
increases, and fewer than 500 trypanosomes/ml can be detected (Büscher and Lejon, 
2004). The mHCT is quite time-consuming and the presence of microfilariae in the blood 
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centrifuge represents the major drawback to the implementation of this technique in the 
field (Jannin and Cattand, 2004). 
1.2.3.5  Miniature anion-exchange centrifugation technique (mAECT) 
Since its adaptation for field diagnostic use in 1979 (Lumsden et al., 1979), the miniature 
anion-exchange centrifugation technique (mAECT) has been continuously improved 
(Kimber, 1984; Zillmann et al., 1996; Truc et al., 1998b; Büscher et al., 2009). This 
method purifies trypanosomes from blood using anion-exchange chromatographical 
columns containing diethylaminoethyl-cellulose (DEAE-52) and then it concentrates them 
by centrifugation before viewing (Lumsden et al., 1979). The chromatographical 
separation depends on difference in surface charges of the blood cells and the parasites, 
which are less negatively charged because their glycoprotein coat keeps the negative 
phospholipid head groups away from the matrix. When infected blood is mixed with PSG 
(phosphate saline glucose) buffer at pH 8 and is added to the column, the red and white 
blood cells adhere to the DEAE gel particles, while trypanosomes, being at their isoelectric 
point, flow through and are collected at the bottom of a sealed glass tube. After low speed 
centrifugation, the tip of the tube is mounted on a special holder and examined for the 
presence of trypanosomes using light microscopy at low magnification. Since a large blood 
volume (300-350 ml) is used, high sensitivity is achieved (the detection limit is less than 
100 trypanosomes/ml) (Louis et al., 2001). The efficiency of the technique could be further 
improved by processing on the column the buffy coat obtained from a larger volume of 
blood (5 ml) (Camara et al., 2010). However, the mAECT also has some drawbacks: the 
manipulations are quite time-consuming, materials are expensive and an energy source is 
needed (Chappuis et al., 2005). Initial evaluation in experimentally infected animal blood 
showed that this technique was more sensitive than the mHCT (Sachs, 1984). Both the 
mAECT and the mHCT need 30 minutes for results, but the microscopy phase for the 
mAECT is faster (1 minute, compared to 5 minutes for the mHTC) (Lumsden et al., 1979). 
The mAECT is currently considered the most sensitive parasitological technique for 
detection of trypanosomes in blood, with sensitivity in the field in the range of 75.3-84.5% 
(Miézan et al., 1994; Lutumba et al., 2006). 
1.2.3.6  Quantitative buffy coat (QBC) 
The quantitative buffy coat (QBC, Becton-Dickinson) is a very sensitive technique initially 
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mHCT method that associates concentration of the parasites by centrifugation with their 
fluorescence staining using acridine orange (Bailey and Smith, 1992; Chappuis et al., 
2005). For sample preparation, 60 ml of finger-prick blood are loaded into capillary tubes 
containing EDTA, acridine orange and a small floating cylinder and are centrifuged at high 
speed for 5 minutes. Fluorescent DNA of motile trypanosomes can be visualised in a 
darkroom in the expanded buffy coat by using a UV light connected to a special objective 
(60×) containing the appropriate filter. The need of this fragile equipment prevents the use 
of this test by mobile teams, limiting its application to referral centres (Chappuis et al., 
2005). The QBC is a very sensitive technique, with a detection limit estimated lower than 
500 trypanosomes/ml (Louis et al., 2001). Compared to the mAECT, the QBC was found 
to have a slightly lower sensitivity both on finger-prick and venepuncture samples, but due 
to its simplicity and rapidity (only 15 minutes instead of the 30-45 minutes needed for 
mAECT result) its use was recommended for routine screening (Truc et al., 1998a). 
Nevertheless, the costs of this technique can represent a major obstacle for its 
implementation in low-income countries. 
1.2.3.7  In vivo and in vitro isolation of trypanosome strains 
Trypanosome strains have always been isolated for research purposes from patients 
through inoculation of infected blood or cerebrospinal fluid into susceptible laboratory 
animals. Immunosuppressed African Mastomys natalensis rats are considered the best 
recipient for primary propagation of T. b. gambiense, with a success rate of 50% (Büscher 
et al., 2005; Maina et al., 2007b), but Grammomys surdaster thicket rats were shown to 
lead to even higher percentages of success (Büscher et al., 2005). The process of isolation 
and propagation in rodents is problematic, especially for the low virulent Gambian strains, 
and requires long incubation times (Brun et al., 2001). A simpler kit for in vitro isolation 
(KIVI) of trypanosome strains under field conditions proved effective both for human and 
animal samples (Truc et al., 1992). The procedure of the kit consists of inoculating, 
aseptically, several millilitres of blood in culture medium, where bloodstream parasites 
transform into procyclics and multiply at room temperature during the successive weeks 
(Büscher and Lejon, 2004). The KIVI kit can have a diagnostic value in detecting 
infections when other parasitological techniques fail, but it is seldom applied due to delays 
to obtain the results (Louis et al., 2001). The long adaptation periods needed to propagate 
isolates can have as a consequence the selection of clones or the modification of the 
original isolate and, for this reasons, the number of passages must be kept at a minimum 
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cerebrospinal fluid of HAT patients by in vitro culture on a fibroblast feeder layer (Giroud 
et al., 2009), a new promising technique which was found more efficient than inoculation 
in BALB/c mice. 
1.2.4 DNA technologies 
The applications of DNA techniques in diagnostics are quickly expanding. This is due to 
the many advantages these technologies offer, first of all their high sensitivity and 
specificity, superior to those of traditional parasitological tools. Moreover, they allow 
differentiating between trypanosomes of veterinary importance and, especially, between 
the two human pathogenic subspecies T. b. rhodesiense and T. b. gambiense, otherwise 
morphologically indistinguishable. This will become a crucial aspect of disease control in 
the case of overlap of the two human forms (Picozzi et al., 2005). The continuous 
simplification of molecular diagnostic procedures makes their use in the field, even in 
relatively simply equipped laboratories, a real option (Mugasa et al., 2009). 
1.2.4.1  PCR 
The polymerase chain reaction (PCR), together with other molecular biology techniques, 
has been widely used for research purposes to identify infecting trypanosome DNA in 
animal and human blood (Gibson, 2001 and 2002a; Becker et al., 2004; Brun and Balmer, 
2006). Different molecular probes have been tested for detection and identification of 
single trypanosome isolates from patients (Jamonneau et al., 2001). Among them, the 
classical TBR 1-2 primers, which recognise a repeated satellite sequence of the subgenus 
Trypanozoon, showed high sensitivity in human blood samples (up to 100%) with a 
specificity higher than 92% (Penchenier et al., 2000; Solano et al., 2002), but these primers 
can not differentiate between the three Trypanosoma brucei subspecies. Other markers are 
available for detection of T. b. gambiense infection, such as the genes encoding for the 
variant surface glycoproteins LiTat 1.3 and AnTat 11.17 (Bromidge et al., 1993), but these 
antigens are not homogeneously expressed in all isolates (Dukes et al., 1992). A specific 
target for the Gambian form has been identified in the receptor-like flagellar pocket 
glycoprotein TgsGP (Berberof et al., 2001), which has been shown to detect down to 10 
trypanosomes/ml of human blood (Radwanska et al., 2002b). For T. b. rhodesiense, a PCR 
based on the use of primers targeting the human serum resistance associated gene (SRA), 
which confers resistance to lysis by human serum and is ubiquitous in this species (Gibson 
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2002a; Njiru et al., 2004). Regardless of the primers utilised, PCR is generally more 
sensitive than other serological and parasitological diagnostic methods currently in use, 
showing detection limits of 0.1 trypanosome/ml of cattle blood and 1 to 40 
trypanosomes/ml of human blood (Jamonneau et al., 2004). Experimental work on animals 
has demonstrated that its application allows detection of active infection or relapse at a 
very early stage (Clausen et al., 1998; Bengaly et al., 2001). Moreover, as PCR can be 
performed on samples from both blood and cerebrospinal fluid, this approach offers a 
possible tool not only for diagnosis but also staging of HAT (Truc et al., 1999; Jamonneau 
et al., 2001; Section 1.2.5). Unfortunately, despite the high potential as a confirmatory 
assay for infection, the use of this technique is restricted to research laboratories and it is 
not commonly used for HAT diagnosis because of the need of expensive thermocyclers 
and of complex DNA purification protocols. Furthermore, PCR can be relatively slow and 
suffers a significant risk of sample contamination (Mugasa et al., 2008). Finally, this 
technique has not been fully validated yet: it has problems of reproducibility and can 
provide results at odds with those of both serological and parasitological tests (Koffi et al., 
2006). 
1.2.4.2   Loop-mediated isothermal amplification (LAMP) 
Efforts have been made in order to simplify PCR protocols and make this technique more 
suitable for field requirements. One of the most promising innovations is a new isothermal 
PCR-like method, called loop-mediated isothermal amplification (LAMP) (Notomi et al., 
2000). This technique, already commercialised for various infectious diseases, allows 
accurate and robust amplification of the target sequence in a single heating step (60-65°C), 
which can be performed in a water bath, and the results can be visualised by a simple 
colorimetric reaction (Njiru et al., 2008a and 2008b; Mori and Notomi, 2009). When 
applied to Trypanozoon isolates using primers targeting the repetitive insertion mobile 
element (RIME), this methodology showed a very high sensitivity (as low as 0.001 
trypanosomes/ml) and reproducibility (Njiru et al., 2008b). Other probes have been 
designed for detection of specific trypanosome species including T. b. gambiense 
(Thekisoe et al., 2007) and T. b. rhodesiense (Njiru et al., 2008a). Moreover, the test is fast 
(results are available in 35 minutes) and less prone to inhibitory factors than classical PCR, 
a characteristic that enables the use of unprocessed template, whether buffy coat, heat-
treated blood or serum (Njiru et al., 2008a and 2008b), although there is some evidence of 
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1.2.4.3  Molecular dipstick test (HAT-PCR-OC) 
The molecular dipstick test is a simple detection tool for PCR products based on 
oligochromatography (OC). In positive samples, amplicons hybridize with a specific gold-
conjugated probe and migrate on a chromatographical membrane where they result in a 
visible line in only 5 minutes. The test developed for T. brucei (HAT-PCR-OC) had 100% 
specificity and sensitivity on blood samples and was able to detect a single parasite in only 
180 ml of blood (Deborggraeve et al., 2006). 
1.2.4.4  Nucleic acid sequence-based amplification (NASBA) and NASBA-OC 
The nucleic acid sequence-based amplification assay (NASBA) consists in a self-sustained 
real-time PCR based on the amplification of RNA targets under isothermal conditions 
(41°C) (Deiman et al., 2002). The detection of the unstable mRNA has two advantages: it 
is indicative of active transcription and it avoids possible DNA contamination (Büscher 
and Lejon, 2004). By amplification of the 18S ribosomal RNA, this assay was able to 
detect specifically Trypanosoma brucei species (without distinction between T. b. 
gambiense and T. b. rhodesiense) with a sensitivity of 70% on clinical samples and a 
detection limit of 10 trypanosomes/ml (Mugasa et al., 2008). The association of NASBA 
with oligochromatography (OC) for amplicon detection makes this assay even easier and 
cheaper. During a study conducted by Mugasa and collaborators, the NASBA-OC showed 
higher sensitivity than standard microscopy both on blood (73%) and cerebrospinal fluid 
(88.2%) (Mugasa et al., 2009). Results were available in only 90 minutes (compared to the 
two or more hours needed for PCR or NASBA alone) and were highly reproducible. 
1.2.4.5  Fluorescence in situ hybridisation test (PNA FISH) 
The peptide nucleic acid fluorescence in situ hybridization (PNA FISH) is a new technique 
designed to facilitate detection of trypanosomes in blood smears by the use of fluorescent 
molecular probes that hybridise to parasitic RNA sequences. The use of fluorescein-
labelled peptide nucleic acid (PNA) probes, targeting the 18S rRNA of the subgenus 
Trypanozoon, showed a detection limit of 500 trypanosomes/ml of blood (Radwanska et 
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1.2.5 Stage determination 
When a HAT case is confirmed, the stage of the disease must be determined in order to 
guide treatment (Bisser et al., 2002; Kennedy, 2006a; Rodgers, 2009). Since specific 
neurological symptoms occur late and no blood test indicating brain involvement is 
available, this can only be done by analysis of a cerebrospinal fluid (CSF) sample obtained 
from the patient by invasive lumbar puncture (Enanga et al., 2002; Kennedy, 2008). Direct 
evidence of central nervous system (CNS) invasion is represented by the finding of 
trypanosomes in the CSF, but since this approach can be very insensitive, WHO also 
recommends the use of other indirect parameters related to the host’s neuroinflammatory 
immune response: white blood cell count and protein concentration (WHO, 1998). 
Positivity of one of these two tests defines the second stage even in absence of parasite 
detection or clinical symptoms (Bisser et al., 2002). Nevertheless, cut-off values for these 
assays are disputed and the exact definition of second stage is not definitive (Kennedy, 
2006a and 2006b). Improved diagnostics for disease staging is urgently needed and 
evaluation of alternative CSF parameters for indirect stage determination is currently under 
investigation (Lejon and Büscher, 2005). 
1.2.5.1  Trypanosome detection in CSF 
Detection of trypanosomes in the CSF is sufficient to classify a subject in the meningo-
encephalitic stage of the illness (Lejon and Büscher, 2005). The CSF has to be examined 
immediately after lumbar puncture, because trypanosomes in this medium seem to be very 
fragile and they start to lyse within 10 minutes (Büscher and Lejon, 2004). This technique 
is simple and cheap, but it suffers from insufficient sensitivity since it can detect parasites 
only when their concentration is >1,000 trypanosomes/ml (Lejon and Büscher, 2002). The 
sensitivity can be increased by single or, especially, by double centrifugation (DC) of the 
CSF sample. The first technique consists of viewing the sediment obtained from 
centrifugation of several millilitres of CSF spread on a glass slide, while in the second 
method this sediment is further centrifuged in a flame-sealed capillary tube which is, then, 
directly examined by microscopy (Cattand et al., 1988). Due to the number of 
manipulations and the equipment required, these techniques are not widely applied 
(Chappuis et al., 2005). A simplification of the DC test was developed by Miézan and 
colleagues, who showed that the direct examination of the CSF sediment at the bottom of a 
sealed Pasteur pipette obtained after a single centrifugation had the same sensitivity as the 
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new plastic collector tube, originally developed for the mAECT, could further ameliorate 
this technique, increasing the sensitivity to <2 trypanosomes/ml of CSF (Büscher et al., 2009). 
1.2.5.2  White blood cell count in CSF 
Despite its lack of specificity, the white blood cell count is the most widely used (and often 
unique) technique for stage determination and follow-up (Lejon and Büscher, 2001 and 
2005). The WHO upper limit for normal white cell concentration is set at 5 cells/ml, but it 
has been proposed to raise this value to 10 cells/ml (Chappuis et al., 2005) or 20 cells/ml 
(Lejon et al., 2003b), since patients found with 6 to 20 cells/ml in their CSF were 
successfully cured by pentamidine (Doua et al., 1996). These subjects, considered to be in 
the so-called “early second stage” or “intermediate stage” of the illness, often present non-
concordant markers that complicate staging (Bisser et al., 2002). Once the CSF is collected 
(at least 5 ml), the leukocyte count must be carried out quickly to prevent cell lysis 
(Chappuis et al., 2005). In African trypanosomiasis, the CSF can present with a special 
type of enlarged B-cell, known as morular cells of Mott, containing cytoplasmic vacuoles 
filled with IgM, which can be considered pathognomic, although they are not specific for 
HAT (Lejon and Büscher, 2005). A recent work showed how the detection and 
quantification of B lymphocytes may be useful to stage the disease (Bouteille et al., 2009). 
1.2.5.3  Protein concentration in CSF 
In CSF of late stage HAT patients protein concentration is elevated (0.4-2 mg/ml) 
(Kennedy, 2006b), but it can also be raised during the first stage of the illness, due to the 
diffusion of the abundant serum immunoglobulins in the CSF (Chappuis et al., 2005). Cut-
off values set by WHO for sleeping sickness vary according to the quantification method 
used (WHO, 1998). Recent data suggest that the protein concentration threshold of 370 
mg/litre for the colorimetric method is too low and should be raised (Lejon et al., 2003b). 
This technique is seldom applied in African sleeping sickness control centres, because the 
methods are sophisticated, reagents needed are unstable and the results do not offer much 
more information than CSF cell count (Lejon and Büscher, 2001 and 2002). 
1.2.5.4  Other markers and tests for second stage determination 
CSF of second stage T. b. gambiense patients contains high levels of immunoglobulins, 
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due to parasite invasion (Bisser et al., 2002), even if other neurological infections could 
cause the same effect (Lejon et al., 2003b). Studies on quotients CSF/serum concentration 
for IgM, IgG and IgA confirmed that the elevated concentration in the CSF was due to 
intrathecal synthesis and only partially to blood-derived immunoglobulins and that the 
predominant IgM presence was the most sensitive (95%) marker for brain involvement 
(Lejon et al., 2003b). Determining the IgM content in the CSF can be very difficult to 
carry out under field conditions but a semiquantitative latex agglutination test for IgM in 
CSF (LATEX/IgM) has recently been designed for field use, thanks to its reagent stability 
at 45ºC for more than 2 years (Lejon and Büscher, 2002). End titres (highest dilution 
causing an agglutination) ≥1:8 were shown to be 89.4% sensitive and 92.7% specific for 
presence of intrathecal IgM synthesis (Lejon et al., 2002b). The possibility to use the 
LATEX/IgM agglutination test also for stage determination of T. b. rhodesiense infection 
is under evaluation (Lejon et al., 2002b). 
Other antibodies with different affinities are being evaluated as possible second stage 
markers (Lejon and Büscher, 2001). Among them, autoantibodies against brain-specific 
components such as neurofilaments and galactocerebrosides have been found in CSF of 
HAT patients (Vincendeau and Bouteille, 2006). Simple test formats to detect these 
antibodies not only in CSF, but also in other biological fluids like saliva, could represent a 
great improvement towards a less invasive assay for staging (Jannin and Cattand, 2004). 
Cytokines and chemokines mediate the host’s neuroinflammatory immune response and 
high levels of these molecules in CSF have been associated to neurological involvement in 
T. b. gambiense disease (Courtioux et al., 2006; Hainard et al., 2009). Interleukin-10, in 
particular, has significantly raised concentrations in plasma (Courtin et al., 2006) and CSF 
of infected patients and it could represent an interesting marker for treatment and follow-
up, since its levels lower immediately after treatment (Lejon et al., 2002a). A combination 
of different markers (two chemokines, CXCL8 and CXCL10 and a brain damage marker, 
H-FABP) was shown to correlate to HAT second stage with 97% sensitivity (Hainard et 
al., 2009). However, the use of these indicators for staging suffers various drawbacks, such 
as the not direct applicability in the field, the necessity of invasive lumbar puncture and the 
need to exclude other brain inflammatory diseases. 
Finally, the finding of trypanosome DNA in CSF by the use of PCR techniques could 
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1.2.5.5  Polysomnography 
Polysomnography is a promising non-invasive diagnostic technique that could be used to 
discriminate between the two stages of African trypanosomiasis (Buguet et al., 2005). It 
combines different tools (electro-encephalogram, electro-oculogram and electro-myogram) 
which allow the monitoring of sleep structure and phases, both known to be seriously 
compromised in second stage HAT patients. The detection of abnormal sleep onset rapid 
eye movement periods (SOREMPs) that occur shortly after CNS involvement, has been 
proven to be proportional to illness severity and to recede after treatment, showing a 
possible application also in follow-up studies. 
1.2.6 Other diagnostic approaches 
Novel diagnostic approaches based on the detection of specific biomarker patterns related 
to the presence of the disease (“fingerprints”) are under study. A proteomic signature 
analysis technique, for example, has been demonstrated to be much more accurate than any 
other diagnostic test, being able to distinguish between trypanosome-infected and non-
infected serum samples with a sensitivity of 100% and a specificity of 98.6% 
(Papadopoulos et al., 2004). The proteomic analysis is impracticable in the field but it 
could represent a very sensitive tool for the identification of new biomarker proteins for 
successive applications in diagnostics or drug discovery (Agranoff et al., 2005). Following 
this principle, Hainard and collaborators evaluated various molecules identified by 
proteomic analysis as possible indicators for HAT second stage (Hainard et al., 2009). 
Similarly, the comparison of metabolite patterns could offer another approach for 
discovering “fingerprints” to use for HAT diagnosis or staging. A study carried out by 
Wang and collaborators demonstrated the utility of the analysis of the metabolome for 
diagnostics, by showing a correlation between T. b. brucei infection in mice and systematic 
perturbations in the metabolites profile of the animal’s urine and plasma (Wang et al., 2008). 
1.2.7 Follow-up 
Ideally, patients should be periodically checked (visits at 3, 6, 12, 18, 24 months) for a 
total period of two years after treatment to confirm complete cure (WHO, 1998), but in 
practice this is hardly achieved in the field, where compliance with follow-up is extremely 
low (Legros et al., 1999). Unfortunately, unsuccesful treatment regimens are far from rare 
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Causes of drug relapses are still unclear. Many phenomena could be involved in this 
process, such as low drug potency, under-dosing, pharmacokinetic differences between 
individuals, presence of co-infections (especially HIV), poor health of the patient at the 
moment of admission to the treatment centre or decreased susceptibility of trypanosomes 
to the drug. To assess chemotherapy success both direct and indirect diagnostic techniques 
are used, but standard operational criteria are still lacking. Since no blood markers for cure 
have been identified so far and the CATT test resulted unreliable during follow-up 
examinations (Lejon et al., 2010), treatment failure is usually identified as a deterioration 
of the CSF parameters. This phenomenon normally occurs in 3-9% of late stage patients 
treated with melarsoprol (Maina et al., 2007a). Detection of trypanosomes in blood, lymph 
nodes or CSF indicates treatment failure or relapse, but due to low sensitivity of 
parasitological techniques, increased leukocyte count and recurrence of neurological 
symptoms are also often evaluated (Lejon and Büscher, 2001 and 2005; Mumba Ngoyi et 
al., 2009). Patients hospitalised with severe brain inflammation or as previous relapsing 
cases are at high risk of treatment failure (Legros et al., 1999; Lejon et al., 2008). A recent 
work on T. b. gambiense patients identified the association between white cell count ≥ 8 
cells/ml and LATEX/IgM end titre ≥ 1:4 as being 97 % and 100% specific for relapse 
prediction after 12 and 18 month from treatment respectively (Lejon et al., 2008). The 
identification of criteria for treatment outcome would have the great advantage of 
shortening the follow-up period of patients with low risk of failure (Mumba Ngoyi et al., 
2010). Since normalisation of CSF values is generally slow, the use of the PCR technique 
for earlier detection of relapses by mean of trypanosome DNA amplification is strongly 
advocated (Truc et al., 1999). 
1.2.8 Diagnosis of drug resistance 
HAT treatment is complex for a number of reasons: need for hospitalisation, toxicity, 
stage-specificity and high costs of the drugs are all major issues in endemic countries. 
Moreover, the loss of efficacy of melarsoprol (the drug most used to treat the second stage 
of the Gambian form and the only one available for late stage T. b. rhodesiense infection) 
has become a pressing problem. In recent years the number of melarsoprol treatment 
failures has increased to alarming levels in some areas, reaching values of 30% in Uganda 
(Legros et al., 1999). Drug resistance of some trypanosome strains to melarsoprol has been 
indicated as an important cause for these chemotherapic failures in individuals infected 
with T. b. gambiense (Brun et al., 2001; Matovu et al., 2001a), but other factors may 
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individuals (Legros et al., 1999). A major problem for drug resistance study is the difficult 
isolation and propagation of trypanosomes from relapsing patients, thus limiting the 
number of samples available for successive in vitro and in vivo drug sensitivity tests in the 
laboratory (Brun et al., 2001; Section 1.2.3.7). 
Various mechanisms, affecting both drug levels inside the parasite and the drug target(s), 
can contribute to reduced sensitivity to trypanocidal compounds (Barrett and Fairlamb, 
1999; Mäser et al., 2003). Resistance to melaminophenyl arsenicals and diamidines has 
been, at least partially, ascribed to altered activity of the T. brucei P2 amino-purine 
transporter involved in their uptake (Carter and Fairlamb, 1993; Barrett and Fairlamb, 
1999; Mäser et al., 1999; Delespaux and de Koning, 2007). The loss of P2 function was 
found responsible for diminished internalisation of these classes of compounds and 
multidrug resistance onset (Barrett and Fairlamb, 1999). Increased drug export through 
over-expression of a T. brucei multidrug-resistance protein, called MRPA, has also been 
found to cause melarsoprol-resistance in vitro, but data were not supported in vivo (Alibu 
et al., 2006). Instead, mutations in the TbAT1 gene, which encodes for the P2 transporter, 
have been identified in resistant trypanosomes both in laboratory strains and field isolates 
(Mäser et al., 1999; Matovu et al., 2001a). The use of a PCR/SfaNI RFLP technique (PCR 
amplification of the TbAT1 gene followed by analysis of the restriction fragment length 
polymorphism for SfaNI) allowed identification of mutated forms of the transporter, but 
this method was not able to identify all resistant strains, since many of them had a wild 
type sequence of the TbAT1 gene (Mäser et al., 1999; Matovu et al., 2001b). Deletion of 
the whole TbAT1 gene is also a rare, but possible, event in field isolates (Matovu et al., 
2001b). The treatment of patients infected with strains less sensitive to melarsoprol has 
both the consequences of unnecessarily exposing them to the highly toxic side effects of 
the arsenical compound and of contributing to the maintenance of the alleles associated 
with resistance in the trypanosome population (Kazibwe, 2008). In a recent paper, 
Kazibwe and colleagues showed how the withdrawal of melarsoprol as first-line drug in a 
focus with high levels of treatment failures correlated with disappearance of mutant alleles 
in the trypanosome isolates, identified with the PCR/SfaNI RFLP technique (Kazibwe et 
al., 2009). This study demonstrates the potential benefits of drug resistance tests for 
treatment decision making and rational management of HAT in resource-poor settings. 
In our laboratory, a rapid and easy fluorescent test able to identify resistance to arsenical 
and diamidine drugs, by exploiting altered activity of the P2 transporter in resistant strains, 
was developed (Stewart et al., 2005). The test utilises the diamidine DB99 [2,5-bis(4-Federica Giordani, 2010    Chapter 1, 31 
amidinophenyl)-3,4-dimethylfuran], which is actively transported by trypanosomes 
through the P2 permease and accumulates in DNA-containing organelles (nucleus and 
kinetoplast). DB99 is intrinsically fluorescent and its internalisation inside parasites can be 
monitored using a standard fluorescence microscope (lEX=330 nm, lEM=400 nm). The test 
was proven able to discriminate between various sensitive (stained) and resistant 
(unstained) strains in mice blood, both from in vitro culture and field isolates, if exposure 
to the drug was kept inferior to 1 minute. 
1.3 Diagnosis of T. b. rhodesiense infection 
T. b. rhodesiense causes an acute, febrile form of HAT in east Africa and can lead to death 
of the patient within months (Barrett et al., 2003). The parasite is harboured in a wide 
animal reservoir (Smith et al., 1998; Stich et al., 2002), infected livestock representing a 
major cause of maintenance and spread of the disease (Hutchinson et al., 2003; Picozzi et 
al., 2005). Before the advent of molecular technologies, the immune trypanolysis test 
(Rickman and Robson, 1970; Van Meirvenne et al., 1995) had been the only tool to 
discriminate between human infective (mainly T. b. rhodesiense) and non-infective 
trypanosome species isolated from animals and it was widely used for epidemiological 
purposes. 
For diagnosis of T. b. rhodesiense an effective serological tool, equivalent to the CATT, is 
still lacking and is difficult to envisage due to the higher degree of VSG variability than in 
T. b. gambiense (Louis et al., 2001). Case-detection for Rhodesiense trypanosomiasis is, 
therefore, based on passive surveillance (Hutchinson et al., 2003) and initial diagnosis 
relies on clinical symptoms (Garcia et al., 2006). For T. b. rhodesiense infection biological 
parameters are generally more abnormal than for T. b. gambiense form, including severe 
anaemia, liver dysfunction, thrombocytopenia and cardiac failure that often causes the 
death of the patient (Lejon and Büscher, 2005). On the contrary, the neurological 
symptoms typical of the Gambian disease are not frequent in Rhodesiense trypanosomiasis 
and a clear distinction between first and second stage is more difficult to determine 
(Kennedy, 2006a). Parasitological confirmation and staging are based on the same methods 
used for T. b. gambiense disease but, since T. b. rhodesiense infection presents a high and 
persistent parasitaemia, the detection of the parasites is relatively easy (Kennedy, 2008) 
and direct examination of thin or thick blood smears or lymph node aspirate is usually 
sufficient (Smith et al., 1998). More sophisticated assays like ELISA and PCR are 
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1.4 African animal trypanosomiasis 
African animal trypanosomiasis (also called nagana) represents a major obstacle to 
livestock production and, therefore, to the development of the rural areas of the continent, 
with a loss estimated at more than $ 1,000 million annually (Kristjanson et al., 1999). The 
disease is mainly caused by three tsetse-transmitted trypanosome species, Trypanosoma 
congolense, Trypanosoma vivax and, at lesser extent, Trypanosoma brucei ssp., which 
infect or co-infect both domestic and wild mammals. Animal trypanosomes are not 
infective to humans because they are susceptible to lysis by the trypanolytic factor present 
in human serum (Pays and Vanhollebeke, 2008). Once injected into the mammalian host, 
T. congolense and T. vivax do not usually leave the blood vessels, even if they can cause 
tissue lesions, while T. brucei can cause cerebral infection (Naessens, 2006). Typical 
clinical features in cattle are fever, anaemia, and immunosuppression, with gradual loss of 
weight and emaciation that usually leads to death of the animal through heart failure. Some 
local bovine breeds are able to control anaemia and parasitaemia and remain productive 
after having contracted trypanosomiasis: a phenomenon defined as trypano-tolerance 
(Naessens, 2006). 
Control of the disease relies on the use of insecticides applied to animals to protect them 
from tsetse bites and on chemotherapy/chemoprophylaxis. Three compounds are used for 
treatment of nagana, independently of the infecting species: diminazene aceturate (a 
diamidine), homidium (the phenanthridine ethidium) and isometamidium (a hybrid 
molecule from ethidium and diminazene). Isometamidium is also used as a prophylactic 
agent (Leach and Roberts, 1981; Connor, 1992). All of these drugs have toxic effects on 
animals and cross-resistance of isometamidium with homidium and, to a lesser extent, with 
diminazene, limits their efficacy (Codjia et al., 1993; Peregrine et al., 1997; Afewerk et al., 
2000; Delespaux and de Koning, 2007). The identification of new molecular markers is 
currently under study to improve drug resistance diagnosis and substitute conventional 
field and laboratory tests, which are laborious and expensive (Delespaux et al., 2008). 
Diagnostic techniques used for detection of animal trypanosomes are essentially the same 
as those applied to humans (Molyneux, 1975; Leach and Roberts, 1981; Connor, 1992) and 
the problems encountered are similar (Uilenberg, 1998). The diagnosis is usually carried 
out on blood samples, while lymph node aspirate is less used and CSF is examined only 
exceptionally. The “gold standard” in the field to detect and differentiate animal 
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represented by the cheap light microscopy examination of wet or dry thin and thick blood 
smears (Connor, 1992). However, as for human African trypanosomiasis, this approach is 
highly insensitive and laborious due to the very low levels of parasitaemia in chronic 
infected animals. For wet preparations, the buffy coat under phase contrast illumination 
(Murray et al., 1977) is the most sensitive technique. Serological techniques like ELISA 
and IFAT are widely used but only for surveillance purposes (Eisler et al., 1998; Reyna-
Bello et al., 1998; Ezeani et al., 2008), as well as new PCR methods, which allow 
differentiation between clinically important species and subspecies (Cox et al., 2005; 
Picozzi et al., 2002 and 2008). 
1.5 Need for new diagnostics 
The fact that so many diagnostic methodologies have been applied and proposed for 
sleeping sickness is a demonstration that none of them meets all the requirements of an 
ideal test with regard to simplicity, efficiency, rapidity and low cost. Despite the crucial 
importance of correct diagnosis for disease management in developing countries, relatively 
limited resources are invested in microbial diagnostics, which remains, together with drug 
research, particularly neglected (Checchi et al., 2006; Perkins and Small, 2006; 
Anonymous, 2007). Several international organisations are trying to address the issue. 
WHO, with its programme for Research and Training in Tropical Diseases (TDR), has set 
up a network to facilitate research and introduction of new diagnostic tests (Remme et al., 
2002). More significantly, a public-private partnership named FIND (Foundation for 
Innovative New Diagnostics, http://www.finddiagnostics.org/), was launched in 2003 to 
fill this gap by promoting the introduction of new products for diagnosis of infectious 
diseases (such as LAMP, the loop-mediated isothermal amplification of DNA) and by 
implementation of those already existing (Steverding, 2006; WHO, 2006a). The FIND 
commitment to HAT is aimed at the improvement of both serological and parasitological 
techniques. Concrete results of these efforts have been the development of a new 
concentration method by lysis of the red blood cells and a new improved kit for mAECT, 
now produced in the Democratic Republic of Congo and marketed in the other endemic 
countries (Büscher et al., 2009). However, as already mentioned (Section 1.2.3.5), the 
mAECT is not ideal and new possibilities have to be explored. For example, since the real 
bottleneck of HAT diagnosis is represented by the low sensitivity of the confirmatory step 
by light microscopy, its improvement by the use of fluorescence microscopy could bring 
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1.6 Fluorescence microscopy for diagnosis of infectious 
diseases 
Light microscopy has always represented the cornerstone of laboratory diagnosis of 
infectious blood and tissue parasites, but, despite the minimal amount of equipment 
required, the low concentration of organisms and their difficult differentiation hamper this 
procedure (Rosenblatt, 2009). In recent years, fluorescence microscopy applications have 
been expanding in many fields of biological research as well as clinical pathology and 
medical diagnosis, becoming one of the most powerful tools for high contrast imaging 
(Lichtman and Conchello, 2005; Yuste, 2005). Compared to traditional light microscopy, 
this technology can offer equal simplicity but higher specificity, sensitivity and rapidity of 
screening and, for these reasons, it has been increasingly exploited for infectious disease 
diagnosis and monitoring (Sanborn et al., 2005). 
The avalability of more affordable instrumentation has allowed the use of fluorescence 
techniques also in countries with little resources, where it has been successfully utilised to 
improve diagnosis of various infections, including tuberculosis and malaria, which 
otherwise still rely on light microscopy of stained films. A systematic review of numerous 
studies on the subject demonstrated that fluorescence microscopy for tuberculosis 
diagnosis was on average 10% more sensitive than classical sputum smear light 
microscopy and equally specific (Steingart et al., 2006). The detection of Mycobacterium 
tuberculosis by auramine O or auramine-rhodamine staining, by enabling microscopists to 
use lower magnifications, also decreased the time needed for smear examination. 
Moreover, auramine O labelling of the specimens is a simpler procedure than the standard 
Ziehl-Neelsen technique (Hendry et al., 2009; Minion et al., 2009). For the diagnosis of 
malaria the same advantages of rapidity and efficacy of fluorescence techniques over 
classical tools (Giemsa-stained blood smears) have been observed (Keiser et al., 2002). 
Both the use of acridine orange for direct staining of blood films (Delacollette and Van der 
Stuyft, 1994; Kong and Chung, 1995; Gay et al., 1996) or in association with the 
quantitative buffy coat (Wongsrichanalai et al., 1991) and the combination of DAPI and 
propidium iodide (Caramello et al., 1993) proved useful, especially for the detection of low 
levels of parasitaemia. A dual staining method for malaria, using a fluorescent dye (SYBR 
Green I), to rapidly detect parasites within red blood cells, and Giemsa, for speciation, has 
also been developed (Guy et al., 2007). The implementation of fluorescence microscopy 
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various problems principally related to a lack of resources, inconsistent electricity supplies 
and the instability of microscopy reagents (Keiser et al., 2002; Steingart et al., 2006). 
Moreover, trained microscopists are needed to distinguish non-specific fluorescent staining 
of debris and the microorganisms for diagnosis (Shapiro and Perlmutter, 2008). The high 
cost and fragility of fluorescent microscopes and their light sources is also a major issue 
(Delacollette and Van der Stuyft, 1994; Hänscheid, 2008). To address this problem a more 
affordable interference filter, specific for acridine orange, to be mounted on normal light 
microscopes was designed for malaria diagnosis (Kawamoto, 1991; Delacollette and Van 
der Stuyft, 1994). The current development of new light sources for fluorescence that 
exploit light-emitting diode (LED) technology (Section 1.6.3), offers considerable promise 
towards the availability of more affordable and simple fluorescence microscopes suited for 
field use (Marais et al., 2008). 
1.6.1 The fluorescence process 
Fluorescence is a property of a small number of molecules called fluorophores or 
fluorochromes, which generally contain polyaromatic hydrocarbons or heterocycles in their 
chemical structure. Fluorochromes include various organic dyes (like fluorescein or 
rhodamine) extensively used for labelling of molecules, cells, and tissues (Suzuki et al., 
2007; Gonçalves, 2009). An increasing number of fluorescent genetically-encoded proteins 
(such as the green fluorescent protein, GFP) are today available and utilised in protein 
localisation and gene expression studies in living cells (Chalfie et al., 1994; Shaner et al., 
2004). Fluorophores are able to absorb light with a specific energy and re-emit it at longer 
wavelengths as fluorescence following a three step process (Lichtman and Conchello, 
2005; Figure 1.6). Initially, the fluorophore absorbs a photon of energy hnEX emitted by an 
external source (such as an incandescent lamp or laser) that allows one of its electrons to 
pass from its ground state S0 to an excited outer orbital (S1’). Conjugated double bonds 
present in these molecules can distribute excited electrons, so that the energy necessary for 
their excitation is relatively low. During the brief period of time (measured in picoseconds) 
in which the fluorophore exists in its excited state, it can undergo internal conversions, 
vibrational relaxation and it can interact with its molecular environment. These events 
have, as a consequence, a partial dissipation of its energy, yielding a relaxed singlet excited 
state (S1). Finally the fluorophore spontaneously returns to its ground state S0 by emitting a 
photon hnEM with a lower energy (and, therefore, a longer wavelength) than the excitation 
photon, because of the energy dissipation that occurred during the excited-state lifetime. Federica Giordani, 2010    Chapter 1, 36 
 
Figure 1.6 – Diagram illustrating the fluorescence process. 
After absorption of a light photon (hn n n nEX), an electron of the fluorophore is excited form the 
ground state (S0) to an outer orbital (S1’). Here, a partial energy dissipation of the excited 
state occurs and the electron is converted into a lower excited state (S1). Finally, the 
fluorophore returns to the ground state by emitting, as fluorescence, a photon hn n n nEM with 
lower energy than the excitation photon (see Section 1.6.1 for more details).       
For molecules in solution, the different discrete electronic transitions give rise to energy 
spectra of excitation and emission, which generally have mirror symmetry (Lichtman and 
Conchello, 2005). Under the same conditions, the wavelength of the emitted light is not 
related to the excitation wavelength and its intensity is proportional to the amplitude of the 
fluorescence excitation spectrum. The difference between the exciting and the emitted 
wavelength, called the Stokes shift, is fundamental to the sensitivity of fluorescence 
techniques, allowing the detection of emitted light against a low background, isolated from 
the excitation one. The high sensitivity is also a consequence of the fact that each 
fluorophore can generate thousands of photons and that they can be cyclically excited and 
detected, unless irreversibly damaged in the excited state (photobleaching phenomenon). 
Photobleaching (Chapter 3) is defined as the chemical destruction of a fluorescent 
molecule as a result of its excitation (Petty, 2007) and must not be confused with 
quenching, which is a reversible loss of fluorescence caused by non-covalent interactions 
between the fluorophore and its environment. 
The fluorescent signal of a fluorophore depends on its absorption and emission 
efficiencies, which are respectively quantified in terms of molar extinction coefficient (e) 
and quantum yield (QY). The value of e is specified for the absorption maximum 
wavelength and represents the probability that the molecule will absorb a photon. Typical 
e values for small fluorophores are comprised between 25,000 to 200,000 M
-1 cm
-1. The 
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fluorescence spectral range and, therefore, of the efficiency with which the absorbed light 
produces fluorescent emission. High fluorescent intensities are obtained for QY close to 1. 
Fluorescence intensity for a given fluorophore is proportional to the product of e and QY 
(Lichtman and Conchello, 2005). 
1.6.2 The fluorescence microscope 
The basic parts of a fluorescence microscope include a high intensity light source to excite 
the fluorophore and a series of filters to select photons of the excitation wavelength and to 
separate them from the light emitted by the fluorophore (Lichtman and Conchello, 2005). 
A detector (usually a digital CCD camera) is needed to collect emitted photons and convert 
them to a recordable output signal (Petty, 2007). The most commonly used light source is a 
low-pressure mercury (or xenon) arc lamp, where the ionization of the gas is obtained by a 
high voltage current. Since these lamps emit in a wide range of wavelengths across the 
visible spectrum (380-750 nm), an excitation filter to preselect the excitation wavelength 
and block all others is required. In epifluorescent microscopes (the most efficient and 
widely used) (Figure 1.7) a dichromatic (also called dichroic) beamsplitter mirror, then, 
reflects the excitation light into the objective while allowing the emitted light, at higher 
wavelength, to pass through. In this system the objective has not only a function of 
imaging and magnification of the specimen, but also of condenser for the excitation light. 
A secondary barrier filter is usually present to prevent any scattered excitation light from 
reaching the eyepiece (Sanborn et al., 2005). In modern fluorescence microscopes barrier 
filters and dichromatic mirror designed for a particular spectral range are all contained in a 
holder, called filter cube. 
Despite the great improvements in optics and detection devices, the illumination sources 
used for fluorescence (mercury and xenon arc lamps) have, until recently, not advanced 
(Cole and Turner, 2008). Apart from their high purchase and operational costs, 
conventional gas discharge bulbs have other technical drawbacks: their broad-spectrum 
emission has wide, uncontrolled intensity variations and high quantities of dangerous UV 
radiation, which can not be completely shielded by blocking filters, is emitted. Moreover, 
these bulbs require several minutes to reach optimal intensity, they produce high amounts 
of heat and their lifespan is short (200-300 hours). In the case of mercury bulbs, 
environmental problems of disposal must also be taken into account (Anthony et al., 2006; 
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Figure 1.7 – Schematic illustration of the light path of an epifluorescence microscope. 
Epifluorescence microscopy utilises the objective both to focus the excitation light on the 
specimen and to collect the emission signal. This technique is preferred to transmitted 
fluorescence (where the excitation light passes through the specimen) because it produces 
a better contrast. In this figure, a LED light source is used, but the same principles are valid 
for traditional mercury or xenon arc lamps. 
(Reproduced with permission from Jones et al., 2007). 
1.6.3 Light-emitting diodes (LEDs) for fluorescence microscopy 
Today, a new generation of microscopes or light source modules, based on light-emitting 
diodes (LEDs), are available both for transmitted light and fluorescence imaging (Jones et 
al., 2005 and 2007; Hänscheid, 2008; Minion et al., 2009). LEDs are small semiconductor 
diodes of different chemical composition, which determine the wavelength of the 
monochromatic light, usually limited to a narrow (15 nm) band of emission (Petty, 2007). 
The numerous advantages that these new illumination sources have over conventional 
fluorescent vapour arc lamps have been pointed out by several authors (Cole and Turner, 
2008; Lang et al., 2008; Shapiro and Perlmutter, 2008; Robertson et al., 2009). LEDs are 
very efficient in terms of converting electricity at low voltage to light and have a very long 
lifespan (up to 50,000 hours). By being roughly monochromatic, they do not generate UV 
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disadvantage, since it limits the number of fluorophores that can be used (Anthony et al., 
2006). The diodes produce only minimal heat, are smaller than classical bulbs and they are 
easier to use: they do not need lamp adjustment, in theory they do not need excitation 
filters and can be repeatedly turned on and off directly without the need of a shutter. All of 
these characteristics make LEDs a very cheap and convenient light source for fluorescence 
applications: their cost is less than 10% of the price of a mercury vapour bulb (Anthony et 
al., 2006). Moreover, since LEDs need only a low voltage power supply, they can be run 
on batteries, a crucial aspect for their use in resource-poor settings. However, since LEDs 
emit photons in all directions, capturing enough light for microscopy is problematic and 
only some of them are sufficiently intense to be exploited for fluorescence applications 
(Cole and Turner, 2008). 
The benefits offered by LED technology have already been tested for diagnostic purposes. 
The simple substitution of traditional light sources with LEDs has proven successful for 
detection of malaria parasites (Guy et al., 2007) and auramine O-stained Mycobacterium 
tuberculosis, giving sharp, even and highly contrasted images (Anthony et al., 2006; Hung 
et al., 2007). LED fluorescence microscopy was shown to be equally sensitive to classical 
mercury lamp source microscopy on sputum specimens (Marais et al., 2008). Shapiro and 
Perlmutter showed the possible application of this new technology to the development of a 
simple and robust fluorescence image cytometer for malaria and tuberculosis diagnosis 
(Shapiro and Perlmutter, 2008). Some studies also reported that the examination of 
samples with LED-illuminated microscopes was still possible in an environment that was 
not completely darkened (Hung et al., 2007; Marais et al., 2008). A recent collaboration 
between FIND and the Zeiss group for the development of a new, affordable LED-driven 
microscope for high burden countries is the latest validation of this new technology for 
diagnosis of infectious diseases (http://www.finddiagnostics.org/). 
1.6.4 Fluorescent probes for trypanosomes 
One of the main difficulties encountered in HAT diagnosis is the direct observation of 
parasites in blood when using light microscopy, given the low numbers of parasite 
generally found in infected individuals. A possible way to raise the sensitivity could be to 
label trypanosomes with fluorochromes, so that they are more easily detectable among 
other blood cells by using a fluorescent microscope. Some fluorescent applications 
designed to improve diagnosis of African trypanosomiasis have already demonstrated to be 
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the quantitative buffy coat technique (Bailey and Smith, 1992; Section 1.2.3.6), or the 
more sophisticated fluorescein-labelled peptide nucleic acid probes developed for in situ 
detection in the PNA FISH technique (Radwanska et al., 2002c; Section 1.2.4.5). Non-
specific staining of dyes like acridine orange can represent a problem since other human 
cells in the sample (especially white blood cells) can become fluorescent. The very 
different morphology between trypanosomes and white blood cells, however, allows easy 
differentiation. Many other studies on trypanosomes have used fluorescence microscopy 
for research purposes, by taking advantage of the innate fluorescence of various 
trypanocidal drugs and related compounds, or by adding specific fluorescent groups to 
non-fluorescent molecules to study their internalisation and localisation inside parasites. 
Azema and collaborators labelled hexoses with a fluorescent adduct (dansyl group) to track 
their accumulation inside trypanosomes through the THT1 hexose transporter (Azema et 
al., 2004). They demonstrated that dansylated hexoses cross the membrane of bloodstream 
form parasites without labelling erythrocytes, despite the fact that their internalisation 
seemed non-specific. This was probably because fluorescence within red cells was 
quenched due to the high concentration of haemoglobin in their cytoplasm. A similar 
approach was followed by other authors to study differential uptake of fluorescent 
compounds into wild type and melarsoprol- or pentamidine-resistant cells: fluorophores 
like DAPI and Hoechst 3342 (both diamidines), ethidium bromide (a phenanthridine 
trypanocidal) and acriflavine (an acridine) were all shown to accumulate at higher rates in 
sensitive cells than in resistant strains (Frommel and Balber, 1987; Bridges et al., 2007). 
Intrinsic fluorescence of the trypanocides isometamidium, ethidium bromide and the 
analog propidium was also exploited to identify their intracellular targets by microscopy 
(Cox et al., 1984; Boibessot et al., 2002). Identically, accumulation and localisation of 
various fluorescent diamidine compounds, including DB75, were extensively studied by 
microscopy (Sturk et al., 2004; Mathis et al., 2006; Lanteri et al., 2008). A work conducted 
in our laboratory by Stewart and collaborators exploited the slower accumulation of 
diamidines in melarsoprol-resistant strains to develop a simple fluorescent arsenical drug 
resistance test (Stewart et al., 2005; Section 1.2.8 and Chapter 3). 
1.7 Aim of this thesis 
The overall objective of this project was to develop new tools to assist in the diagnosis of 
African trypanosomiasis and to improve the current test for drug resistance detection by 
exploiting LED fluorescence microscopy. Starting from the arsenical drug resistance assay 
designed in our laboratory (Stewart et al., 2005), we explored its validity using a  Federica Giordani, 2010    Chapter 1, 41 
 
Figure 1.8 – The prototypical SMR portable LED fluorescence microscope (Cytoscience). 
This compact microscope has a standard epifluorescence design (see Figure 1.7) and 
utilises a 472 nm excitation LED light source. Technical details are in Section 2.5.4.2. 
(Reproduced with permission from Jones et al., 2007). 
microscope equipped with a UV LED light instead of the traditional mercury arc used by 
Stewart and collaborators. A large part of the work was, then, focused on the evaluation of 
various chemical fluorescent probes for their ability to selectively enter and label 
trypanosomes, in order to identify valid compounds to use in the design of a more effective 
fluorescence field diagnostic test. Prof. D. Jones (Philipps University, Marburg, Germany) 
collaborated with the project by providing the UV LED prototype and the Cytoscience 
SMR LED epifluorescence microscope (Jones et al., 2005), a very compact, high 
resolution instrument designed for field use (Figure 1.8). The SMR scope, in addition to 
having relative low cost (~1,000 €) compared to traditional fluorescence microscopes, is 
battery-driven and is sealed against dust and water (Jones et al., 2007). We deliberately 
avoided the use of expensive fluorophores present on the market including, for example, 
fluorescently tagged antibodies, and focused on more affordable chemical dyes that were 
compatible with the range in which the Cytoscience microscope operates (λEX=472 nm, 
λEM>500 nm). Nevertheless, since LED sources are today available for nearly all 
wavelengths across the visible spectrum, and appropriate devices could eventually be 
developed, we also tested some fluorochromes excited outside the range covered by the 
Cytoscience instrument, utilising a standard epifluorescence microscope. Some of the 
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molecules kindly provided by Prof. D. W. Boykin (Georgia State University, Atlanta, 
USA), or personally synthesised in collaboration with Dr. A. Sutherland’s group 
(University of Glasgow, Glasgow, UK). Particular attention was paid to the ability of the 
fluorochromes to yield a bright, specific and stable signal, all important requirements when 
considering the use of fluorescence for field diagnostics. 
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2.1 T. b. brucei in vitro culture 
Non-human infective T. b. brucei bloodstream forms (monomorphic Lister 427 strain wild 
type and derived lines) were cultured in HMI-9 medium (Gibco, Appendix A) including 
10% heat-inactivated foetal calf serum at 37°C in a humidified, 5% CO2 environment 
(Hirumi and Hirumi, 1994). An aliquot of cells (1-2×10
5 cells/ml) was subpassaged in 
fresh medium every 48 h, when parasites had reached the mid-log phase concentration of 
approximately 2×10
6 cells/ml. The bloodstream form 449 line (kind gift of Dr. Christine 
Clayton, University of Heidelberg), a wild type line stably expressing the tetracycline 
repressor from the integrated pHD449 plasmid (Biebinger et al., 1997), was cultured in 
HMI-9 plus 10% FCS, including 0.2 mg/ml phleomycin. To maintain the culture as stable 
as possible, the same cell aliquot was subpassaged for a maximum of 30 times and then 
substituted with a new one. All cell line stabilates were maintained in liquid nitrogen in a 
freezing medium (HMI-9) containing 10% glycerol. 
2.2 Cell line genotyping 
All bloodstream T. b. brucei cell lines used during the experiments were regularly checked 
by PCR. The presence of four genetic markers was assessed: TbAT1, the gene encoding the 
P2 amino-purine transporter present in T. b. brucei S427 wild type (Mäser et al., 1999); the 
genes for neomycin resistance (NEO) and puromycin resistance (PAC), the selective 
markers used to replace both alleles of the TbAT1 gene in the tbat1
-/- line (Matovu et al., 
2003) and also present in tbat1
-/--derived lines; actin (ACT), as a positive internal control. 
Primer sequences for the four markers are shown in Table 2.1. 
Sequence 
amplified   Primer pair   Primer sequence 
MB183 (f)  5’-GACTGTCGACATGCTCGGGTTTGACTCAGCC-3’  TbAT1 
MB184 (r)  5’-GACTCTGCAGTAGTGCTACTTGGGAAGCCCC-3’ 
MB37   (f)  5’-ATGATTGAACAAGATGGATTGC-3’  NEO 
MB38   (r)  5’-TCAGAAGAACTCGTCAAGAAG-3’ 
MB308 (f)  5’-ATGACCGAGTACAAGCCCACGG-3’  PAC 
MB309 (r)  5’-TTGCGGGTCATGCACCAGGT-3’ 
MB173 (f)  5’-CCGAGTCACACAACGT-3’  ACT 
MB174 (r)  5’-CCACCTGCATAACATTG-3’ 
Table 2.1 – Oligonucleotides used for cell line genotyping. 
NEO: neomycin resistance gene; PAC: puromycin resistance gene; ACT: actin; (f): forward; 
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TbAT1, NEO and ACT were usually amplified all together in a multiplex PCR reaction 
containing 2× PCR Master Mix buffer (Thermo Scientific), 0.1 mM of each primer, 1.25 U 
GoTaq
® DNA polymerase (Promega) and template gDNA (0.5-1 ng/ml final concentration) 
extracted from cells grown in vitro using the DNeasy
® Blood and Tissue Kit (Qiagen), 
following manufacturer’s instructions. Negative controls (without any DNA) were always 
included. 
Cycling conditions of the multiplex PCR for TbAT1, NEO and ACT were as follow: 
1- Polymerase activation  94°C for 5 min 
2- Denaturation    94°C for 1 min 
3- Annealing      55°C for 1 min 
4- Extension      65°C for 4 min 
5- Repeat steps 2-4    35 cycles 
5- Final extension    65°C for 8 min 
PAC was amplified in a single marker PCR reaction. The mastermix was prepared as 
described above for the multiplex reaction but using 1× PCR Master Mix buffer. 
Cycling conditions for PAC were the following: 
1- Polymerase activation  95°C for 1 min 
2- Denaturation    94°C for 30 sec 
3- Annealing      60°C for 30 sec 
4- Extension      72°C for 1 min 
5- Repeat steps 2-4    35 cycles 
5- Final extension    72°C for 2 min 
PCR products were separated on a 1% agarose gel and visualised with SYBR
® Safe DNA 
gel stain (Invitrogen) under a UV light transilluminator (UVP Inc.). 
2.2.1 Retrieval of DNA from FTA
® card for PCR analysis 
Occasionally, gDNA was extracted from samples absorbed to FTA
® cards (Whatman, GE 
Healthcare). Cards were prepared both for in vitro culture genotyping and, especially, for 
PCR testing of trypanosomes in blood, to check for the presence or absence of the TbAT1 
gene. Each card was spotted with 50-100 ml of the sample (trypanosomes in medium or Federica Giordani, 2010    Chapter 2, 46 
blood), air-dried and kept at 4°C until use. Small card disks, cut using a punch tool, were 
thoroughly washed in 200 ml FTA purification reagent (Whatman, GE Healthcare) 3 times 
at r.t. (5 min per wash). Disks were then washed twice in 200 ml TE buffer (Appendix B) 
for 5 min and finally dried for at least 1 h at r.t.. For PCR reaction, the disk was directly 
immersed in the mastermix solution. TbAT1 was successfully amplified from blood 
samples absorbed on FTA
® cards using a reaction solution containing 1× PCR buffer 
(Promega), 0.1 mM of each primer, 1.25 U GoTaq
® DNA polymerase (Promega), 2.5 mM 
MgCl2 and 0.3 mM dNTPs. 
For TbAT1 amplification from FTA
® cards cycling conditions were as follow: 
1- Polymerase activation  94°C for 2 min 
2- Denaturation    94°C for 1 min 
3- Annealing      55°C for 1 min 
4- Extension      72°C for 90 sec 
5- Repeat steps 2-4    30 cycles 
5- Final extension    72°C for 2 min 
2.3 Trypanosome-infected blood samples 
Monomorphic bloodstream form trypanosomes were grown in vivo either in adult ICR 
Swiss and BALB/c female mice or Wistar female rats. Due to the high number of blood 
samples needed during this project, for routine ex-vivo fluorescence microscopy 
experiments we decided to use the discarded rat blood left after elimination of the buffy 
coat, which is often used for uptake assays in our laboratory. This had the double 
advantage of avoiding the sacrifice of too many animals and of obtaining a blood sample 
with, ideally, a not excessively high parasitaemia. Nevertheless, elimination of the buffy 
coat containing the trypanosomes also removed the white blood cells from the sample and, 
therefore, whole blood infected samples (usually from mice) were also used. 
For growth in mice, 1×10
6 parasites of the cell line under study were injected 
intraperitoneally. Parasitaemia was monitored daily by tail-prick blood examination. At 
peak parasitaemia (1-2×10
8 parasites/ml, 3-4 days post-infection), infected blood was 
collected by cardiac puncture in a tube containing CBSS (Appendix B) and heparin and 
kept ice-cold until use without any other processing. Aliquots of the infected blood were 
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Wistar rats were inoculated with 8×10
6 trypanosomes and parasitaemia was checked daily, 
as for mice. Parasites were harvested at peak parasitaemia by cardiac puncture. The 
collected blood sample was centrifuged at 1,300×g for 15 min at 4°C to separate the buffy 
coat (used in other experiments in the laboratory). The upper layer of plasma was 
transferred to a new tube and mixed again with the lower layer containing the red blood 
cells. Fresh aliquots of this new blood sample, from which most parasites were eliminated, 
were incubated ex-vivo with the appropriate fluorochrome and used for fluorescent 
microscopy experiments. 
The rat blood buffy coat containing concentrated trypanosomes obtained after 
centrifugation was further purified to prepare protein samples for Western blot (Chapter 6). 
Parasites were resuspended 1:1 in PSG buffer at pH 8 (Appendix B) and separated from 
blood cells by anion exchange chromatography, using a DE52 cellulose column. The 
eluted trypanosomes were collected in a 50 ml polypropylene falcon tube and washed 
twice (1,300×g, 10 min) in CBSS to eliminate every residue of PSG buffer. Parasites were, 
then, counted on a haemocytometer and resuspended at 1×10
8 cells/ml in CBSS. Protein 
extraction protocols are described in Section 2.7.7. 
2.4 Alamar Blue assay 
Trypanotoxicity of target compounds on different T. b. brucei cell lines was assessed by 
the Alamar Blue assay (adapted from Räz et al., 1997). Bloodstream form trypanosomes 
(100 ml at 4×10
4 cells/ml) were added to each well of a 96-well flat-bottomed white plate, 
where doubling serial dilutions of the test compounds (100 mM - 0.024 nM) had been 
previously prepared in a volume of 100 ml HMI-9. After 48 h incubation at 37°C and 5% 
CO2, 20 ml of Alamar Blue solution (resazurin sodium salt from Sigma-Aldrich; 0.49 mM 
in 1× PBS, pH 7.4) were added to each well, and plates were incubated for further 24 h. 
The reduction of the blue reagent to a colourless form by living parasites was measured 
with a FLUOstar OPTIMA fluorimeter (BGM Labtech) using a 544 nm excitation 
wavelength and a 590 nm emission wavelength. Fluorescence data were plotted as a 
function of drug concentration using the IC50 algorithm of Prism 5.0 software (GraphPad) 
to obtain inhibitory concentrations (50% fluorescence reduction). Untreated cells were 
used as negative control and known trypanocidal drugs, such as pentamidine, as positive 
control. All experiments were carried out in duplicate and repeated on at least three 
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2.5 Microscopy techniques 
2.5.1 Fluorophores 
Fluorescent compounds were obtained both from academic laboratories and from various 
commercial sources. DB75 dihydrochloride salt (Chapter 3), the five green fluorescent 
diamidines DB1464, DB1465, DB1645, DB1680 and DB1692 (Chapter 4) and the dansyl 
derivative diamidine DB1919 (Chapter 5) were kindly provided by Prof. D. W. Boykin 
(Georgia State University, Atlanta). DAPI dihydrochloride (Chapter 3), ethidium bromide 
and acridine orange (Chapter 4) were purchased from Sigma-Aldrich. Propidium iodide 
was supplied by Molecular Probes (Invitrogen). Pure isometamidium (May and Baker 
4180; Chapter 4) was a gift from Mr. Brian Cover (University of Kent, Canterbury). I 
personally synthesised the amino acid derivatives FG10, FG70 and FG400 in Dr. A. 
Sutherland’s chemistry laboratory (University of Glasgow) (Chapter 5). 
Stock solutions of the five green fluorescent diamidines synthesised in Prof. D. W. 
Boykin’s laboratory and of DB75 were prepared at 10 mM in DMSO (2.5 mM for 
DB1680). DB1919 stock solution was at 20 mM in DMSO. Stocks of ethidium bromide, 
propidium iodide and isometamidium chloride were at 10 mM in 1× PBS. Acridine orange 
stock was prepared at 17 mM in dH2O and DAPI at 50 mM in dH2O. The three amino acid 
derivatives were solubilised at 10 mM in DMSO (methanol for FG10). Aliquots of stock 
solutions were kept at -20°C protected from the light. 
2.5.2 In vitro trypanosome samples for fluorescence microscopy 
2.5.2.1  Fluorescent staining and sample preparation 
Live trypanosomes from culture (2×10
7 cells/ml) were treated, at the desired temperature, 
with the test concentration of fluorochrome, in 1.5 ml Eppendorf tubes (for treatment times 
up to 4 h) or, for longer times of incubation, in 24-well plates (kept at 37°C in a 
humidified, 5% CO2 environment). Wet films of stained live parasites in culture medium, 
or resuspended in 1× PBS (Appendix B) after washing, were prepared by spreading 50 ml 
of the sample onto a slide using a coverslip and immediately viewed under a fluorescence 
microscope. Otherwise, stained cells were immobilised in agarose to facilitate imaging 
(Section 2.5.2.2). Methanol-fixed trypanosomes from in vitro culture (Sections 2.5.2.3) 
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onto the specimen at the desired concentration and by covering it with a coverslip (this 
procedure was only used for fading quantification of UV diamidines, Section 2.5.5). 
2.5.2.2  Cell immobilisation in agarose 
To reduce the motility of cultured live trypanosomes for image acquisition, cells were 
embedded in agarose (Widener et al., 2007; Lanteri et al., 2008). After incubation with the 
fluorophore under study, cells (2×10
7 cells/ml) were collected by centrifugation (1300×g 
for 10 min) and resuspended in a small volume (50 ml or less) of 1× PBS. After an equal 
volume of 2% w/v low melting point agarose (Sigma-Aldrich) at 37°C was mixed with the 
cell suspension, an aliquot of the sample was immediately put onto a slide and covered 
with a coverslip. The agarose was left to solidify at room temperature, or by chilling the 
slides for 10-15 min at 4°C, before viewing. 
2.5.2.3  Cell fixation in methanol 
To prepare methanol-fixed parasites to use for photobleaching studies, 50 ml of a 2×10
6 
cells/ml culture of T. b. brucei w.t. S427 in HMI-9 (10% FCS) were directly spread onto a 
glass microscope slide using the edge of a coverslip and left to air-dry. Slides were, then, 
dipped into 100% cold methanol and left overnight at -20°C. Afterwards the methanol was 
allowed to evaporate from the specimens under a fume-hood and slides were kept in a box 
at 4°C until use. Before staining, fixed cells were rehydrated by addition of 1-2 ml of PBS 
for 10 minutes. The excess of PBS was then removed by tilting and the specimen directly 
soaked with 50 ml of the fluorochrome solution and, eventually, the mounting medium 
(Section 2.5.2.6) and covered with a coverslip. 
2.5.2.4  Cell fixation in glutaraldehyde 
Glutaraldehyde was one of the fixatives tested to prepare specimens of transfected 
trypanosomes produced during the molecular biology work (Chapter 6). 10
7 cells were 
collected in 1 ml of medium and washed once in 1× PBS at 4°C, before being submerged 
for 5 min in chilled 2.5% v/v glutaraldehyde (Sigma-Aldrich) solution, prepared in  
1× PBS. The fixative was removed from the pelleted parasites by pulse centrifuging at 
8,000 rpm in a benchtop centrifuge for several seconds. Parasites were, then, resuspended 
in 20 ml of 1× PBS, smeared onto a lysine-coated slide (0.1% w/v poly-L-lysine solution 
from Sigma-Aldrich) and left to settle for 5 min: the negative charges of cells in solution Federica Giordani, 2010    Chapter 2, 50 
interacted electrostatically with the positive charges of the polylysine, allowing them to 
adhere to the slide in a dispersed monolayer (Husain et al., 1980). Mounting medium  
(40 ml) containing a counterstain for DNA (Section 2.5.2.6) was spread on the specimen by 
addition of a coverslip, which was successively sealed with nail varnish. 
2.5.2.5  Cell fixation in formaldehyde 
Fixation in formaldehyde was the method adopted to fix transfected trypanosomes for 
fluorescence microscopy imaging (Chapter 6). After washing in 1× PBS, transfected and 
parental lines trypanosomes (1×10
7 cells) were resuspended in 0.5 ml of the buffer and 
mixed with an equal volume of 6% v/v formaldehyde (Sigma-Aldrich) solution, prepared 
in 1× PBS. Cells were fixed for 10 min at 4ºC and then separated from the fixative by 
centrifuging at 8,000 rpm for several seconds. The cell pellet was resuspended in 1× PBS 
(40 ml) and spread onto lysine-coated slides (20 ml per slide). After the solution had settled, 
40 ml of mounting medium containing the DNA counterstain (Section 2.5.2.6) were added 
and covered with a coverslip, which was sealed in place with nail varnish. 
2.5.2.6  Mounting media 
The mounting medium for DNA counterstaining was prepared by mixing 0.1% v/v DAPI 
and 2.5% w/v DABCO (both from Sigma-Adrich) in 9:1 glycerol/1× PBS. 
Various mounting media containing antifading agents were tested in attempts to decrease 
DB75 photobleaching in methanol-fixed cells. Two different solutions containing 5% w/v 
n-propyl gallate (NPG, [3,4,5-trihydroxybenzoic acid propyl ester]) were prepared in 9:1 
buffered glycerol (9 parts of glycerol and 1 part of 1× PBS) and 1:1 buffered glycerol. 
Another antioxidant agent, DABCO, [1,4-diazobicyclo-(2,2,2)-octane], was prepared as a 
2.5% w/v solution in 9:1 buffered glycerol (Johnson et al., 1982; Florijn et al., 1995). The 
third antioxidant agent used was Trolox, [6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid], a cell-permeable, water soluble derivative of vitamin E, which was 
prepared at 2 mM in PBS and was used on DB75-stained fixed cells but also in living 
samples. All three antifading agents were from Sigma-Aldrich. For fading profile 
measurements, 50 ml of each mounting media containing 3 mM of DB75 were spread onto 
the slide containing methanol-fixed cells and covered with a coverslip, which was sealed 
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2.5.3 Ex-vivo trypanosome samples for fluorescence microscopy 
2.5.3.1  Thin and thick blood film preparation 
Thin blood smears were prepared by spreading a drop of infected blood (5 ml) along the 
glass slide by using the edge of a coverslip (Houwen, 2000). The smears were covered 
with a coverslip to produce wet films, which were immediately viewed under the 
fluorescence microscope. Otherwise, thin films were left to air-dry and, generally, fixed in 
cold 100% methanol for 2 min. After fixation, blood smears were air-dried again and kept 
in a slide box until viewing (usually under a 40× objective). 
Thick blood films were prepared by putting a drop of blood (20 ml) onto a slide and by 
spreading it in a circle (1-2 cm in diameter) using the corner of another clean slide. Thick 
films were thoroughly air-dried but not fixed (since fixation would prevent lysis of 
erythrocytes by the aqueous stain solution, usually Giemsa, needed to see through the 
several layers of blood) and viewed under a 100× oil-immersion objective. 
2.5.3.2  Staining procedures for blood films 
Live ex-vivo trypanosomes were stained with various fluorophores by incubating aliquots 
of fresh infected rat blood with the dye under study inside 1.5 ml Eppendorf tubes, kept at 
the desired temperature. At the end of the incubation time, aliquots of blood containing 
stained parasites were used to prepare fresh thin smears. Staining properties of some 
fluorophores were also assessed after application of a drop of the dye (50 ml) directly to the 
wet smear, which was, then, covered with a coverslip. 
For fluorescent stain of fixed thin films (Section 2.5.3.1), a solution of the fluorochrome 
(50 ml) was directly applied to the specimen and spread by covering with a coverslip. 
These samples were viewed under a fluorescence microscope without further processing or 
washing steps. To stain thick blood films various procedures were followed. These 
included (1) application of the dye (30 ml) and of a coverslip to the dry smear; (2) 
dehaemoglobinisation of the dry thick film in dH2O (5 min), fixation in methanol (2 min) 
and subsequent staining with 30 ml of the fluorophore solution (Caramello et al., 1993); (3) 
addition of the fluorescent dye directly to the drop of blood before preparing the smear. 
The efficacy of these protocols is discussed in Chapter 4. Federica Giordani, 2010    Chapter 2, 52 
2.5.3.3  Giemsa stain 
For trypanosome visualisation under light microscopy, fixed thin blood films and air-dried 
thick smears were put in a Coplin jar and immersed in a 5% v/v Giemsa stain solution 
(BDH Laboratory Supplies) in phosphate buffer (Appendix B) for 1 h. Excess dye was 
washed by briefly immerging the slides in dH2O (5 min). Slides were then allowed to air-
dry and kept in a box until viewing. 
2.5.4 Image acquisition 
2.5.4.1  Zeiss Axioplan fluorescence microscope 
Most of the fluorophores studies were performed in a dark room, using a motorized Zeiss 
Axioplan 2 Imaging epifluorescence microscope (Carl Zeiss) equipped with a HBO 100W 
short arc mercury lamp (Osram) and 10× eyepieces, and coupled with a Hamamatsu 
C4742-80-12AG digital CCD camera (Hamamatsu Photonics). Three standard filter sets 
were generally used (all filter sets were from Carl Zeiss): filter set 49 for DAPI (excitation 
filter G 365 nm, beamsplitter FT 395 nm and emission filter BP 445/50 nm); filter set 10 
for FITC (excitation filter BP 450-490 nm, beamsplitter FT 510 nm and emission filter BP 
515-565 nm); filter set 15 for RHOD (excitation filter BP 546/12 nm, beamsplitter FT 580 
nm and emission filter LP 590 nm). Other filter cubes were occasionally utilised, such as 
filter set 43 for DsRed (excitation filter BP 545/25 nm, beamsplitter FT 570 nm and 
emission filter BP 605/70 nm). Emission was recorded through a PlanNEUFLUAR 40× 
air, NA 0.75 objective, or a 100× oil-immersion, NA 1.4 objective (both from Carl Zeiss). 
Typical camera exposure times for imaging were: 33 ms for DAPI, 68 ms (or 100 ms) for 
FITC and 68 ms for RHOD (the precise values used during each experiment are indicated 
underneath every figure). 
Image acquisition, image processing and quantification studies were performed using the 
Volocity imaging software (Improvision). Z-stack images, collected at 0.4 mm intervals, 
were deconvolved using the Volocity Iterative Restoration algorithm, set with a confidence 
limit of 97.5-98%. Images obtained using different channels were merged using the Adobe 
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2.5.4.2  SMR LED microscope and UV LED microscope (Cytoscience) 
The portable microscope we used during this project was the prototype for the SMR 
Cytoscience epifluorescent microscope (Jones et al., 2005). This instrument (Figure 1.8) 
used a 472 nm Golden Dragon LED as excitation light source (Osram) and it had a single, 
fixed, 40× achromat DIN objective (NA 0.65, 160 mm tube length) (Lambda Praha). The 
filter set was composed of a 500-510 nm blocking filter (some LED output was in this 
region), a 580 nm 45° dichromatic mirror and a 515-750 nm emission filter for all 
wavelengths from green to red. The cost of the microscope was ~1,000 euros. 
The UV LED microscope (Figure 3.6) was an adapted Hund bench microscope, equipped 
with a 365 nm UL LED 500 mA light source (Nichia) and a 40× achromatic objective (NA 
0.65) (Hund). The prototype was designed and built by Prof. D. Jones (Cytoscience). Its 
cost was ~1,200 euros. To acquire images we used a 1.4 MP 160 camera (Lumenera) 
which had a 2/3 inch Sony Extra HAD (hile accumulation diode) and was connected to a 
ScopePhoto software (ScopeTek). The cost of the camera was 3,500 euros. 
2.5.5 Fluorescence fading measurement 
Fading profile of DB75 and DAPI was measured in stained in vitro T. b. brucei w.t. S427 
cells fixed in methanol. Before the experiment, slides were always freshly stained in the 
dark with 50 ml of a 3 mM solution in 1× PBS of one of the two fluorophores and covered 
with a coverslip. Photobleaching of DB75 was quantified either in the absence of 
antifading agents or after mounting with different mounting media (Section 2.5.2.6). Slides 
were left to set for 15-30 minutes at room temperature before viewing under the DAPI 
filter of the Zeiss Axioplan microscope (Carl Zeiss). Images of the continuously 
illuminated field were captured every 5 seconds for a total period of 5 minutes for DB75 
and every 15 seconds for a total period of 12 minutes for DAPI by using the Volocity 
Imaging software (Improvision). Illumination conditions and acquisition settings were kept 
identical for experiments with both fluorophores (144 gain, 14 offset, 33 ms exposure time 
for DAPI filter, 40× air objective NA 0.75). Fluorescence fading was quantified using the 
quantitation program of the Volocity Imaging software (Improvision). All images were 
processed by subtracting the background (i.e. the illuminated sample with no cells in the 
field of view) and then percentage of intensity of fluorescence of the nucleus and 
kinetoplast of every cell was measured for each time point. Only trypanosomes with a 
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the different mounting media used in association with DB75, fluorescence decay of at least 
100 stained cells was measured. Since fluorescence intensity of individual cells can vary 
between samples, several slides were analysed for both fluorophores. All data were plotted 
using an exponential algorithm of Prism 5.0 software (GraphPad). 
2.6 Fluorescence spectra measurement 
Excitation and emission spectra of a specific fluorophore were recorded using the LS 55 
Luminescence Spectrometer (PerkinElmer), connected to the FL WinLab software 
(PerkinElmer). Samples were diluted in dH2O until unsaturated signal strength was 
achieved. An aliquot of the samples (1 ml) was put in 10 mm quartz cuvettes (Merck) and 
a pre-scan was performed over the full spectrum range for excitation (200-800 nm) and 
emission (200-900 nm) with both slits set to 5 nm and the scan speed set to 150 nm/min. 
The approximate values for the excitation and emission maxima obtained during the pre-
scan were, then, used to record the excitation and emission spectra with more accuracy, by 
running successive scans while keeping either value (excitation or emission maximum) fixed. 
2.7 Molecular biology techniques 
2.7.1 Genomic DNA extraction 
To isolate large quantities of gDNA, 100 ml of a mid-log phase cell culture (1-2×10
6 
cells/ml) were initially washed twice in 1× PBS. The pellet was resuspended in 500 ml of 
lysis buffer (Appendix C), added with 100 mg of protease K and incubated overnight at 
50°C. After mixing with an equal volume of phenol-chloroform-isoamyl alcohol (25:24:1) 
(Sigma-Aldrich) for 5 min, the DNA was extracted in the aqueous layer by centrifugating 
at 855×g for 10 min. The aqueous phase was transferred to a new tube and washed twice 
by addition of an equal volume of chloroform. The DNA was precipitated in 0.1 volume of 
3 M NaCl and 2 volumes of 100% EtOH and then washed in 70% EtOH, left to air dry and 
finally resuspended in 100 ml TE buffer (Appendix B). 
A DNeasy
® Blood and Tissue Kit (Qiagen) was used, following the manufacturer’s 
instructions, to quickly isolate gDNA from transfected clones in order to screen for the 
presence of the correct mCherry::TbAT1 or TbAT1::mCherry construct (Section 2.7.2.2). 
In this case, cells from a 5 ml dense culture (2×10
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The concentration of extracted gDNA and of purified plasmids was measured using a ND-
1000 V31.0 NanoDrop instrument (Thermo Fisher Scientific Inc.). 
2.7.2 PCR 
2.7.2.1  Amplification of TbAT1 and mCherry ORF 
The polymerase chain reaction (PCR) was used to amplify DNA fragments both from 
genomic material and plasmids. For the project involving the construction of a TbAT1-
RFP reporter system (Chapter 6), four sets of primers, containing the required restriction 
sites, were designed for amplification of TbAT1 (form gDNA) and mCherry (from vector 
p2664, described in Kelly et al., 2007) coding sequences: two sets for the N-t construct 
(mCherry::TbAT1) and two sets for the C-t construct (TbAT1::mCherry) (Table 2.2). 
Sequence 
amplified  Primer pair  Primer sequence 
MB405 (f)  5’-ATTAAGCTTATGGCAACTAGCGGCATGGT-3’ 
mCherry (N-t) 
MB406 (r)  5’-ATTGGGCCCTCCTCCTGCGGTACCAGAACCTTTGT-3’ 
MB407 (f)  5’-ATTGGGCCCATGCTCGGGTTTGACTCAGC-3’ 
TbAT1 (N-t) 
MB408 (r)  5’-ATTGGATCCCTACTTGGGAAGCCCCTCAT-3’ 
MB409 (f)  5’-ATTGGGCCCATGGCAACTAGCGGCATGGT-3’ 
mCherry (C-t) 
MB410 (r)  5’-TTAGGATCCTTATGCGGTACCAGAACCTT-3’ 
MB411 (f)  5’-ATTAAGCTTATGCTCGGGTTTGACTCAGC-3’ 
TbAT1 (C-t) 
MB412 (r)  5’-ATTGGGCCCTCCTCCCTTGGGAAGCCCCTCATTGA-3’ 
Table 2.2 – Oligonucleotides used for TbAT1 and mCherry ORF amplification. 
Restriction sites introduced for cloning purposes are underlined; stop codons are in bold; 
glycine-encoding codons are in italics. 
(f): forward; (r): reverse. 
All oligonucleotides were synthesised by Eurofins MWG Operon. A high fidelity enzyme 
(KOD Hot Start DNA polymerase, Novagen) was used to obtain fragments for subsequent 
cloning (while for routine PCR applications a GoTaq
® DNA polymerase, by Promega, was 
used). PCR mastermix was prepared in a total volume of 25 ml per reaction, containing 1× 
buffer, 0.3 mM dNTPs, 1.5 mM MgCl, 0.3 mM both of sense (5’) and anti-sense (3’) 
primer, 1.25 U of polymerase and the template (~100 ng gDNA, or 0.5 ng plasmidic 
DNA). The thermal cycler PTC200 DNA Engine Thermal Cycler (MJ Research) was used 
for DNA amplification. Reaction conditions were optimised for each experiment. In 
particular, the best annealing temperature for each set of primers was determined by 
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For TbAT1 amplification from gDNA, cycling conditions were as follow: 
1- Polymerase activation  95°C for 2 min 
2- Denaturation    95°C for 20 sec 
3- Annealing      58.4°C for 10 sec 
4- Extension      70°C for 35 sec 
5- Repeat steps 2-4    30 cycles 
For mCherry amplification from p2664, cycling conditions were as follow: 
1- Polymerase activation  95°C for 2 min 
2- Denaturation    95°C for 20 sec 
3- Annealing      64.8°C for 10 sec 
4- Extension      70°C for 15 sec 
5- Repeat steps 2-4    25 cycles 
PCR amplicons were isolated and visualised by electrophoresis on a 1% agarose gel 
stained with SYBR
® Safe DNA gel stain (Invitrogen) and then purified from the gel using 
the QIAquick PCR Purification Kit (Qiagen) following the manufacturer’s instructions. 
2.7.2.2  PCR screening of transfected trypanosomes 
PCR amplification of a fragment spanning TbAT1 and mCherry domains was used to check 
for the presence of the constructs pMB-G94 (containing mCherry::TbAT1) and pMB-G95 
(containing TbAT1::mCherry) inside transfected trypanosomes. Primers used for screening 
are shown in Table 2.3. PCR reactions were prepared as previously described (2.7.2.1), 
using as template ~0.5-1 ng/ml gDNA, extracted with the DNeasy
® Blood and Tissue Kit 
(Qiagen). 
Sequence 
amplified  
Primer 
pair   Primer sequence 
MB363 (f)  5’-AGCCCTCAATTCATGTATGG-3’  mCherry::TbAT1 
(fragment)  MB182 (r)  5’-TCATCGCCTCCGTGGGGGTC-3’ 
MB181 (f)  5’-CAGAGTTCCGATATGCAGC-3’  TbAT1::mCherry 
(fragment)  MB410 (r)  5’-TTAGGATCCTTATGCGGTACCAGAACCTT-3’ 
Table 2.3 – Oligonucleotides used for amplification of a fragment spanning TbAT1 and 
mCherry domains in transfected trypanosomes. 
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PCR conditions were as follow: 
1- Polymerase activation  95°C for 1 min 
2- Denaturation    95°C for 1 min 
3- Annealing      53.4°C for 1 min 
4- Extension      72°C for 90 sec 
5- Repeat steps 2-4    30 cycles 
5- Final extension    72°C for 1 min 
2.7.3 Plasmid and vector construction 
In order to ligate PCR amplicons into the plasmid pGEM-T Easy (Promega), which has 
additional overhanging thymidine at both 3’ terminals, they had first to be added with a 
single 3’-terminal adenosine. This was obtained by incubating the PCR products with  
2.5 U of GoTaq
® DNA polymerase at 72°C for 15 min before gel extraction. The ligation 
reactions (10 ml total volume) were prepared by mixing 50 ng of plasmid, 1× T4 ligation 
buffer, 3 U of T4 DNA ligase polymerase (Promega) and 5 ml of purified PCR product. 
Reactions were incubated overnight at 4°C. 
After bacterial amplification and purification (Section 2.7.4), ligation products were 
checked for presence of the correct insert size by electrophoretic migration of digested 
products on a 1% agarose gel. 1 ml of plasmid was digested with 10 U of the specific 
restriction enzymes in a 10 ml reaction mixture containing 1× of the appropriate restriction 
enzyme buffer. Digest reactions were always carried out for 2 h at 37°C. Correctness of the 
ligated sequences was verified by sequence analysis (Eurofins MWG Operon). If the insert 
proved correct, a higher amount of plasmid containing the PCR amplicon (5 ml) was 
digested to isolate the inserts for subsequent cloning. When the two enzymes used to 
isolate the fragments needed different buffers, digest was carried out in two distinct 
reactions separated by a purification step to eliminate the buffer used for the first reaction 
(the PCR Purification Kit from Qiagen was used for this purpose). Fragments were then 
separated from the plasmid backbone by running the digest products on a 1% agarose gel 
and purified (QiAquick Gel Extraction Kit, Qiagen). 
TbAT1 and mCherry amplicons were first joined together in pGEM-T Easy and only 
afterwards cloned into the final expression vector pHD676 (Figure 2.1), kind gift of Dr. 
Christine Clayton, University of Heidelberg (Biebinger et al., 1997), as HindIII-BamHI  Federica Giordani, 2010    Chapter 2, 58 
 
Figure 2.1 – Schematic representation of the steps taken to build pMB-G94 and pMB-G95 
vectors. 
TbAT1 and mCherry sequences for the N-t construct (mCherry ORF upstream the TbAT1 
gene) and C-t construct (mCherry ORF downstream the TbAT1 gene) differed for the 
restriction sites introduced by PCR for subsequent cloning into the expression vector 
pHD676. TbAT1 and mCherry genes cloned inside pGEM-T Easy (Promega) were first 
cleaved and linked together into another pGEM-T Easy plasmid by exploiting the indicated 
restriction sites contained in its polylinker, in order to generate the fused sequences 
mCherry::TbAT1 (N-t) and TbAT1::mCherry (C-t). These inserted gene sequences were 
successively cut as HindIII-BamHI fragments and cloned into the expression vector pHD676, 
generating vectors pMB-G94 and pMG-G95. Names of the intermediate constructs are also 
indicated. 
A: ApaI; B: BamHI; H: HindIII; N: NotI; S: NsiI. Federica Giordani, 2010    Chapter 2, 59 
fragments. This strategy was chosen since direct insertion of the genes inside the final 
vector proved unsuccessful. To ligate together TbAT1 and mCherry into pGEM-T Easy 
various restriction sites contained inside the plasmid polylinker were used (these sites are 
indicated in Figure 2.1). All ligation reactions were carried out using a 1:1 or 1:2 
vector/insert(s) ratio as described above. Final vectors (pMB-G94 and pMB-G95) were 
sent to Eurofins MWG Operon for sequencing. 
2.7.4 E. coli transformation and plasmid purification 
Large quantities (required for trypanosome transfection) of plasmids containing the gene(s) 
of interest were obtained by heat shock bacterial transformation and subsequent plasmid 
purification. The E. coli competent cell line DH5a (50 ml) was mixed with the plasmid  
(10 ml if a ligation product, 1 ml if a miniprep product) for 30 min in ice. Cells were then 
heat-shocked for 45 sec at 42°C, returned to ice for 1 min, added with 200 ml of LB 
medium (Appendix B) and left to recover by shaking for 45 min at 37°C. An aliquot of the 
transformed bacteria was then spread on an LB agar (Appendix B) plate containing  
100 mg/ml ampicillin and allowed to grow overnight at 37°C. 
When the plasmid pGEM-T Easy (Promega) was used, a preliminary blue-white colony 
screening was performed to confirm the presence of the target gene(s). Insertion of a 
fragment into this plasmid disrupts the LacZ gene and stops the production of the encoded 
b-galactosidase. When cells are plated on agarose containing 40 ml of 5-bromo-4-chloro-3-
indolyl-b-D-galactopyranoside (X-Gal, 2% w/v, a chromogenic substrate of the enzyme) 
and 100 ml of 0.1 M isopropyl-b-D-1-thiogalactopyranoside (IPTG, which induces the 
system by inactivating the LacZ repressor), if the insert is present the X-Gal remains 
unmetabolised and the colony appears white, while in the absence of insert X-Gal is 
cleaved to a blue product. 
Single colonies were cultured in LB plus ampicillin (100 mg/ml) by shaking overnight at 
37°C. Bacteria were collected by centrifugation (4,500×g, 10 min) and the plasmidic DNA 
was purified using the QIAprep Spin Miniprep Kit (Qiagen) according to the 
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2.7.5 Trypanosome transfection 
Before transfection, vectors pMB-G94 and pMB-G95 were linearised, sterilised and 
concentrated. Linearisation was obtained by digesting at the unique NotI site overnight at 
37°C. The reaction (300 ml total volume) was prepared by mixing a large amount of 
purified vector (>50 mg) with 1× buffer D (Promega), 0.1 mg/ml BSA and 2.5 U NotI/mg 
of vector (Promega). After checking for complete digest by 0.8% agarose gel 
electrophoresis, the restriction enzyme was heat-inactivated at 65°C for 20 min. The whole 
digest product was then loaded on an agarose gel and purified by gel extraction using the 
QiAquick Gel Extraction Kit (Qiagen). Vectors were allowed to precipitate in 2 volumes of 
100% cold EtOH and 1/10 volume of 3 M sodium acetate (pH 5), for at least 2 h at -80°C. 
After washing in 1 ml of 70% EtOH, the pelleted constructs were left to air-dry for 30 min 
under a sterile hood and then resuspended in sterile water (20 ml). Samples were heated 30 
min at 37°C and other 20 min at 65°C to help solubilisation. After concentration, the 
linearised vectors were checked again by 0.8% agarose gel electrophoresis. 
For transfection, 1×10
7 cells from a mid-log phase culture (1-2×10
6 cells/ml) were pelleted 
and resuspended in 100 ml Amaxa Human T-cell buffer (Lonza Group Ltd.) at 4°C, mixed 
with 10 mg of linearised vector and immediately put into a cuvette for nucleofection. 
Program X-001 of the Amaxa Nucleofector
® II Device (Lonza Group Ltd.) was used. 
Transfected parasites were then put into 20 ml of pre-warmed, complete HMI-9 and left to 
recover overnight at 37°C. The day after, cells were cloned by limiting dilution in 96-well 
plates in the presence of the selective drug (hygromycin, 5 mg/ml). All clones obtained 
were then maintained in culture flasks with 10 mg/ml of hygromycin (Clayton et al., 2005). 
2.7.6 Southern blot 
2.7.6.1  gDNA preparation and capillary transfer to membrane 
Southern blot analysis was performed to study the integration of linearised pMB-G94 and 
pMB-G95 vectors into the non-transcribed rRNA spacers (Chapter 6). Genomic DNA  
(6 mg) obtained by phenol-chloroform extraction (Section 2.7.1) from 449 cell line and two 
derived clones was digested with seven different restriction enzymes (PstI, HindIII, StuI, 
BglII, NcoI, XhoI, SpeI, all from Promega). Each reaction was performed in a total volume 
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(Promega) and 5 U of each enzyme/mg of gDNA (a second aliquot of enzyme was added 2 
h after the set up of the restriction digest). The reactions were carried out overnight at 37°C 
and the day after another aliquot of enzyme was eventually added if digests had proven 
incomplete (as visualised by running 2 ml of each sample on a 1% agarose gel). Digested 
gDNA was then loaded on a 0.7% agarose gel and run at low voltage (40 V) for more than 
12 h in 1× TAE buffer (Appendix B) to allow improved separation of DNA fragments. 
To prepare the gel for blotting, it was first soaked in 500 ml of depurination solution, to 
depurinate DNA (twice for 7 min), then in a denaturation solution, to denature the nucleic 
acids (twice for 15 min) and finally in a neutralisation solution (twice for 15 min) to re-
equilibrate the pH to 7.4 (Appendix C). The gDNA fragments were transferred overnight 
to a neutral nylon Hybond
TM-N membrane (GE Healthcare) through upward capillary 
transfer in 20× SSC (Appendix C) as described by Sambrook and Russell (Sambrook and 
Russell, 2001). After a brief wash in 6× SSC, the membrane was exposed to UV irradiation 
to immobilise the DNA onto it by cross-linking, and stored at 4°C until hybridization with 
radiolabeled probes. 
2.7.6.2  Preparation of radiolabeled probes 
The whole ORFs of TbAT1 and mCherry were used as probes. The two genes were cleaved 
from vector pMB-G94 by restriction digest, separated on a 1% agarose gel and purified. 
Radioactive labelling was carried out using the Prime-It II Random Labeling Kit 
(Stratagene) following the manufacturer’s instructions. Briefly, 25 ng of probe DNA were 
mixed with 10 ml of random oligo primers in a final volume of 37 ml in water. The solution 
was heated for 5 min at 95°C before addition of 10 ml of 5× buffer, 2 ml deoxyadenosine 
5’-triphosphate [a-
32P] (PerkinElmer) and 1ml Exo(-)Klenow (5 U/ml). The radionucleotide 
incorporation reaction was incubated for 10 min at 38°C and then stopped by addition of 2 
ml of Stop mix. Radiolabelled probes were successively purified by eluting through an 
illustra MicroSpin
TM S-200 HR Columns (GE Healthcare). Before addition to the bottle 
containing the membrane soaked in prehybridisation solution (Section 2.7.6.3), probes 
were denatured for 5 min at 95°C. 
2.7.6.3  Blot hybridisation and autoradiography 
Before probing, the membrane was prehybridised in a roller bottle with 15 ml 
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(200 mg/ml) (Promega) was added to the solution after denaturation for 5 min at 95°C. 
Boiled radiolabeled probe was added to the hybridisation solution and incubated with the 
membrane for at least 16 h at 42°C. The blot was then washed with a low stringency 
washing solution (0.3× SSC, 0.1% SDS) twice at r. t. and a further twice at 50°C (for 20 
and 45 min respectively). Finally, the filter was covered with an X-ray film (Kodak) and 
left at -80°C. The film was exposed for the appropriate length of time in order to obtain 
clear bands and finally developed using the X-OMAT SRX-101A film processor (Konica 
Minolta). 
2.7.6.4  Removal of hybridised probe from membrane 
To remove the probe from the membrane in order to reprobe it with another 
oligonucleotide, the blot was first soaked for 30 min at 42°C in a stripping solution (0.4 M 
NaOH) and then washed for another 30 min at 42°C with a washing solution at pH 7.6 
(Appendix C). To check for complete removal of bound probe the membrane was exposed 
to an X-ray film as described before (Section 2.7.6.3). 
2.7.7 Protein extraction from trypanosomes 
2.7.7.1  Total cell lysates 
For total protein extraction from trypanosomes, cells (5×10
7 cells/ml) were first washed in 
STEN buffer (Appendix D) by spinning at 2,500×g for 10 min at 4°C. The pellet was then 
resuspended in PBS containing 1× complete protease inhibitor cocktail (Roche), in order to 
have 1×10
7 cells/ml per 10 ml of solution. The suspension was added with an equal volume 
of 2× Laemmli buffer (Appendix D) and thoroughly mixed by pipetting. If samples 
resulted too viscous, they were passed thorough a syringe several times using a 0.45 × 16 
mm needle. Samples were then heated at 65°C for 5 min before spinning at full speed for 1 
min to separate supernatant from cell debris and finally stored at -20°C until use. 
2.7.7.2  Preparation of protein-enriched fractions 
To prepare protein-enriched fractions, 5×10
8 cells were harvested by centrifugation at 
1300×g for 10 min at 4ºC and washed once in ice-cold PBS. The resulting pellet was 
resuspended in 2 ml of ice-cold 1% Triton X-114 in 1× PBS, containing 1× complete 
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after which a 200 ml aliquot was collected and immediately frozen at -20ºC (total lysis 
sample). The remainder was centrifuged twice at 40,000×g for 30 min at 4ºC to precipitate 
the detergent insoluble fraction. The obtained supernatant was incubated for 10 min at 
30ºC and then spun at 5,000×g for 20 min at 30ºC, without using the brake during 
deceleration, to separate the upper aqueous from the detergent-organic phase. Both 
fractions were put in ice and returned to a volume of 2 ml by adding ice-cold 1× PBS to the 
detergent phase and ice-cold 10% Triton X-114 in 1× PBS to the aqueous phase for 
washing. Samples were first vigorously stirred on ice for 60 min and then incubated 10 min 
at 30ºC. After centrifugation at 5,000×g for 20 min at 30ºC, the aqueous wash was 
separated from the original detergent phase and the detergent phase from the original 
aqueous phase and discarded. Samples were stored frozen at -20ºC until analysis by SDS-
PAGE. 
2.7.8 Protein quantification 
Protein concentration was determined by the Bradford method using the Bio-Rad Protein 
Assay (Bio-Rad Laboratories). A small amount of sample (usually 1 ml) was mixed with 
200 ml of Bio-Rad dye reagent and 1× PBS (to a total volume of 1 ml) in a 1 cm disposable 
cuvette. The solution was incubated at room temperature for 30 min to allow colour change 
of the dye in response to the concentration of protein in the sample. Absorbance (OD) was 
then determined using a Spectronic Helios-Gamma spectrophotometer (Thermo Fisher 
Scientific) set at 595 nm and corrected for “blank” (reagent plus buffer). Experimental 
OD595 were finally plotted versus concentration of standards, measured for bovine serum 
albumin (Sigma-Aldrich), and unknowns were extrapolated. 
2.7.9 SDS-PAGE 
Protein samples (usually 25 mg) were separated by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis. Gels (0.75 mm thick) were prepared using 10% polyacrylamide for the 
running gel and 3% for the stacking gel (Appendix D). Before loading, protein-enriched 
fractions were added of Laemmli buffer (5 ml of buffer added to 20 ml of sample) and then 
boiled at 65°C for 5 min. Total protein extracts and prestained protein marker (New 
England Biolabs Inc.) were also denatured at the same temperature just before loading. 
Gels were run at 50-70 V for a few hours in 1× running buffer (Appendix D) and then 
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stained with a Coomassie Brilliant Blue solution (Appendix D) to check for transfer 
efficiency. 
2.7.10  Western blot 
Samples separated by SDS-PAGE were transferred onto an Amersham Hybond
TM-ECL 
nitrocellulose membrane (GE Healthcare) by electrophoretic transfer. Once the 
electrophoretic block was assembled (membrane placed on the side of the gel facing the 
anode), immunoblotting was performed at a constant voltage (0.1 Amp, for 4 h at 4°C) in 
1× transfer buffer (Appendix D). To optimise protein transfer, a Tris-glycine buffer 
without MeOH was used (Small et al., 1988). The membrane was then blocked for at least 
1 h at r.t. in 40 ml 1× PBS containing 0.05% Tween-20 (PBS-T) and 5% powdered milk 
(Marvel). After three washes with 0.05% PBS-T (15 min each, at r.t.), the blot was 
incubated overnight at 4ºC with the Living Colors
® DsRed monoclonal primary antibody 
(Clontech Laboratories) prepared at a 1:250 dilution in 0.01% PBS-T containing 5% milk. 
Membrane was then washed thoroughly in 0.05% PBS-T to remove unbound or excess 
antibodies, and successively incubated (for 3 h at 4°C) with a goat anti-mouse IgG 
peroxidase conjugate secondary antibody (Calbiochem) at 1:2,000 dilution in blocking 
solution (0.05% PBS-T containing 5% milk). After 3 further washes in 0.05% PBS-T (15 
min per wash) to remove excess antibodies, protein detection was carried out using the 
chemiluminescent SuperSignal
® HPR Substrate kit (Novagen). After the blot was coated 
with an appropriate quantity of reagent and put into a cassette, a film (Amersham 
Hyperfilm ECL, GE Healthcare) was exposed to the chemiluminescent signal for the time 
needed to obtain clear bands. Films were developed using the X-OMAT SRX-101A film 
processor (Konica Minolta). 
2.8 Chemical synthesis: general experimental details 
All reactions described in Chapter 5 were carried out in oven-dried glassware and under an 
inert atmosphere, unless otherwise stated. Starting materials and reagents were obtained 
from commercial sources (Sigma-Aldrich, Alfa Aesar) and used as received without 
further purification. All solvents were of reagent grade and distilled or dried, if needed, 
before use. Purification by flash column chromatography was carried out using Matrex 
Silica 60Ǻ silica gel, mesh size 35-70 mm (Thermo Fisher Scientific Inc.) as the stationary 
phase. Thin layer chromatography was performed using aluminium backed plates pre-
coated with silica gel 60 (UV254) (Macherey-Nagel) and visualised by staining with Federica Giordani, 2010    Chapter 2, 65 
KMnO4. 
1H NMR and 
13C NMR spectra were recorded on a DPX 400 spectrometer 
(Bruker). Chemical shifts (d) are given in ppm relative to tetramethylsilane, used as 
internal standard. All NMR J values are given in Hz. IR spectra were recorded using 
sodium chloride plates on a FT/IR 410 spectrometer (JASCO). Samples for IR analysis 
were used neat or prepared as KBr disks. Mass spectra were recorded on a JMS-700 
spectrometer (JEOL). Optical rotations were determined as solutions irradiating with the 
sodium D line (l=589 nm) using an AA series Automatic Polarimeter. [a]D values are 
given in units 10
-1 degcm
2 g
-1. Melting point of compound FG10 was measured using a 
Gallenkamp apparatus.  
 
 
 
 
3   
Fluorescence-based diagnostic tests 
 involving the UV fluorescent diamidine DB75 Federica Giordani, 2010    Chapter 3, 67 
3.1 Introduction 
3.1.1 DB75 
DB75 (furamidine, [2,5-bis(4-amidinophenyl)furan], Figure 3.1) is a diphenyl-diamidine 
compound extremely active against human African trypanosomes (Boykin, 2002; Mathis et 
al., 2006; Thuita et al., 2008) and Plasmodium species (Yeramian et al., 2005) both in 
vitro and in vivo. Its oral prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-
methylamidoxime] had reached phase III clinical trials for treatment of HAT early stage, 
before being dismissed for excessive toxicity in volunteers during a retrospective phase I 
trial, dosing for 14 days at 100 mg twice daily (Thuita et al., 2008; Wenzler et al., 2009). 
DB75, like several other compounds of the DB-series of heterocyclic diamidines, is 
fluorescent (Wilson et al., 2005; Mathis et al., 2006 and 2007), with λEX=356 nm and 
λEM=458 nm (Mathis et al., 2007). It quickly accumulates at millimolar levels inside 
trypanosomes, where it concentrates in the DNA-containing organelles: within minutes of 
incubation with the fluorophore the nucleus shows a bright blue fluorescence, while the 
kinetoplast can appear with a white-yellow colour when 330-380 nm excitation and ≥420 
nm emission wavelengths are used (Mathis et al., 2006). With same filter set, Mathis and 
collaborators found that at later time points (after 2 h) trypanosomes from mice treated 
with DB75 (7.5 mmol/kg) also demonstrated a yellow fluorescence in other cytoplasmic 
organelles, believed to be acidocalcisomes (Mathis et al., 2006). Like other diamidines, 
DB75 uptake is mostly dependent on the P2 amino-purine transporter, but a secondary, 
slow route of internalisation must exist, since trypanosomes lacking this transporter retain 
some sensitivity to the drug (Lanteri et al., 2006). Molecules belonging to this class of 
compounds bind to the DNA minor groove at AT-rich sites, which are abundant in the 
minicircles of the kinetoplast DNA, where AT sequences reach 70-75% of the total 
(Wilson et al., 2005; Liu et al., 2007; Mathis et al., 2007). The high affinity for DNA has 
been suggested as a possible cause for the biological activity of dications as DB75, which 
can induce DNA structure instability or interfere with DNA-targeted proteins, such as the 
mitochondrial topoisomerase II (Shapiro and Englund, 1990; Wilson et al., 2005). The 
finding of other organelles (identified as acidocalcisomes) targeted by the drug, though, 
may indicate different additional mechanisms of action for DB75 (Mathis et al., 2007). 
Moreover, the fact that akinetoplastic (i.e. without kDNA) Trypanosoma evansi (an animal 
pathogenic species) are also susceptible to diamidines might render the kinetoplast an 
unlikely target (Gillingwater et al., 2009). Federica Giordani, 2010    Chapter 3, 68 
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Figure 3.1 – Chemical structure of DB75 and DAPI. 
 
Despite its disappointing failure as a trypanocidal drug, DB75 could still have other 
applications as a fluorescent marker. Since this compound enters predominantly via the P2 
transporter it can, for example, be used to discriminate wild type trypanosomes from drug-
resistant parasites, which have lost the P2 transporter, in the arsenical drug resistance test 
(Stewart et al., 2005; Lanteri et al., 2006). Another option would be to use DB75 as a more 
general fluorescent DNA marker for trypanosomes or any cell type, both for research and 
diagnostic purposes. Thanks to its cost-efficient synthesis (Gillingwater et al., 2009), this 
compound could represent a valid alternative to the widely used, but expensive (~£10 for 1 
mg from Sigma-Aldrich) DAPI, another diamidine with very similar fluorescent properties 
(Kapuscinski, 1995). Both these aspects were investigated. 
3.1.2 DAPI 
DAPI, [4’,6-diamidino-2-phenylindole] (Figure 3.1), is a widely used, DNA-specific, 
fluorescent stain, initially synthesised during the search for new trypanocidal agents 
(Kapuscinski, 1995). As DB75, this fluorophore is a UV-excited dication which binds to 
DNA in a sequence-dependent way, even though the interactions between this compound 
and the double helix of DNA seem to be more complex than for DB75. DAPI attaches 
strongly to the minor groove at AT sites, but it also seems to intercalate between the GC 
base pairs of DNA (Banerjee and Pal, 2008) and at AU sites of RNA (Tanious et al., 
1992). DAPI-DNA complexes involving GC sequences inside the major groove have also 
been suggested (Kim et al., 1993). Upon binding to DNA, the maximum excitation 
wavelength of DAPI is red-shifted from 347 nm to 363 nm (bathochromic effect), while 
the emission has a hypsochromic shift (from 453 nm to 448 nm) and its quantum yield 
increases more than 20-fold compared to the unbound dye (Kapuscinski, 1990 and 1995). 
DB75 fluorescence intensity, instead, was found to decrease by 17% in the presence of 
DNA (Mathis et al., 2007). DAPI is known to have good trypanocidal activity (Borowy et 
al., 1985; Lanteri et al., 2006). A study carried out by Bridges and collaborators showed 
that this compound has high affinity for all of the three pentamidine transporters of T. b. Federica Giordani, 2010    Chapter 3, 69 
brucei (TbAT1/P2, HAPT1 -high affinity pentamidine transporter- and LAPT1 -low 
affinity pentamidine transporter-) (Bridges et al., 2007). These authors showed that 
fluorescence in S427 wild type cells treated with 10 mM of the compound was already 
visible after 5 minutes of incubation. Loss of P2 had no significant effects on DAPI 
internalisation, while additional absence of HAPT increased significantly the time of 
fluorescence development inside the cells. 
3.1.3 Fluorophore photobleaching 
Photostability of a fluorochrome is a major issue in fluorescence microscopy. A specific 
dye must have a relatively long half-life in order to allow acquisition of well-defined 
images over an extended period of time of exposure under the excitation source. 
Unfortunately, the most commonly used dyes suffer from photobleaching, a process that 
causes the photochemical decomposition of the fluorophore especially when exposed under 
optimal conditions (Petty, 2007). This phenomenon depends on many factors such as the 
environment, the concentration of the fluorophore and the excitation conditions 
(Widengren et al., 2007). The mechanisms of this complex process are still poorly 
understood, but it seems that loss of signal is due to a process of photo-oxidation and 
photoionisation, involved in the formation of reactive radical species of the excited state of 
the fluorophore (Widengren et al., 2007; Vogelsang et al., 2008). Apart from reducing 
illumination levels and time of exposure, three methods are routinely used, often in 
combination, to retard dye photobleaching: (1) removal of oxygen from the mounting 
medium, (2) increasing the viscosity of the mounting medium to retard oxygen diffusion or 
(3) the use of an antifading reagent (Johnson et al., 1982; Ono et al., 2001; Vogelsang et 
al., 2008). There are several mounting media that can be added to retard bleaching (Valnes 
and Brandtzaeg, 1985; Longin et al., 1993; Florijn et al., 1995; Ono et al., 2001). They 
include antioxidant and triplet state quenchers that act as radical scavengers (Widengren et 
al., 2007). Most of them, despite retarding fading, have the drawback of reducing 
fluorescence intensity, especially when used at high concentrations (Valnes and 
Brandtzaeg, 1985; Longin et al., 1993; Widengren et al., 2007). 
During our experiments, the use of DB75 for fluorescent staining of trypanosomes showed 
a fast photobleaching, especially under certain conditions. Therefore, efforts were made to 
decrease this effect by the use of homemade mounting media. Since different antifading 
agents vary in efficacy in increasing photostability in a dye-specific manner, three different 
antioxidant compounds were tested: n-propyl gallate [3,4,5-trihydroxybenzoic acid propyl Federica Giordani, 2010    Chapter 3, 70 
ester], DABCO [1,4-diazobicyclo-(2,2,2)-octane] and Trolox [6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid]. n-Propyl gallate is a well known antioxidant that 
acts as an electron donor to reduce a damaged fluorophore back to its fluorescent state 
(Widengren et al., 2007). DABCO is another cheap antifading agent, usually used to retard 
bleaching of FITC or DAPI (Johnson et al., 1982; Florijn et al., 1995). Both are widely 
utilised for mounting of fixed specimens. Trolox, finally, is a cell-permeable, water soluble 
derivative of vitamin E that has been used to recover photoionized fluorophores and to 
remove singlet oxygen (Rasnik et al., 2006; Vogelsang et al., 2008). This strong 
antioxidant is easily applicable also to living specimens. 
3.1.4 Arsenical drug resistance test 
Arsenical drug resistance has always represented a major issue in the history of African 
trypanosomiasis (Ollivier and Legros, 2001; Delespaux and de Koning, 2007). Recently, 
this phenomenon has been indicated as an important cause for the increasing number of 
relapses following melarsoprol treatment in patients infected with T. b. gambiense (Matovu 
et al., 2001a; Kazibwe et al., 2009). Causes of decreased sensitivity of parasites to 
trypanocidal compounds are still unclear. They could involve various mechanisms 
including decreased drug import or increased drug export, compound sequestration or 
inactivation inside parasites, or decreased affinity for the target (Borst and Ouellette, 1995; 
Barrett and Fairlamb, 1999). Melarsoprol can enter the cells through passive diffusion, but 
high levels of uptake into trypanosomes involve internalisation of melarsoprol’s in vivo 
metabolite, melarsen oxide, through one of trypanosome’s adenosine transporters called P2 
(Mäser et al., 1999). Low resistance to the drug was obtained in vitro by knocking down 
the TbAT1 gene that encodes for this transporter (Matovu et al., 2003). Higher resistance 
levels were achieved when the HAPT1 (high affinity pentamidine transporter) activity was 
also eliminated (Bridges et al., 2007). Loss of TbAT1 gene function can also arise as a 
consequence of mutations in its sequence, rather than complete loss of the whole ORF, and 
also when stable expression of the gene is lost (Stewart et al., 2010). These findings have 
been partially confirmed in field isolates, which presented with a similar pattern of 
mutations in the TbAT1 ORF (Mäser et al., 1999; Matovu et al., 2001a). Molecular biology 
methods such as the PCR/SfaNI RFLP have been described for identification of 
melarsoprol-resistant strains in field isolates (Mäser et al., 1999; Matovu et al., 2001b; 
Kazibwe et al., 2009), but this approach is not able to identify all resistant strains, since 
some present with a wild type sequence of the TbAT1 gene (Stewart et al., 2010). The 
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would be extremely useful in chemotherapeutic decision making and for disease 
management. 
The rapid and easy arsenical resistance assay developed in our laboratory (Stewart et al., 
2005) could represent a useful option. This assay is able to identify the altered activity of 
the P2 transporter in resistant strains, regardless of the genetic changes to TbAT1, by the 
diminished uptake of a fluorescent substrate. The original compound used in the test was 
the diamidine DB99 [2,5-bis(4-amidinophenyl)-3,4-dimethylfuran], which, like other 
diamidines, is mainly internalised by P2. Being intrinsically fluorescent, DB99 
accumulation in DNA-containing organelles can be monitored under a standard fluorescent 
microscope (lEX=330 nm, lEM=400 nm) and its signal used to discriminate between 
sensitive and resistant strains, since only wild type cells develop fluorescence within 1 
minute of incubation. For longer treatment times other routes of entry for diamidines may 
contribute to the internalisation of the fluorophore inside resistant parasites, thus making 
distinction between resistant and sensitive strains less certain (Lanteri et al., 2006). 
The fluorescent test could prove useful for arsenical drug resistance identification in 
reference laboratories of endemic countries and the use of a simple and robust LED-
illuminated microscope could make it readily applicable. The Cytoscience LED 
microscope currently available (Jones et al., 2007) does not work in the UV spectrum (it 
being fitted with a higher wavelength emitting LED and filter set, Section 1.7) and can not 
excite fluorophores in the range needed for DB99. Therefore, Prof. D. Jones (Philipps 
University, Marburg) developed a new microscope prototype, comprising a simple white 
light bench microscope, equipped with a UV LED light source (lEX=365 nm) with a 
suitable filter set and a digital camera, fitted directly inside one of the eyepieces for image 
acquisition (Figure 3.6). The efficiency of this new microscope was evaluated on 
trypanosomes from culture and in infected rat blood after treatment with two different 
diamidines: DB75 and DAPI (both having similar fluorescent characteristics as DB99). 
The feasibility of the arsenical drug resistance test using this LED light source to excite 
DB75-stained T. b. brucei cells was also tested, as previously done by other authors with a 
conventional fluorescence microscope (Stewart et al., 2005; Lanteri et al., 2006). Federica Giordani, 2010    Chapter 3, 72 
3.2 Results 
3.2.1 DB75 fluorescence in in vitro trypanosomes 
DB75 is excited under a UV light source (λEX and λEM for this compound are, respectively, 
356 and 458 nm) and it stains the DNA-containing organelles (nucleus and kinetoplast) in 
a very similar way to another nucleic acid-targeting dye, DAPI. For DB75, though, the 
kinetoplast always appeared as the brightest and most easily detectable organelle under the 
DAPI filter of our Zeiss Axioplan epifluorescence microscope. When live, wild type, in 
vitro-cultured trypanosomes (S427) were treated with 10 mM DB75, 15-30 minutes were 
needed to obtain a good signal inside the nucleus and the kinetoplast. Incubation at 37°C, 
instead of room temperature, accelerated uptake, consistent with the transport-mediated 
model for internalisation of the compound (Lanteri et al., 2006). This fluorescence pattern 
(nucleus plus kinetoplast) was maintained for long incubation times: treatment of wild type 
cells with 500 nM DB75 showed no changes in cell distribution up to 24 hours, when, in a 
high number of trypanosomes, the kinetoplast was no longer visible (Figure 3.2). This is in 
agreement with previous observations that ascribed this effect to the toxic mechanism of 
action of diamidines (i.e. disintegration of the kinetoplast, possibly due to an inability to 
replicate) (Mathis et al., 2006). At this time point (24 h) also in many trypanosomes treated 
with the same concentration of DAPI the kinetoplast was no more detectable (Figure 3.2). 
3.2.2 DB75 fluorescence in ex-vivo trypanosomes 
DB75 UV fluorescence development in ex-vivo trypanosomes (i.e. trypanosomes in rodent 
blood) was always much faster than in cells from culture: 1-5 minutes exposure to 10 mM 
of the dye were sufficient for staining ex-vivo samples, the shortest times needed when 
cells were incubated at 37°C instead of room temperature. This difference can be explained 
by the significant in vitro downregulation of the activity of the P2 amino-purine transporter 
(the permease mainly responsible for DB75 uptake) compared to cells grown in vivo (Pui 
Ee Wong, unpublished; Chapter 6). 
For air-dried fixed blood films a lower concentration of the dye (3 mM) was sufficient to 
obtain a bright fluorescence. In these preparations white blood cells were also highly 
fluorescent and, for red blood cells, “halos” appear on the background (Figure 3.3). On the 
other hand, fluorescence of white blood cells was low in wet blood preparations (up to 2 h  Federica Giordani, 2010    Chapter 3, 73 
 
Figure 3.2 – DB75 and DAPI fluorescence acquisition in live, in vitro trypanosomes. 
T. b. brucei S427 w.t. parasites were treated with 0.5 m m m mM of either fluorophore at 37° C. At the 
indicated time points an aliquot of culture containing live cells was washed, spread on a 
slide with a coverslip and directly viewed under the Zeiss fluorescence microscope (DAPI 
filter). 
DAPI 33 ms exposure; 40× objective. *: kinetoplast; ►: nucleus. Bar: 10 m m m mm. 
 
 
Figure 3.3 – DB75 fluorescence in fixed and fresh infected murine blood samples. 
(A) DB75 staining (3 m m m mM, r.t.) of air-dried, fixed thin blood films was nearly immediate. In 
these preparations the kinetoplast and nucleus of trypanosomes (T. b. brucei S427 w.t.) 
were clearly visible on a blue background of red blood cells, but also the white blood cells 
DNA was highly fluorescent under DAPI filter set. 
(B) In wet blood films the cell membrane integrity ensured specific staining of DB75 (10 m m m mM, 
r.t., 30 min), with wild type parasites accumulating the fluorophore at higher rates than white 
blood cells. Note that live trypanosomes in the wet specimen (B) moved during acquisition 
of the fluorescence and bright field images. 
DAPI 33 ms exposure; 40× objective. →: white blood cell. Bar: 10 m m m mm. Federica Giordani, 2010    Chapter 3, 74 
incubation), consistent with the selective high level of DB75 uptake by the trypanosome P2 
transporter. Studies carried out in our laboratory, nevertheless, have shown that DB75 can 
be internalised into various living human cell lines, with time needed for visible 
fluorescence to develop depending on the cell line and varying from 15 minutes to several 
hours (Chris Ward, personal communication). 
3.2.3 DB75 photobleaching 
The bright UV fluorescence of DB75 made this diamidine a very interesting DNA probe 
for trypanosomes (both in fixed and live specimens) and, eventually, also for other cell 
lines (at least in fixed samples, where the cell membrane integrity is lost and the DNA is 
freely accessible to the dye). Nevertheless, a key drawback was observed during testing of 
this fluorophore: the dye suffered a fast photobleaching, especially under certain 
conditions. In wet preparations of living cells from culture and also in methanol-fixed and 
successively stained specimens, DB75 UV fluorescence was very unstable, hampering cell 
viewing and image acquisition, in particular at high magnification. Fading of the 
compound in live trypanosomes in blood samples, instead, was less marked compared to 
wet or fixed slides prepared from culture (as already observed by Mathis et al., 2007). Air-
dried blood films stained with the fluorochrome also showed a more stable signal when 
observed upon low magnification (40× objective). 
3.2.3.1  DB75 and DAPI photobleaching quantification 
To quantitatively compare DB75 fluorescence stability to that of the widely used DNA 
marker DAPI, fading of both fluorophores bound to DNA was measured on methanol-
fixed cells stained with 3 mM of either compound and exposed to UV light (Section 2.5.5). 
Results showed a clear difference between the photobleaching of the two fluorochromes 
(Figure 3.4). Under our experimental conditions DAPI lost 50% of its fluorescence within 
90.8 seconds of continuous illumination, following a single phase decay pattern. The curve 
did not reach values close to zero because of a small percentage of cells (around 10%) that 
appeared to be over-stained (due to variation in staining intensities of individual cells) and 
faded in a lower, more linear way. Previous work had found faster times for DAPI fading 
(Gallardo-Escárate et al., 2007), with loss of half of its fluorescence intensity after only 20 
seconds of continuous illumination, but differences in sample preparation and illumination 
and cell type do not allow direct comparison with this previous study. Under the same  Federica Giordani, 2010    Chapter 3, 75 
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Figure 3.4 – Fading profile of DB75 and DAPI. 
T. b. brucei S427 w.t. cells fixed in methanol were stained with 3 m m m mM of either compound and 
exposed to continuous UV light (l l l lEX=365 nm). Fluorescence bleaching was measured using 
the Volocity software quantitation package (Improvision) (see Section 2.5.5 for detailed 
protocol). For each time point data represent the mean of the % of initial intensity of 100 
cells, considering the fluorescence of the nucleus and the kinetoplast DNA as a single mean 
value. 
exposure conditions, DB75 fading also showed a single phase decay, but for this dye 
fluorescence loss was much faster: within 9.8 seconds 50% of all its fluorescence was lost. 
3.2.4 DB75 photobleaching in the presence of antifading agents 
In attempts to diminish DB75 photo-instability various mounting media were used in 
association with the fluorochrome. A new reference curve of DB75 fading (in absence of 
any mounting medium) was measured for this set of experiments (Figure 3.5) and this time 
the profile appeared closer to a two phase decay curve, with a fast half-life (i.e. loss of 50% 
fluorescence intensity) of 5.3 seconds and a slow half-life of 60.3 seconds. The rate of 
fluorescence intensity fall was slower than that measured previously (Figure 3.4). This 
difference with the former DB75 fading profile could be mainly ascribed to the different 
illumination conditions used during this series of experiments (an older bulb with a 
different alignment, while all others parameters remained unchanged), known to have 
important effects on bleaching processes (Petty, 2007; Widengren et al., 2007). DB75 
fading rate, after addition of different antioxidant agents, was then compared to this new 
curve of the fluorochrome alone under the same experimental conditions. Federica Giordani, 2010    Chapter 3, 76 
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Figure 3.5 – Fading profile of DB75 in the presence of different mounting media. 
Fixed T. b. brucei w.t. cells were stained with 3 m m m mM DB75 and added with each mounting 
medium (see Section 2.5.2.6 for sample preparation) before exposure under UV excitation 
light (l l l lEX=365 nm). Fluorescence bleaching was measured using the Volocity software 
quantitation package (Improvision). Fluorescence decay of DB75-stained trypanosomes in 
the presence of antifading agents is expressed as relative % of intensity to DB75 alone 
(arbitrarily considered as 100%). Fading of DB75 alone was measured for 300 cells (6 
different slides), while fading of DB75 in the presence of antioxidant agents was measured 
for 200 cells on 4 different slides (150 cells on 3 slides for TLX). 
TLX: Trolox (2mM in PBS); DABCO: 1,4-diazabicyclo(2,2,2)-octane (2.5% in 9:1 buffered 
glycerol); NPG: n-propyl gallate (5% in 1:1 or 9:1 buffered glycerol). 
3.2.4.1  DABCO 
The addition of DABCO (an antifading agent often used in association with DAPI) at 2.5% 
in buffered glycerol had no significant effects on DB75 fading (Figure 3.5). 
3.2.4.2  n-propyl gallate 
The use of 5% n-propyl gallate did decrease the photobleaching of DB75 to a more linear 
pattern, but it also had a detrimental effect on the initial fluorescence intensity of the dye 
(Figure 3.5). The use of n-propyl gallate in 1:1 buffered glycerol decreased DB75 initial 
fluorescence of 35%, while the quenching of this agent in 9:1 buffered glycerol was less 
marked (9% decrease of initial intensity). Moreover, the antioxidant in 1:1 glycerol/PBS 
solution tended to precipitate and needed to be warmed up to solubilise before use. The 
fluorescence quenching of n-propyl gallate, when used at high concentrations, is a 
phenomenon previously observed with other fluorochromes (Valnes and Brandtzaeg, 1985; 
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3.2.4.3  Trolox 
Unlike n-propyl gallate, addition of 2 mM Trolox in PBS enhanced the overall intensity of 
DB75 (22% increase in initial intensity) and consequently retarded the photobleaching 
yielding a sigmoidal curve (Figure 3.5). This fading profile was only obtained using a 
Trolox solution that had already turned to a yellowish colour (due, possibly, to partial 
oxidation). When a freshly made solution of Trolox was used, it still enhanced initial DB75 
fluorescence intensity, but this initial emission increase was followed by a fast, single 
phase decay similar to that measured for DB75 alone (data not shown). The positive effect 
of Trolox on DB75 fading was confirmed during experiments using living cells, although 
in these conditions it was not possible to determine the effect of this antioxidant 
quantitatively, due to fast cell movement. 
3.2.5 Assessment of a new UV LED microscope for DB75 and 
DAPI excitation 
When this project started, the use of DB75 and other UV-excited diamidines for 
fluorescence-based field diagnostics of trypanosomiasis was mainly hampered by the 
absence on the market of suitable UV LED-driven fluorescence microscopes. Our 
collaborator Prof. D. Jones (Philipps University, Marburg), therefore, developed a new 
LED microscope prototype working in this region of the spectrum (Figure 3.6). 
The new UV microscope proved easy to use and extremely efficient in exciting DB75 and 
DAPI, both of which absorb in the UV spectrum range. The fluorescence of live T. b. 
brucei parasites from cell culture, treated with 10 mM of either compound, was particularly 
sharp. Nucleus and kinetoplast were clearly visible. In particular, the kinetoplast appeared 
very brilliant following DB75 treatment. After long incubation times (2 h, 37°C) with  
10 mM of each compound, a fluorescent tubular structure connected to the kinetoplast and 
elongating towards the anterior part of the cell body became evident in many trypanosomes 
(Figure 3.7). This organelle, identified as the mitochondrion based on its peculiar shape, 
was never observed using the same fluorophores, following the same treatment conditions, 
under the standard Zeiss fluorescence microscope. However, it was not possible to perform 
colocalisation studies with the mitochondrion-specific red fluorescent marker Mito Tracker 
(Field et al., 2004) because of the monochromatic UV light source fitted in the LED 
instrument. Federica Giordani, 2010    Chapter 3, 78 
 
Figure 3.6 – The UV LED microscope built by Prof. D. Jones (Philipps University, Marburg). 
This adapted microscope was equipped with a 365 nm LED fluorescent light source (Nichia), 
whose intensity could be simply regulated by changing the voltage using the knob at the 
top of the module. A digital camera (Lumenera), fitted into one the two ocular lenses, was 
used for image acquisition. Technical details are in Section 2.5.4.2. 
 
Figure 3.7 – Fluorescence images of trypanosomes stained with DAPI or DB75 acquired 
using the UV LED microscope. 
Wild type T. b. brucei parasites from in vitro culture were incubated with 10 m m m mM of either 
compound for 2 h at 37° C and immobilised in 1% agar ose before viewing using the UV LED 
prototype (l l l lEX=365 nm). Bright field images are shown on the right of the corresponding 
fluorescence micrograph. 
LED 65 ms exposure; 60× objective. *: kinetoplast; ►: nucleus; →: mitochondrion. Federica Giordani, 2010    Chapter 3, 79 
3.2.5.1  DB75 photobleaching upon excitation with the UV LED light source 
DB75 UV fluorescence suffered a fast fading upon excitation with a conventional mercury 
arc, especially for samples from culture (Section 3.2.3). The use of the LED-driven 
microscope was expected to have a less detrimental effect on the fluorophore stability, 
since these light sources do not produce any heat that can damage the sample. 
Nevertheless, the fading of DB75 did not appear to be diminished under LED excitation. 
Loss of fluorescence of this compound when exposed to the UV LED light was very fast in 
in vitro live and fixed samples. DB75 appeared less photostable than DAPI also using this 
new instrument, although a direct comparison with the decay rate measured for the 
fluorophores under the mercury bulb was not possible. Decreasing the LED power to half 
the maximum intensity reduced fading, facilitating viewing and imaging during some 
experiments. In blood samples, photobleaching of DB75 was decreased, as already 
observed using the mercury arc-driven microscope. 
3.2.6 Assessing the suitability of the new Cytoscience UV LED 
microscope for use with the arsenical drug resistance test 
The test developed to report on the presence or absence of the P2 amino-purine transporter 
associated with drug resistance depends on using UV fluorescent diamidines such as DB99 
(Stewart et al., 2005) or DB75 (Lanteri et al., 2006). Unfortunately, typical field 
microscopes (i.e. the Cytoscience SMR instrument, Section 1.7) work at longer 
wavelengths and are not compatible with these fluorophores. The UV LED source 
microscope developed by Prof. D. Jones at Cytoscience, instead, proved very efficient in 
exciting DB75 (Section 3.2.5); hence, the possibility to perform the arsenical drug 
resistance test using this instrument in association with the fluorophore was explored. 
For the test, T. b. brucei S427 wild type (w.t.) and tbat1
-/- (lacking the P2 transporter) were 
grown in mice (female BALB/c) and collected in heparinized blood. The test was repeated 
only twice because we only had the prototypical microscope at our disposal for a limited 
period of time. On both occasions the test was carried out on different days for the two 
lines, since the tbat1
-/- reached a similar parasitaemia as the w.t. (6×10
7 cells/ml) only after 
24 hours longer growth. Aliquots of whole infected blood were directly incubated with  
10 mM DB75 and wet thin films were prepared at different time points as previously 
reported (Lanteri et al., 2006). When viewed under the UV light the w.t. line appeared 
highly fluorescent already after 30 seconds of incubation (Figure 3.8). The kinetoplast and Federica Giordani, 2010    Chapter 3, 80 
the nucleus were brightly stained, but DB75 was also visible in the cytoplasm of the w.t. 
parasites making the whole cell body distinguishable. For this cell line, the fluorescence 
pattern remained the same over the 5 minutes of observation, with an increase of intensity 
over time. The tbat1
-/- line accumulated the diamidine at a much slower rate than w.t., as 
expected. Nevertheless, DB75 fluorescence in cells incubated for only 30 seconds could 
still be detected under the LED light source. In particular, the kinetoplast could be seen as 
a moving spot in the specimen, as a function of the whole cell moving. After a few more 
minutes the nucleus could also be identified. By contrast, Stewart et al. observed a 
complete lack of fluorescence in T. b. brucei tbat1
-/- line up to 10 minutes of incubation 
using a standard fluorescence microscope (Stewart et al., 2005). One difference between 
the test conditions we utilised and those adopted in the published assay was the use of wet 
smears instead of dried blood films. DB75 uptake in wet samples is not blocked and 
accumulation of the fluorophore continues during sample preparation and viewing, a factor 
that could slightly increase fluorescence of the tbat1
-/- line at earlier time points. 
Nevertheless, the same arsenical resistance test was performed using wet blood smears 
stained with DB75 by Lanteri and collaborators, who also could not detect any 
fluorescence in the tbat1
-/- line up to 10 minutes incubation using a traditional fluorescence 
microscope (Lanteri et al., 2006). During our experiments, on the other hand, P2-deficient 
trypanosomes could always be detected, by fluorescence staining, at the earliest time point 
(30 seconds) in the various blood smears prepared. When these same specimens containing 
the tbat1
-/- line were observed under the mercury bulb of the Zeiss microscope, no 
trypanosomes could be detected by 5 min incubation with 10 mM DB75. Only a very faint 
autofluorescence emitted by the moving cells could be visualised. After this incubation 
time, UV emission of P2-deficient parasites could be detected using both microscopes 
(mercury arc and LED-driven) even when a lower dye concentration (5 mM) was used. 
PCR amplification technique on aliquots of the blood samples used during these 
experiments and collected on FTA
® cards (Whatman, GE Healthcare; Section 2.2.1) 
confirmed the absence of the TbAT1 gene in the P2-knockout line utilised (data not 
shown). 
DB75 excitation in tbat1
-/- cells using the UV LED-driven microscope seemed, therefore, 
to be more sensitive than with mercury arc-lamps. This prototypical instrument was able to 
provide very bright and sharp images of trypanosomes stained with diamidines like DB75 
and DAPI, showing up particulars that could be lost by excitation with a traditional broad 
spectrum mercury bulb.  
 
F
i
g
u
r
e
 
3
.
8
 
–
 
T
i
m
e
 
c
o
u
r
s
e
 
o
f
 
D
B
7
5
 
i
n
t
e
r
n
a
l
i
s
a
t
i
o
n
 
i
n
 
w
i
l
d
 
t
y
p
e
 
a
n
d
 
t
b
a
t
1
-
/
-
 
c
e
l
l
s
 
a
s
 
o
b
s
e
r
v
e
d
 
u
n
d
e
r
 
t
h
e
 
U
V
 
L
E
D
 
f
l
u
o
r
e
s
c
e
n
c
e
 
m
i
c
r
o
s
c
o
p
e
.
 
T
.
 
b
.
 
b
r
u
c
e
i
 
S
4
2
7
 
w
.
t
.
 
a
n
d
 
t
b
a
t
1
-
/
-
 
l
i
n
e
 
(
M
a
t
o
v
u
 
e
t
 
a
l
.
,
 
2
0
0
3
)
 
w
e
r
e
 
c
o
l
l
e
c
t
e
d
 
f
r
o
m
 
m
i
c
e
 
i
n
 
h
e
p
a
r
i
n
i
z
e
d
 
b
l
o
o
d
 
a
n
d
 
t
r
e
a
t
e
d
 
w
i
t
h
 
1
0
 
m
m
m
m
M
 
o
f
 
D
B
7
5
 
a
t
 
3
7
°
C
.
 
A
t
 
d
i
f
f
e
r
e
n
t
 
t
i
m
e
 
p
o
i
n
t
s
 
(
0
.
5
,
 
1
,
 
2
,
 
5
 
m
i
n
)
 
w
e
t
 
b
l
o
o
d
 
s
m
e
a
r
s
 
w
e
r
e
 
p
r
e
p
a
r
e
d
 
a
n
d
 
i
m
m
e
d
i
a
t
e
l
y
 
o
b
s
e
r
v
e
d
 
u
n
d
e
r
 
t
h
e
 
L
E
D
 
l
i
g
h
t
 
(
l
l
l
l
E
X
=
3
6
5
 
n
m
)
 
o
f
 
t
h
e
 
p
r
o
t
o
t
y
p
i
c
a
l
 
U
V
 
L
E
D
 
i
n
s
t
r
u
m
e
n
t
 
(
d
e
v
e
l
o
p
e
d
 
b
y
 
P
r
o
f
.
 
D
.
 
J
o
n
e
s
 
a
t
 
C
y
t
o
s
c
i
e
n
c
e
)
 
u
s
i
n
g
 
i
t
s
 
m
a
x
i
m
u
m
 
i
n
t
e
n
s
i
t
y
.
 
R
e
p
r
e
s
e
n
t
a
t
i
v
e
 
b
r
i
g
h
t
 
f
i
e
l
d
 
i
m
a
g
e
s
 
a
r
e
 
s
h
o
w
n
 
o
n
 
t
h
e
 
r
i
g
h
t
 
(
a
 
p
r
o
b
a
b
l
e
 
i
m
p
e
r
f
e
c
t
 
a
l
i
g
n
m
e
n
t
 
o
f
 
t
h
e
 
w
h
i
t
e
 
l
i
g
h
t
 
s
o
u
r
c
e
 
c
a
u
s
e
d
 
t
h
e
 
u
n
e
v
e
n
n
e
s
s
 
a
t
 
t
h
e
 
l
e
f
t
 
s
i
d
e
 
o
f
 
t
h
e
 
f
i
e
l
d
)
.
 
L
E
D
 
7
0
 
m
s
 
e
x
p
o
s
u
r
e
;
 
4
0
×
 
o
b
j
e
c
t
i
v
e
.
 
A
r
r
o
w
s
 
i
n
d
i
c
a
t
e
 
t
b
a
t
1
-
/
-
 
t
r
y
p
a
n
o
s
o
m
e
s
.
 Federica Giordani, 2010    Chapter 3, 82 
3.2.7 DB75 fluorescence under FITC filter 
In addition to its blue emission following UV excitation, DB75 had also been shown to 
fluoresce at longer wavelengths once inside various trypanosome cytoplasmic organelles, 
some of them identified as acidocalcisomes (Mathis et al., 2006). Using the FITC filter of 
the Zeiss Axioplan microscope (λEX=470 nm, λEM=519 nm) we could detect various 
fluorescent dots generated by the fluorochrome (given at 10 mM) in ex-vivo cells, as soon 
as 5-10 minutes of exposure to DB75 at 37°C (Figure 3.9). The kinetoplast was also 
always visible and brilliant under this filter set, but the nucleus was never observed. Some 
of these dots could also be identified under the DAPI filter using the 100× objective. Under 
our experimental conditions, we could observe around a dozen green fluorescent spots 
distributed across the whole length of the cell, forming a “pearl necklace” pattern, also 
visible as electron-dense corpuscles under phase contrast. The number of detectable spots 
was quite stable up to 2 hours of exposure, after which they seemed to decrease in 
fluorescence. In order to visualise this green emission, the UV filter had to be avoided, 
since photons emitted in this region of the spectrum also caused the bleaching of the 
fluorescence emitted at longer wavelengths. If UV light was not utilised, the fluorescence 
observed using the FITC filter block appeared more photostable than the emission upon 
DAPI excitation and it could still be visualised after drying the blood smears and viewing 
them 24 hours later. 
This specific fluorescent pattern of DB75 inside trypanosomes was the product of an active 
accumulation of the compound inside the cells. After staining the kinetoplast and the 
nuclear DNA (the first two organelles that could be visualised using UV light), DB75 
started to be detectable inside these other cytoplasmic corpuscles, where its concentration 
increased with time (visualised as an increase of fluorescence intensity). DB75 
fluorescence upon FITC excitation needed living cells to develop and it could not be seen 
when the fluorochrome was used to stain air-dried blood smears, where it only produced 
the DAPI-like blue emission. 
The identity of these cytoplasmic fluorescent corpuscles visualised under FITC filter, 
following DB75 treatment, is still uncertain and under investigation. Considering their 
dimension and distribution, they partially seemed to correspond to those viewed by Mathis 
and collaborators (Mathis et al., 2006) in trypanosomes treated up to 2 hours incubation 
with the dye (Figure 3.10). These authors observed that DB75 fluorescence initially 
developed inside various (unidentified) punctate cytoplasmic vesicles, before concentrating  
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Figure 3.10 – DB75 fluorescence development within bloodstream trypanosomes as 
visualised during our experiments and in the published work by Mathis et al., 2006. 
(A) For our experiments, T. b. brucei w.t. cells grown in rats were treated ex-vivo with 10 m m m mM 
DB75 at 37° C for different lengths of time, and the  wet smears were viewed under a standard 
FITC filter (λEX=470 nm, λEM=519 nm). 
(B) Mathis and collaborators (Mathis et al., 2006) administered an intravenous dose of the 
dye (7.5 m m m mmol/kg) to mice infected with the same trypanosome strain and viewed the blood 
films using a DAPI filter set (λEX=330-80 nm, λEM>420 nm). 
(Image reproduced from Mathis et al., 2006, with permission from American Society for 
Microbiology; doi:10.1128/AAC.00192-06). 
*: kinetoplast; →: nucleus; ►: acidocalcisomes. 
inside a myriad of smaller organelles (which started to appear by 1 hour incubation dosing 
7.5 mmol/kg), indicated as acidocalcisomes (that we could not visualise under our 
experimental conditions). 
The peculiar linear pattern, throughout the whole cell length, of the green dots observed 
suggested a possible compartmentalisation inside the tubular elongated structure of the 
mitochondrion, a known target of DB75 (Lanteri et al., 2004 and 2008). Colocalization 
studies of the dye with the mitochondrial marker Mito Tracker Red (Invitrogen) seemed to 
confirm this hypothesis, showing a close association of the green spots and the 
mitochondrion structure (Figure 3.11). Cells from culture were used for these 
colocalization experiments and, in this case, the green fluorescent emission of DB75 had 
much lower intensity and became detectable at longer times of incubation than in ex-vivo 
trypanosomes (Figure 3.9). Federica Giordani, 2010    Chapter 3, 85 
 
Figure 3.11 – Cellular localization of DB75 and the mitochondrial marker Mito Tracker Red. 
In vitro-cultured T. b. brucei w.t. parasites (2×10
7 cells/ml) were treated with 10 m m m mM DB75 for 
2 hours at 37°C, to allow the development of a dete ctable fluorescence under FITC filter. 
Cells were then added with 100 nM Mito Tracker Red CMXRos (Invitrogen) and incubated for 
further 10 min at 37° C. After washing in PBS, aliqu ots of cells were added with an equal 
volume of agarose (1% final concentration) and mounted on slides. The green fluorescence 
of DB75 was viewed under FITC filter, and its blue emission (DAPI channel) was used to 
localise the nucleus and the kinetoplast. The emission of the mitochondrial marker Mito 
Tracker Red was visualised using the RHOD filter of the Zeiss Axioplan microscope. Images 
were merged using the Adobe Photoshop 7.0 software. 
FITC and RHOD 68 ms exposure; DAPI 33 ms exposure; 100× objective. *: kinetoplast;   
►: nucleus; →: mitochondrion. Bar: 10 m m m mm. 
3.2.7.1  Use of DB75 as fluorescent probe for HAT in association with the 
LED Cytoscience SMR microscope 
The green fluorescent emission of DB75 presented various advantages for its eventual use 
in diagnostic tests for live trypanosomes. The characteristic “pearl necklace” staining 
pattern viewed under FITC filter could allow an easy detection of parasites among other 
blood components. Moreover, the signal of the dye observed under this filter was more 
stable than that generated by exposure to highly energetic UV light. Another important 
aspect to take into consideration is that it is easier to obtain LED microscopes that work in 
this region of the spectrum, rather than at low wavelengths. 
Interestingly, the green fluorescence of DB75 could be viewed under the LED Cytoscience 
SMR epifluorescent microscope (lEX=472 nm) (Section 1.7). No images can be shown for 
this microscope (as a suitable camera was not available), but under this instrument 
trypanosomes appeared very similar to those visualised under the Zeiss Axioplan FITC 
filter using the 40× objective (Figure 3.9 B), the only difference being the more yellowish 
colour of DB75 under the LED light of the field microscope.Federica Giordani, 2010    Chapter 3, 86 
3.3 Discussion 
3.3.1 DB75 fluorescence in live and fixed specimens 
DB75 is a fluorescent diamidine that is actively concentrated into wild type trypanosomes, 
where it binds to DNA of the nucleus and kinetoplast yielding a bright emission upon UV 
excitation. Its fast uptake through the parasite amino-purine transporter termed P2 (Mäser 
et al., 1999) enables this compound’s utilization as a specific fluorescent marker for T. 
brucei when living specimens are used. In wet preparations of infected murine blood, 
staining of trypanosomes was practically instantaneous after exposure at 37°C, while 
leukocytes present in the sample showed only a low fluorescence (Figure 3.3 B). When air-
dried thin blood smears were stained with DB75 after fixing, this specificity was lost due 
to cell membrane disruption in these preparations, meaning that white blood cell nuclei 
were also exposed and were easily labelled by the fluorochrome (Figure 3.3 A). The rapid 
accumulation of DB75 into live trypanosomes is an important property when considering a 
possible application of the dye for diagnostic staining of trypanosomes derived from 
infected human fluids (whether blood or lymph node aspirate or CSF). Parasites in fresh 
human samples can be very fragile and lyse quickly (Chappuis et al., 2005); therefore, fast 
processing of the specimen becomes essential. 
3.3.2 DB75 photobleaching 
The photochemical instability of DB75 when excited under UV light represents another 
important aspect to consider when assessing the suitability of this dye as a reagent to assist 
diagnosis of trypanosome infections in fluids other than blood. During our experiments, the 
compound bleached rapidly in wet and fixed specimens prepared from cell culture, while 
fading appeared less marked in blood samples (whether fixed or fresh). 
A range of antifading agents was tested for their impact on DB75 fluorescence. Among 
them, Trolox acted as a reasonable antifading compound for this fluorophore (Figure 3.5) 
and it could be easily used in wet as well as fixed samples. Although specimen preparation 
using mounting media adds to the overall cost and laboriousness of fluorescence 
microscopy, it could also prove useful for sample storage (Valnes and Brandtzaeg, 1985), 
by preserving the fluorescent signal for longer periods of time (this aspect was no further 
investigated). Federica Giordani, 2010    Chapter 3, 87 
The use of LED light sources has been suggested to have a retarding effect on 
photobleaching, since these semiconductor diodes produce very little heat. However, when 
we excited DB75 under our UV LED microscope, we did observe a fast decrease in its 
fluorescence intensity even under this light source. Stability of fluorochromes also depends 
on optimal storage and handling. Stock DB75 solutions used for the experiments were 
always kept at -20°C, protected from light by wrapping storage bottles in silver foil. 
Further work would be needed to find optimal conditions for field use. 
3.3.3 Assessment of the UV LED microscope for the arsenical 
drug resistance test 
The high dependence of DB75 uptake on the P2 transporter represents a very useful 
property for its application in the arsenical drug resistance tests, an assay developed to 
detect resistant trypanosome strains in which this transporter is no more active (Stewart et 
al., 2005). As for other diagnostic fluorescent approaches, the use of this kind of tests is of 
difficult implementation in poor income endemic countries due to the high costs of 
purchase and maintenance of fluorescence microscopes. A new generation of LED light 
sources can overcome these drawbacks and facilitate the introduction of this technology in 
the field. Since typical LED field microscopes (such as the Cytoscience SMR) work in the 
FITC range of the spectrum (i.e. green emission), Prof. D. Jones (Philipps University, 
Marburg) developed and kindly provided us a new UV LED microscope that we tested for 
its efficacy in exciting UV fluorochromes and in performing the arsenical drug resistance 
test. 
The prototypical microscope proved very efficient in exciting DB75 and DAPI, giving 
brilliant and sharp images of stained trypanosomes (Figure 3.7). When performing the drug 
resistance test using this instrument (Figure 3.8), although the difference in DB75 
accumulation of T. b. brucei sensitive (wild type) and resistant (tbat1
-/-) lines was evident, 
a low fluorescent signal could always be detected in the P2-deficient line at the earliest 
time point (30 seconds). This observation was in disagreement with pervious work using 
the same diamidine (Lanteri et al., 2006) or a different one (Stewart et al., 2005) as 
fluorescent probes, excited under traditional mercury arc-driven microscopes. When 
considering a field application of the test, this result of fluorescence versus low 
fluorescence is not ideal, since a subjective judgement of the technician would be 
necessary to decide on the positivity or negativity of the assay (i.e. if the signal, at a certain 
time point, is bright enough to state that the isolate under examination is drug-sensitive). Federica Giordani, 2010    Chapter 3, 88 
Determination of a fluorescent threshold could be even more difficult to assess for human 
pathogenic strains, where the differences in diamidines internalisation time between 
resistant and wild type lines could be less evident, as already observed for DB99 (Stewart 
et al., 2005). Therefore, a re-optimisation of the test in association with the UV LED 
microscope will be needed, in order to go back to the situation of fluorescence versus non-
fluorescence of the originally designed assay. This could be done by adjusting the 
microscope settings (such as the LED intensity) or by modifying the preparation of the 
sample (different dye doses and times of incubation, use of dried blood films, assessment 
of other fluorescent substrates). 
The reasons for the images’ definition obtained using the UV LED instrument are still 
unclear and under investigation. Sharpness and resolution of microscopy micrographs 
mainly depend on the objectives used and their numerical aperture (Petty, 2007). In our 
case, this factor did not seem to have any discriminatory effect, since the objectives fitted 
in the LED microscope belonged to a standard light bench microscope. The different focus 
of the mercury gas discharge bulb compared to the LED light source could have more 
significant consequences on the final specimen image (Jones et al., 2005) and this aspect 
should be further evaluated. 
3.3.4 DB75 fluorescence under a FITC filter 
Whereas accumulation of DB75 in the nucleus and kinetoplast formed the basis of the 
original proposed test for P2-deficiency related drug resistance (Stewart et al., 2005; 
Lanteri et al., 2006), this compound also accumulates to concentrations allowing detection 
in other cell compartments that can be visualised under a standard FITC filter (Figure 3.9). 
In live wild type trypanosomes various fluorescent inclusions became highly stained after 
only 10 minutes incubation with 10 mM DB75. The kinetoplast was also always visible 
using the FITC filter set. DB75 emission at this longer wavelength was more photostable 
than the signal emitted upon UV excitation, but it needed living cells to develop and could 
not be seen in fixed specimens directly stained with the compound. 
The “pearl necklace” staining pattern of the fluorochrome could also be visualised under 
the LED Cytoscience SMR microscope already available. This very peculiar fluorescent 
pattern (kinetoplast plus cytoplasmic dots) could be useful to identify trypanosomes in a 
complex blood sample, where many other components are often stained and hamper the 
identification of parasites. These blood components do render the detection of the punctate Federica Giordani, 2010    Chapter 3, 89 
nucleus and kinetoplast after DB75 treatment, upon UV excitation, problematic for 
diagnosis. This is due to the fact that these organelles may be difficult to distinguish from 
the contaminants of the specimen, appearing merely as small dots among many other 
fluorescent components, especially in fixed samples at low parasitaemia (the use of the 
Cytoscience UV LED instrument, instead of a classical fluorescence microscope, however, 
also allowed evidencing the low cytoplasmic emission of DB75-stained cells). When 
considering this aspect, a fluorochrome able to stain the whole trypanosome cell body, thus 
providing a clear trypanosomal form, or, as in this case, a dye that produces a very 
characteristic fluorescent pattern, would enable an easier discrimination from debris as 
well as other co-infecting parasites. Future work will study the development of DB75 
green emission in tbat1
-/- line, for its eventual use in the arsenical drug resistance test. 
The exact identity of the green fluorescent dots visualised under FITC filter following 
DB75 treatment is unknown. They do not seem to correspond to the vesicles proposed to 
be acidocalcisomes (Mathis et al., 2006), since these only appeared at longer time of 
incubation with DB75 (after 1 hour), they were smaller in size and higher in number. The 
organelles we observed using the FITC filter, instead, started to appear already after 5 min 
of treatment with 10 mM DB75 in ex-vivo samples and were never more than a dozen. Also 
Mathis and collaborators visualised similar punctate corpuscles (Figure 3.10), but their 
number and distribution was not identical to that we were able to detect. This discrepancy 
could be ascribed to the different filter set used (FITC filter set with λEX=470 nm and 
λEM=519 nm for us, UV excitation at 330-80 nm with detection of emission at ≥420 nm for 
Mathis et al.), but a different accumulation and compartmentalisation of DB75 in 
trypanosomes treated in vivo (Mathis and colleagues) and ex-vivo (our experiments) can 
not be excluded. The fluorescence compartmentalisation pattern of DB75 had also been 
demonstrated to be dose-dependent (Wilson et al., 2005) and our use of 10 mm DB75 
instead of the 7.5 mmol/kg to treat mice in Mathis et al. work could be another reason for 
the differences we found. 
The organelles visualised under FITC filter during our experiments were distributed 
throughout the whole cell body and this observation exclude possible identification with 
endocytic and secretory vesicles, which are confined in the posterior part of the cell 
(Morgan et al., 2002). The green fluorescent dots evidenced in trypanosomes after 
treatment with DB75, instead, appeared to localise within the mitochondrion (Figure 3.11), 
a known target of this diamidine (Lanteri et al., 2008). The compartmentalisation of the 
fluorescent corpuscles inside the elongated mitochondrial tubular structure would explain Federica Giordani, 2010    Chapter 3, 90 
their linear “pearl-necklace” pattern extending from the kinetoplast towards the anterior 
part of the cell. The cause of DB75 fluorescent emission shift from blue to longer 
wavelengths once inside this organelle, though, is still poorly understood. Spectral 
properties of a fuorochrome are often strictly dependent on the pH of the environment, but 
previous work did not find any correlation between acidification of the medium and a 
DB75 fluorescent shift (Mathis et al., 2006). Another important factor affecting the 
emission maximum of a fluorophore is its condensation with various cellular components. 
This phenomenon has already been observed for the closely related diamidine DAPI, 
which presents with a large bathochromic emission shift (yellow fluorescence) upon 
binding with polyanions such as RNA, mucopolysaccharides and polyphosphates 
(Kapuscinski, 1995). We hypothesize that DB75 is actively accumulated by living cells 
inside the mitochondrion where it condensates with polyanions until a critical 
concentration, which causes precipitation of the complexes and fluorescence shift to longer 
wavelengths. Discrete distribution of these negatively charged cellular components inside 
the mitochondrion could cause the punctate fluorescence pattern visualised. The identity of 
these components is unknown: although crystalline masses have been found in the 
mitochondrion of Trypanosoma evansi, no similar dense incusions were observed in other 
salivarian trypanosomes (Vickerman, 1977). The compartmentalisation of the green 
corpuscles inside the mitochondrial organelle would also explain why DB75 green 
emission is evidenced in association with the kinetoplast but not with the nucleus (both 
stained by the fluorophore upon DAPI excitation). Understanding the cause for the 
fluorescence shift of DB75 emission from blue to longer wavelengths will give important 
information regarding the identity of the corpuscles visualised under FITC filter and, 
possibly, on the mechanism of action of this trypanocidal compound. 
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4.1 Introduction 
The diamidine DB75 proved to be an interesting fluorophore for diagnosis of 
trypanosomiasis. This compound is cost-efficient to synthesise, it is quickly and 
specifically internalised into parasites and it emits bright fluorescence when excited using 
standard DAPI and FITC filters (Chapter 3). Moreover, LED-driven microscopes 
(Cytoscience), compatible with the emission maxima of the compound, are available. 
Nevertheless, the use of DB75 as a fluorescent marker also presents some issues: for 
example, the drug resistance test using this diamidine in association with the prototypical 
UV LED microscope still needs to be optimised, while the photoinstability of this 
fluorophore and its inability to stain the whole parasite cell body with bright emission are 
not ideal properties for an ultimate use as a general diagnostic dye. 
A variety of other fluorophores was, therefore, screened in order to find compounds with 
more advantageous properties than DB75. A series of green fluorescent diamidines, with 
higher wavelength absorbance and emission spectra, was also studied for their use as 
fluorescent substrates for the arsenical drug resistance test. 
4.1.1 Green fluorescent pentamidine analogues 
When the arsenical drug resistance test was initially developed (Stewart et al., 2005), no 
UV LED microscopes were available, thus hampering its development into a format more 
suited for field use. To tackle this problem, two solutions were considered: the 
development of a new instrument compatible with the UV-excited diamidines (DB75 and 
DB99) originally used in the test (this aspect is discussed in Chapter 3), or the search for 
other P2-specific substrates compatible with the Cytoscience SMR LED microscope 
already available (λEX=472 nm, λEM>500 nm) (Jones et al., 2005). 
A series of pentamidine analogues was specifically synthesised by Prof. D. W. Boykin’s 
group (Georgia State University, Atlanta) with the intention of generating other fluorescent 
substrates for the arsenical drug resistance test. These compounds (Figure 4.1) maintained 
the basic dicationic backbone of others diamidines (containing the recognition motif for the 
P2/TbAT1 transporter), but were added with a series of ultra-conjugated ring structures in 
the linker, which provided them with emission wavelengths higher than DB75 (and, 
therefore, more likely to be compatible with the already available Cytoscience SMR 
microscope) (Table 4.1). Federica Giordani, 2010    Chapter 4, 93 
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Figure 4.1 – Chemical structure of the five green fluorescent pentamidine analogues. 
These compounds shared the same diamidine backbone (for P2 recognition) with DB75 and 
pentamidine and had various combinations of furan, thiophene and phenyl rings in the 
linker between the two amidine groups, which gave them fluorescent properties. 
Compound  lEX (nm)  lEM (nm) 
DB1464  413  540 
DB1465  405  525 
DB1645  426  575 
DB1692  400  545 
DB1680*  397  515 
Table 4.1 – Excitation and emission wavelengths of the five green fluorescent diamidines. 
The spectrum of DB1680 (*) was measured in our laboratory using a 1 m m m mM solution in dH2O 
(see also Figure 4.6 A). The excitation and emission maxima of the other four diamidines 
were determined in Prof. D. W. Boykin’s laboratory (Georgia State University, Atlanta). 
l l l lEX: wavelength of maximum excitation; l l l lEM: wavelength of maximum emission. 
The ability of these promising compounds to selectively stain trypanosomes was studied 
both in vitro (on cultured bloodstream parasites) and in ex-vivo infected rat blood samples. 
Their potential use as substrates for the arsenical drug resistance test was also evaluated 
both by studying their uptake-dependence on the P2 amino-purine transporter (using a drug 
sensitivity assay) and by fluorescence microscopy on strains either expressing, or not 
expressing, this permease. 
4.1.2 Phenanthridines 
Phenanthridines are a group of molecules containing a nitrogen heterocyclic core that 
makes them fluoresce in the red region of the visible spectrum. Phenanthridines were Federica Giordani, 2010    Chapter 4, 94 
considered of interest for our project since some of them also possess trypanocidal activity, 
implying selective internalisation inside these parasites. Ethidium bromide (homidium 
bromide, Ethidium
®, [3,8-diamino-5-ethyl-6-phenylphenanthridinium bromide]) is a 
fluorophore widely applied in molecular biology as nucleic acid stain. Both ethidium and 
isometamidium chloride (Samorin
®, [8-[(m-amidinophenylazo)amino]-3-amino-5ethyl-6-
phenylphenanthridinium chloride hydrochloride]) (Figure 4.2) are phenanthridines used for 
the treatment of animal African trypanosomiasis (Leach and Roberts, 1981). 
Isometamidium is also applied to livestock as a prophylactic agent (Kinabo and Bogan, 
1988). The chemical structure of isometamidium is a hybrid from homidium and the p-
aminobenzamide moiety of diminazene aceturate (an aromatic diamidine also used in 
veterinary trypanosomiasis). Despite possessing the recognition motif for the P2/TbAT1 
transporter, however, the internalisation of isometamidium inside parasites only partly 
occurs through this route (Delespaux and de Koning, 2007). Instead, it has been proposed 
that this compound freely crosses the plasma membrane and is, then, actively concentrated 
inside the mitochondrion, a main target of the drug (de Koning, 2001b). The high cross-
resistance of isometamidium with ethidium (Peregrine et al., 1997) suggests the 
involvement of a common route of uptake for the two compounds. Propidium iodide [3,8-
diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide] is a 
phenanthridinium analogue of ethidium, but it is characterised by a more hydrophilic 
nature, due to the presence of a bulky ionic substituent on the phenanthridine ring (Figure 
4.2). Propidium is widely used as nucleic acid stain in fluorescence techniques and to 
identify dead cells in a population, since it is a membrane-impermeant molecule and it is 
normally excluded from live cells (Suzuki et al., 1997; Riccardi and Nicoletti, 2006). 
Propidium has also been shown to have trypanocidal activity in vivo (Cox et al., 1984) and 
in vitro (Gould et al., 2008). 
Phenanthridines bind to DNA by intercalating between the bases (one molecule of dye for 
every four or five nucleotides), apparently with no significant sequence preference 
(Waring, 1965). All of the three phenanthridines considered in this study also stain 
cytoplasmic RNA (Waring, 1965; Suzuki et al., 1997). As occurs with DAPI (Chapter 3), 
DNA binding changes the spectral properties of these phenanthridine molecules, inducing 
a shift of both the excitation and emission maxima (Table 4.2) and enhancing the overall 
fluorescence emission intensity 20- to 30-fold for ethidium and propidium (Waring, 1965) 
and more than 4-fold for isometamidium (Zilberstein et al., 1993; Wilkes et al., 1995). The 
high affinity of phenanthridines for nucleic acids is also responsible for their mutagenicity 
and it appears to be related to the trypanocidal activity of these compounds, which involves  Federica Giordani, 2010    Chapter 4, 95 
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lEX (nm)  lEM (nm) 
Compound 
free dye  +ds DNA  free dye  +ds DNA 
Ethidium bromide   480  518  620  605 
Propidium iodide   482  540  608  608 
Isometamidium chloride
   374   -  600  584 
Table 4.2 – Excitation and emission maxima of the three phenanthridines tested. 
Peak values in the absence (free dye) or presence of DNA (+ds DNA) are indicated. 
Wavelengths for ethidium bromide and propidium iodide are from the Sigma-Aldrich 
website (http://www.sigmaaldrich.com/life-science/cell-biology/detection/learning-
center/wavelength-index.html). The emission and excitation spectra data for isometamidium 
chloride are from Zilberstein et al., 1993. These authors used lysates of T. congolense (IL 
1180) for the spectra measurements in the presence of DNA. Free isometamidium has a 
second emission peak at 645 nm, which is not affected upon DNA binding. 
dsDNA: double-stranded DNA; l l l lEX: wavelength of maximum excitation; l l l lEM: wavelength of 
maximum emission. 
inhibition of DNA synthesis (Leach and Roberts, 1981; Kinabo and Bogan, 1988). 
Isometamidium chloride, in particular, was shown to cause linearization of kinetoplast 
DNA minicircles in T. equiperdum by interacting with the complexes formed by 
topoisomerases and the kinetoplast DNA (Shapiro and Englund, 1990). Another study 
showed that dyskinetoplastic trypanosomes were not responsive to ethidium bromide 
treatment in an in vivo model, suggesting that the kinetoplast was an important target for 
the action of the phenanthridine (Agbe and Yielding, 1995). 
The intrinsic fluorescence of ethidium, propidium and isometamidium has been used to 
study their distribution in trypanosomes, in order to identify their intracellular targets. 
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showed that this compound localised inside the kinetoplast and the nucleus of the cells, 
with a fluorescent intensity proportional to the drug concentration (Cox et al., 1984). The 
same authors showed a more diffuse cytoplasmic fluorescence for propidium iodide, which 
appeared to stain the kinetoplast with a less intense emission than the nucleus (Cox et al., 
1984). Isometamidium revealed a greater affinity for the kinetoplast than ethidium 
(Boibessot et al., 2002). Boibessot and collaborators also observed that the absorption of 
ethidium into trypanosomes was slower than that of isometamidium, confirming data 
published previously (Hawking and Sen, 1960). 
4.1.3 Acridine orange 
Acridine orange [3,6-bis(dimethylamino)acridine] is a basic nucleic acid dye, isomer of 
phenanthridine (Figure 4.3). The fluorescence characteristics of this molecule are complex. 
In diluted aqueous solutions (10
-7 M) the fluorophore is present as a monomer, while the 
dimeric form prevails in more concentrated solutions (>10
-2 M). These two forms have 
different spectral properties (Table 4.3) and give rise to specific complexes with nucleic 
acids (Tomita, 1967; MacInnes and McClintock, 1970; Zelenin, 1999). Complex I is 
formed when the monomer of acridine orange intercalates within bases of double-stranded 
DNA (with a ratio of one molecule of dye per four bases of DNA). This interaction 
increases the green fluorescence yield 2- to 2.5-fold as compared to the free dye. Complex 
II has a red emission and arises from binding of the dimer to single-stranded nucleic acids 
and RNA, apparently by ionic interactions with the sugar-phosphate backbone (Gardner 
and Mason, 1967). This interaction induces a 10-fold decrease in the fluorescence yield 
(Zelenin, 1999) (spectral characteristics of these complexes are indicated in Table 4.3). 
Acridine orange can also form salt-like complexes with polysaccharides and, at pH>7, it 
binds to proteins, yielding red fluorescence (Zelenin, 1999). 
The fluorescent properties of acridine orange have been intensively exploited for a wide 
range of purposes. Its double green and red emission can allow discrimination between 
double-stranded DNA and single-stranded nucleic acids (Watson and Chambers, 1977). By 
being a membrane-permeant compound, acridine is also used in association with other 
exclusion dyes (such as propidium iodide) to distinguish living from apoptotic cells (Bank, 
1988; Foglieni et al., 2001). Another use of this fluorophore is as an in vivo marker for 
acidic cell compartments, such as lysosomes (Zelenin, 1966; Brunk et al., 2001) or the 
trypanosome’s acidocalcisomes (Docampo and Moreno, 1999), inside which acridine is 
actively accumulated, protonated and sequestered. Federica Giordani, 2010    Chapter 4, 97 
N N N
Acridine orange
N N N
Acridine orange  
Figure 4.3 – Chemical structure of acridine orange. 
 
lEX (nm)  lEM (nm) 
 
free dye  + NA  free dye  + NA 
AO monomer/Complex I  494  502-504  530  530 
AO dimer/Complex II  465  475  640  640 
Table 4.3 – Excitation and emission maxima of acridine orange. 
Peak values in the absence (free dye) or presence of nucleic acids (+ NA) are indicated. In 
aqueous solutions (free dye) the fluorophore exists in two forms, depending on its 
concentration. At low molarities acridine orange is present as a monomer, which binds to 
double-stranded DNA by intercalation, yielding green fluorescence (Complex I). The dimer is 
formed at high concentrations and it binds to single-stranded DNA or RNA yielding red 
fluorescence (Complex II). 
AO: acridine orange; NA: nucleic acids; l  l  l  lEX: wavelength of maximum excitation;  
l l l lEM: wavelength of maximum emission. 
Acridine orange is used as fluorescent probe for the diagnosis of malaria: protocols include 
direct application of the dye to the specimen on microscopy slides (Kawamoto, 1991; 
Delacollette and Van der Stuyft, 1994; Keiser et al., 2002) or coating the interior of the 
capillary tubes used in the quantitative buffy coat system (Baird et al., 1992). This last 
technique has also been applied to detect trypanosomes in human blood (Bailey and Smith, 
1992; Chappuis et al., 2005), but its high cost makes it difficult to implement in field 
settings (Section 1.2.3.6). 
The fluorescence spectra of this fluorophore match the wavelength range of the standard 
FITC filter, which is the spectral region also covered by the LED Cytoscience SMR 
microscope (Jones et al., 2007). Federica Giordani, 2010    Chapter 4, 98 
4.2 Results 
4.2.1 Fluorescence properties of the five pentamidine analogues 
To evaluate if the five green fluorescent pentamidine analogues could represent useful 
diagnostic probes for trypanosomiasis, their staining properties were studied in parasites 
both in culture medium (in vitro) and in murine blood (ex-vivo). Compatibility with the 
LED-driven Cytoscience fluorescence microscope was also assessed. 
4.2.1.1  Fluorescence in in vitro trypanosomes 
Fluorescence experiments on in vitro-grown T. b. brucei wild type cells showed that the 
five pentamidine analogues were actively internalised and accumulated into parasites 
(Figure 4.4). When given at 50 mM, the fluorophores stained the kinetoplast and cytoplasm 
of live trypanosomes with a green fluorescence, clearly visible upon FITC excitation 
(λEX=470 nm, λEM=519 nm) at low magnification (40× objective), after 10-15 minutes of 
treatment. Uptake was highly dependent on the temperature of incubation: the fluorescent 
signal inside the cells was nearly completely inhibited when treatment was carried out at 
4°C and it developed only when cells were treated at room temperature or 37°C, consistent 
with a mediated uptake of the five diamidines into trypanosomes (Figure 4.5). 
Fluorescence intensity of parasites stained with the green fluorescent diamidines increased 
with time of incubation, but the overall yields were never very high, despite the fact that 
the excitation wavelengths of the fluorophores matched the 405 nm emission peak of the 
mercury lamp. The use of higher dye concentrations did not improve their signal, nor did it 
significantly increase their rate of uptake into parasites (another result consistent with 
carrier-mediated uptake). The low emission intensity of this series of compounds could be 
due to their intrinsic low fluorescent yields. A comparison between the spectrum of 
DB1680 and that of the related diamidine DB75, for example, showed a 6-fold lower 
emission intensity for DB1680 than DB75, although the green fluorescent dye was used at 
a higher concentration (20-fold) (Figure 4.6). Another factor which could have lead to 
suboptimal fluorescence intensity emission of the five compounds could have been the 
discrepancy between their excitation maxima, all close to 400 nm (Table 4.1), and the 
standard FITC filter wavelength (λEX=470 nm) utilised for microscopy experiments. The 
use of another filter set, which better matches the spectral excitation characteristics of the 
green fluorescent diamidines, may allow obtaining of higher fluorescence emission yields. Federica Giordani, 2010    Chapter 4, 99 
 
Figure 4.4 – Fluorescence development within in vitro trypanosomes treated with the five 
green fluorescent pentamidine analogues. 
T. b. brucei w.t. cells from culture were incubated with 50 m m m mM of each compound at r.t.. At 
the indicated time points, wet films were prepared and directly viewed under the FITC filter 
(λEX=470 nm, λEM=519 nm) of the Zeiss Axioplan microscope. Parasites incubated for 8 h, 
were treated with 500 nM of each compound at 37°C. 
FITC 33 ms exposure; 40× objective. *: kinetoplast; →: unidentified cytoplasmic corpuscles. 
Bar: 10 m m m mM. 
 
Figure 4.5 – Effect of temperature on the internalisation of DB1680 and DB1692 into T. b. 
brucei. 
In vitro w.t. parasites were incubated with 50 m m m mM of either compound for 1 h at 4° C, room 
temperature (r.t.) or 37° C. Wet films were prepared  and directly viewed under the FITC filter 
of the Zeiss microscope. The effects of temperature on the uptake of the other three 
diamidines of the series (not shown here) were similar to those illustrated in the figure. 
FITC 33 ms exposure; 40× objective. Bar: 10 m m m mM. Federica Giordani, 2010    Chapter 4, 100 
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Figure 4.6 – Fluorescence spectra of DB1680 and DB75. 
(A) The spectrum of DB1680, measured using a 1 m m m mM solution of the compound in dH2O. 
(B) The spectrum of DB75, measured using a 50 nM solution of the compound in dH2O.  
Note the different scale of the axis of ordinates. 
EX: excitation spectrum; EM: emission spectrum. 
4.2.1.2  Uptake and intracellular distribution 
When wild type trypanosomes, stained with 50 mM of each diamidine, were viewed using 
the FITC channel (Figure 4.4 and 4.9), two common features, shared by all of the five 
green fluorescent compounds, could be identified: (1) all of them rapidly concentrated 
inside the kinetoplast, which remained the brightest organelle beyond 8 hours incubation 
time; (2) the nucleus could never be visualised. With the exception of DB1464, where this 
characteristic was less marked, the fluorophores accumulated inside the cytoplasm, making 
the whole cell shape distinguishable even at low magnification. Punctate fluorescent 
granules, spread throughout the whole cell length and similar to those observed for DB75 
upon FITC excitation (Section 3.2.7), could be detected among the diffuse cytoplasmic 
signal. 
A more pronounced fluorescent spot present in an area between the kinetoplast and the 
nucleus of the cells was consistently detected by 15 minutes treatment with DB1645, 
DB1692 and DB1680 (Figure 4.4). Since this region of the trypanosome cell is occupied 
by the endomembrane compartments (Golgi complex and endosomes, Figure 1.3) and it is 
in this area that all membrane trafficking takes place (Field et al., 2007; Field and 
Carrington, 2009) we speculated a possible involvement of endocytosis (a highly active 
process in bloodstream form) in the internalisation of these compounds. This hypothesis 
was strengthened by the Alamar Blue results, which suggested alternative routes of entry, 
other than P2, for the fluorophores (Section 4.2.2.1), and by the loss of diamidine 
internalisation when incubating at 4°C (Figure 4.5), a temperature known to inhibit 
endocytosis (Brickman et al., 1995; Coppens et al., 1995; Liu et al., 2000), as well as other Federica Giordani, 2010    Chapter 4, 101 
active mechanisms of uptake. To further test this idea, the fluorescence patterns were 
assessed in in vitro wild type trypanosomes pre-treated with endocytic inhibitors before 
staining with the diamidines DB1680 and DB1692. For these experiments we used 
cytochalasin D (10 mM for 1 h at 37°C), a cell-permeable potent inhibitor of actin 
polymerisation, which in bloodstream trypanosomes is required for the formation of coated 
vesicles from the flagellar pocket membrane (García-Salcedo et al., 2004). The use of this 
toxin, together with other membrane stabilizing drugs, was shown to reversibly inhibit 
human serum lysis, a process that involves endocytosis (Rifkin, 1983; Ortiz-Ordóñez et al., 
1994). However, fluorescent micrographs did not evidence any significant change in dye 
distribution following cytochalasin pre-treatment (Figure 4.7), the fluorophores continuing 
to accumulate as posteriorly localised spots (although their number and size appeared 
slightly increased following incubation with the toxin). Similarly, no evident effects were 
observed after pre-treating with chloroquine (up to 200 mM for 1 h at 37°C), a 
lysomotropic amine which had previously been used as a receptor-mediated endocytosis 
inhibitor in both procyclic form (Liu et al., 2000) and bloodstream T. brucei (Coppens et 
al., 1993 and 1995) (data not shown). These experiments did not, therefore, demonstrate an 
endosomal localisation of the green fluorescent diamidines. 
To study in more depth these fluorescent inclusions, trypanosomes had to be immobilised. 
Methanol fixation of stained trypanosomes, however, proved inadequate, since it washed 
away most of the incorporated fluorophore. A better system was to immobilise labelled 
living parasites by embedding them in agarose (Section 2.5.2.2). This system allowed the 
study of the fluorophores’ intracellular distribution in live parasites, avoiding artefacts 
often produced by common fixation protocols. 
When cells were immobilised in agarose and viewed at high magnification the cytoplasmic 
fluorescent inclusions, already visible under 40× objective, became more obvious (Figure 
4.8). Following DB1680 treatment, the vesicular structures tended to be localised to the 
posterior of the cell, while after incubation with DB1692 other inclusions, present in the 
anterior part of the cell, were clear, again inconsistent with endocytic vesicles. 
Interestingly, fluorescent emission from cytoplasmic corpuscles could also be detected at 
longer wavelengths, using the RHOD filter set (λEX=546 nm, λEM=590 nm), a phenomenon 
already noticed for the diamidine DB75 (for which we observed fluorescence in the blue 
and green regions of the spectrum; Chapter 3). The red fluorescent signal mostly 
colocalised with the green emission, but intensity of each fluorescent corpuscle was 
variable under the different filter sets. For DB1692, a prominent red fluorescent spot  Federica Giordani, 2010    Chapter 4, 102 
 
Figure 4.7 – Effect of cytochalasin D on the uptake of DB1680 and DB1692. 
In vitro T. b. brucei w.t. cells (2×10
7 cells/ml) were pre-incubated with 10 m m m mM cytochalasin D 
(Cyt. D, Sigma-Aldrich) for 1 h at 37°C and then tr eated with 50 m m m mM of either diamidine for 1 h 
at 37° C. Aliquots of live parasites were put on a m icroscope slide, covered with a coverslip 
and directly viewed under the FITC filter of the Zeiss Axioplan microscope. Trypanosomes 
not pre-treated with cytochalasin and used as control are shown on the left panels. 
FITC 33 ms exposure; 100× objective. *: kinetoplast; →: hypothetical endosomal vesicles. 
Bar: 10 m m m mM. 
 
 
Figure 4.8 – Fluorescence images at high magnification of trypanosomes treated with 
DB1680 and DB1692. 
T. b. brucei w.t. cells from culture were incubated with 50 m m m mM of either compound for 1 h at 
37° C and successively put into ice to stop dye upta ke. DAPI (20 m m m mM) was added to the cells 
as DNA counterstain and left for 30 min before mounting in 1% agarose. Trypanosomes 
were also viewed without addition of counterstain to exclude possible interference of DAPI 
in the emission of the green fluorescent diamidines. Cells were viewed using various filters 
of the Zeiss Axioplan fluorescence microscope, as indicated in the images. Micrographs 
were merged using Adobe Photoshop 7.0 software. 
Time of exposure of the camera for the three filters (DAPI, FITC, RHOD) was not kept 
constant; 100× objective. *: kinetoplast; ►: nucleus. Bar: 10 m m m mM. Federica Giordani, 2010    Chapter 4, 103 
appeared in a region between nucleus and kinetoplast after 1 hour treatment with the 
fluorophore, but it was not visible at shorter time of incubation. The other three compounds 
of the series yielded similar punctate emission upon RHOD excitation (data not shown). 
These fluorescent corpuscles could be the same as those observed using the FITC channel 
following DB75 treatment (Figure 3.9), although, following incubation with DB1692, they 
appeared less homogeneous in size and some were localised at the posterior of the 
kinetoplast (Figure 4.8). Further studies will be needed in order to understand the origin of 
these spots. The general low intensity yield and the punctate fluorescent pattern meant that 
this red emission will be of limited use as a fluorescent diagnostic marker for 
trypanosomes. 
4.2.1.3  Fluorescence in viable ex-vivo trypanosomes 
To be useful for fluorescence-based trypanosomiasis diagnostics, it is important that 
fluorophores are able to specifically label parasites among a complex blood matrix, the 
fluid most widely used for parasitological examination in the field. The five green 
fluorescent diamidines fulfilled this criterion, since they provided a specific staining of 
trypanosomes without labelling erythrocytes in infected rat blood films, when given at  
50 mM (Figure 4.9). As for in vitro samples, in ex-vivo-treated specimens the kinetoplast 
appeared the brightest organelle. The other cytoplasmic fluorescent corpuscles were also 
visible in these samples. Green fluorescent trypanosomes were readily detectable among 
blood cells based on their movement and fluorescent dots (especially the bright 
kinetoplast), which allowed them to be easily distinguished from crystals or debris that 
fluoresced in the background using a low magnification objective (40×). As already 
noticed for DB75, however, also these diamidines suffered a relatively fast photobleaching, 
although the fading appeared less marked in blood samples compared to culture samples. 
4.2.1.4  Fluorescence in fixed thin blood smears 
When they were applied to fixed thin blood smears, fluorescence of the five pentamidine 
analogues proved generally quite poor and suffered photobleaching. DB1692 appeared to 
be the best of the series, labelling trypanosomes in methanol-fixed films with discrete 
yields (Figure 4.10 A). When a dry thin smear, not fixed in methanol, was stained with the 
same amount of the compound (10 mM), the quality of fluorescence was highly affected 
(Figure 4.10 B). DB1692 could also be used to stain methanol-fixed trypanosomes from 
culture, but in these samples fluorescence yields were low (Figure 4.10 C). Federica Giordani, 2010    Chapter 4, 104 
 
Figure 4.9 – Fluorescence images of live trypanosomes treated ex-vivo with each of the five 
green fluorescent pentamidine analogues. 
Aliquots of rat blood infected with T. b. brucei w.t. parasites were incubated with 50 m m m mM of 
each compound at 37°C and at the indicated time poi nts wet blood smears were prepared 
and viewed under the FITC filter of the Zeiss Axioplan microscope. Bright field images are 
shown on the left of the corresponding fluorescent micrograph (note that position of motile 
trypanosomes can change in the two images). 
FITC 100 ms exposure; 40× objective. *: kinetoplast; →: cytoplasmic corpuscles. Bar: 10 m m m mM. 
 
Figure 4.10 – Fixed T. b. brucei w.t. trypanosomes stained with DB1692. 
(A) Thin blood smear fixed in methanol and labelled with 10 m m m mM DB1692. (B) Thin blood 
smear, air-dried but not fixed in methanol, and labelled with 10 m m m mM DB1692. (C) 
Trypanosomes from culture, fixed in methanol and stained with 10 m m m mM DB1692. For all of the 
three samples, 50 m m m ml of dye solution were applied and spread with a coverslip. Specimens 
were viewed under the FITC filter of the Zeiss Axioplan microscope. 
FITC 68 ms (A and B) or 450 ms (C) exposure; 40× objective (A and B); 100× objective (C). 
→: white blood cell. Bar: 10 m m m mM. Federica Giordani, 2010    Chapter 4, 105 
4.2.1.5  Compatibility with the LED Cytoscience SMR microscope 
The green fluorescent series of pentamidine analogues was specifically designed to create 
P2 substrates with longer wavelengths than the UV diamidine DB75, in order to generate 
new substrates to use in the arsenical drug resistance test (Stewart et al., 2005), in 
association with the already available LED Cytoscience SMR field fluorescence 
microscope (Jones et al., 2005 and 2007). Unfortunately, although of longer excitation 
wavelength than DB75 (Table 4.1), the excitation maxima of the compounds of this series 
were still too short to be compatible with the narrow band-emitting LED source of the 
Cytoscience instrument (λEX=472 nm). DB1680 and DB1692 were the only two 
compounds out of the five that yielded an extremely faint emission when observed under 
this microscope (no images are available because no suitable camera could be connected 
with the instrument). As previously discussed (Section 4.2.1.1), the standard FITC filter of 
the Zeiss fluorescence microscope was not ideally matched with the spectral characteristics 
of these diamidines, and the use of a more appropriate filter set (also for the LED 
instrument) might allow a better exploitation of their fluorescent properties. 
4.2.2 Use of the green fluorescent pentamidine analogues as 
substrates for the arsenical drug resistance test 
The five green fluorescent diamidines appeared to be accumulated into wild type 
trypanosomes by a carrier-mediated process, although low fluorescence emission allowed 
detection of the intracellular dyes only after 10-15 minutes. As with other diamidine 
molecules, these compounds were expected to be internalised mainly by the P2/TbAT1 
amino-purine transporter and, therefore, to enter only marginally into arsenical- and 
diamidine-resistant parasites lacking this transporter’s activity. Tight dependence on the P2 
carrier for their uptake would have made these compounds alternative probes to the UV 
diamidines DB99 and DB75 for the arsenical drug resistance test. 
4.2.2.1  Trypanocidal effect on wild type and P2-deficient T. b. brucei strains 
To investigate the involvement of the P2 transporter in the molecules’ uptake, the Alamar 
Blue assay was first performed. For the test, three different T. b. brucei strains were used: 
wild type S427 line, tbat1
-/- line, which lacks the gene that encodes for the P2 transporter 
(Matovu et al., 2003) and B48 line, a pentamidine-adapted clone derived from tbat1
-/- and 
in which the HAPT (high affinity pentamidine transporter) activity is lost (Bridges et al., 2007). Federica Giordani, 2010    Chapter 4, 106 
IC50 (nM)      Resistance factor 
Compound 
w.t.  tbat1
-/-  B48     tbat1
-/-  B48 
DB1464  0.87 ± 0.57  6.92 ± 4.12  7.25 ± 1.51     8.0  8.3 
DB1465  6.85 ± 3.72  71.40 ± 8.80  333.90 ± 24.52    10.4  48.7 
DB1645  14.50 ± 6.32  232.93 ± 86.19  610.44 ± 133.21    16.1  42.1 
DB1692  17.64 ± 9.79  436.10 ±82.39  344.20 ± 31.29    24.7  19.5 
DB1680  266.20 ± 45.93  590.95 ± 84.94  340.48 ± 23.51    2.2  1.3 
Pentamidine  0.61 ± 0.65  0.91 ± 0.41  166.95 ± 20.04     1.5  273.7 
Table 4.4 – Trypanocidal activity of the five pentamidine analogues against T. b. brucei S427 
w.t., tbat1
-/- and B48 cell lines. 
IC50 values (drug concentration required to inhibit trypanosome proliferation by 50%) were 
measured using the Alamar Blue assay (Section 2.4). Trypanotoxicity of pentamidine was 
used as positive control. Resistance factors were calculated by dividing the IC50 value 
obtained for each compound on the tbat1
-/- and B48 lines by the value obtained on the w.t. 
line. All data are reported ± the standard deviation and represent the mean of at least three 
independent experiments. 
The Alamar Blue results on the wild type strain showed a potent trypanotoxicity for all of 
the five diamidines, with IC50 in the nanomolar range (Table 4.4). DB1464 was the most 
active trypanocide, having an IC50 close to the value of pentamidine. For this molecule, 
loss of P2 (tbat1
-/- line) corresponded to 8-fold decrease of toxic activity, indicating an 
involvement of this permease in its uptake into the parasite. Similar loss of activity against 
the tbat1
-/- line, but more marked, was also observed for DB1465 and DB1645 (10- and 16-
fold resistance factor respectively), which had a very similar molecular structure to 
DB1464 (Figure 4.1). Unlike DB1464, however, these last two compounds showed a high 
dependence on HAPT for internalisation, their IC50 further increasing 38- and 26-fold, 
respectively, when also activity of this transporter was lost (B48 line). DB1692 appeared to 
be the diamidine most dependent on P2 activity, showing an IC50 nearly 25-fold higher on 
the tbat1
-/- line as compared to the wild type strain, with no further loss of toxicity in the 
B48 line. The resistance factors measured for these four green fluorescent diamidines were 
in the same order of magnitude (10- to 20-fold higher for tbat1
-/- line compared to wild 
type) of those reported for DB75 and diminazene, two trypanocidal drugs highly dependent 
on P2 transport (Lanteri et al., 2006; Bridges et al., 2007). The addition of a single furan 
ring in the linker of DB1680 drastically affected its trypanocidal activity (the molecule was 
the less toxic of the series). The IC50 of this compound on tbat1
-/- line was only 2-fold that 
measured on the wild type strain, a value similar to that of pentamidine, a drug that only 
partially relies on the P2 permease for uptake. However, if pentamidine internalisation was 
highly disrupted by loss of HAPT (B48 line), the same effect was not observed for 
DB1680, indicating that other routes of internalisation must play a role for its uptake. 
In conclusion, the Alamar Blue results suggested that the pentamidine analogues 
synthesised in Prof. D. W. Boykin’s laboratory were substrates for the P2 amino-purine Federica Giordani, 2010    Chapter 4, 107 
transporter, although other carriers (such as HAPT for DB1465 and DB1645), or other 
routes of uptake (for DB1680), may play a role for their internalisation into trypanosomes. 
Endocytosis could represent an alternative mechanism of entrance, but our experiments 
failed to support this hypothesis (Section 4.2.1.2). 
4.2.2.2  Fluorescence in wild type and P2-deficient
 T. b. brucei strains 
The Alamar Blue results proved the presence of a link between the compounds’ 
cytotoxicity and active expression of the P2 amino-purine transporter, as expected for 
diamidine compounds. Fluorescence microscopy was then used to assess if this correlation 
also resulted in a differential fluorescence development in parasites lacking or expressing 
the P2 permease, the crucial aspect for their use in the arsenical drug resistance test. For 
microscopy, the same parasites lines used to perform the Alamar Blue assay (Section 
4.2.2.1) were treated with each compound of the series (50 mM) for 15 min and viewed 
under the FITC filter of the Zeiss fluorescence microscope (Figure 4.11). Unfortunately, 
fluorescence micrographs did not reveal any significant difference in the diamidines’ speed 
of uptake when comparing wild type, tbat1
-/- and B48 lines. No differences were noticed 
even after longer times of incubation (up to 2 hours). 
The fact that we could not observe differential uptake in wild type and tbat1
-/-cells after 15 
minutes of incubation was not completely surprising: differences in intracellular 
fluorescence development linked to the presence or absence of the P2 transporter are more 
evident within the first minutes of incubation (Stewart et al., 2005), after which other 
lower affinity transporters, or differential routes of uptake, can compensate for the absence 
of this permease’s activity. Unfortunately, the low fluorescence yields observed for the 
green diamidine series, under our experimental conditions, did not allow detectable signal 
inside trypanosomes at shorter times of treatment (up to 10 minutes). For this reason we do 
not consider these fluorescent diamidines to be suitable probes for the arsenical resistance 
test, unless higher yields are obtained with a more compatible filter set. 
4.2.3 Ethidium bromide and isometamidium chloride 
The compounds belonging to the green fluorescent diamidine series did not possess all of 
the necessary requisites to become fluorescent diagnostic markers for trypanosomiasis. The 
main problems associated with their use were a low fluorescent yield upon FITC excitation 
and a relatively fast photobleaching. Therefore, the staining properties of other Federica Giordani, 2010    Chapter 4, 108 
 
Figure 4.11 – Fluorescence images of T. b. brucei w.t., tbat1
-/- and B48 line treated with each 
of the five green fluorescent pentamidine analogues. 
Cells from culture were incubated with 50 m m m mM of each compound for 15 min at r.t. and 
directly viewed under the FITC filter of the Zeiss Axioplan microscope. 
FITC 33 ms exposure; 40× objective. Bar: 10 m m m mM. 
commercially available fluorophores were assessed, in order to find better probes to label 
trypanosomes. The phenanthridines ethidium bromide and isometamidium chloride were 
considered of interest for our project, being both fluorescent and specifically absorbed by 
trypanosomes (Cox et al., 1984; Boibessot et al., 2002). Fluorescence of propidium iodide 
(an analogue of ethidium) and of acridine orange (an isomer of phenanthridine) were also 
assessed (Sections 4.2.4 and 4.2.5 respectively). 
4.2.3.1  Fluorescence in ex-vivo viable trypanosomes 
Ethidium bromide quickly permeated live ex-vivo trypanosomes, yielding a bright 
fluorescence of the kinetoplast after only 5-10 minutes incubation with low doses of the 
compound (0.5, 1 mM) (Figure 4.12). However, we noticed that not all of the cells in the 
sample were equally stained by the fluorochrome. At these concentrations, fluorescence  Federica Giordani, 2010    Chapter 4, 109 
 
Figure 4.12 – Ethidium bromide fluorescence development within live ex-vivo 
trypanosomes. 
Rat blood samples infected with T. b. brucei w.t. line were incubated ex-vivo with different 
concentrations of ethidium bromide at 37°C. At the  indicated time points thin wet smears 
were prepared and viewed under the RHOD filter (λEX=546 nm, λEM=590 nm) of the Zeiss 
Axioplan microscope. 
RHOD 68 ms exposure; 40× objective. *: kinetoplast; ►: nucleus. Bar: 10 m m m mM. 
 
Figure 4.13 – Isometamidium chloride fluorescence development within live ex-vivo 
trypanosomes. 
Rat blood samples infected with T. b. brucei w.t. line were incubated with different 
concentrations of isometamidium chloride at 37°C. At the indicated time points thin wet 
smears were prepared and viewed under the RHOD filter of the Zeiss Axioplan microscope. 
No fluorescence could be detected for treatment with 0.5 m m m mM up to 10 min of incubation. 
RHOD 68 ms exposure; 40× objective. *: kinetoplast. Bar: 10 m m m mM. Federica Giordani, 2010    Chapter 4, 110 
 
Figure 4.14 – Fixed thin blood smears stained with ethidium bromide and isometamidium. 
Specimens were stained with 50 m m m ml of 5 m m m mM ethidium bromide (A) or isometamidium (B) and 
immediately viewed under the RHOD filter of the Zeiss Axioplan microscope. The fixed 
smears had been prepared a fortnight before the experiments, using murine blood infected 
with T. b. brucei w.t. trypanosomes. Slides were kept in a box until use.  
RHOD 68 ms exposure; 40× objective. →: white blood cell. Bar: 10 m m m mM. 
development inside the nucleus was slightly delayed compared to that of the kinetoplast. 
At 5 mM the nucleus was, however, already visible after 5 minutes of treatment, although 
its emission was comparable to that of the kinetoplast only after further 10 minutes. 
Nucleus and kinetoplast were the main detectable organelles, but ethidium also produced a 
low fluorescence from the cell cytoplasm. Red blood cells remained unstained. After 
longer times of incubation (1 hour when given at 5 mM and 2 hours when given at 1 mM) 
treatment with ethidium caused bursting of parasites present in the samples. 
Treatment of ex-vivo trypanosomes with isometamidium chloride, using the same 
concentrations utilised during the experiments with ethidium bromide, showed a much 
lower fluorescence (Figure 4.13). The only bright signal easily detectable while examining 
these samples under RHOD filter was a spot corresponding to the kinetoplast of the 
parasites. No other organelles could be detected up to 30 minutes incubation using these 
doses and only a very faint fluorescence in the cell’s cytoplasm was evident. 
4.2.3.2  Fluorescence in fixed thin blood smears 
Ethidium bromide proved a good probe for trypanosome staining in thin fixed blood 
smears. A low concentration of the dye (5 mM) was sufficient to give a bright red 
fluorescence to the parasites, while leaving the erythrocytes unlabelled (Figure 4.14 A). 
Application of an isometamidium solution (5 mM) to the smear, instead, stained the red 
blood cells (Figure 4.14 B), which yielded a low background emission, only slightly lower Federica Giordani, 2010    Chapter 4, 111 
than that emitted by trypanosomes. For these experiments, films that were several weeks 
old were used. Storage could have determined a slight deterioration of the specimens, 
causing the homogeneous staining of the parasites’ cytosol and hampering the distinction 
of the nucleus and the kinetoplast. 
4.2.4 Propidium iodide 
4.2.4.1  Fluorescence in in vitro viable trypanosomes 
Despite being considered a membrane-impermeant dye, propidium iodide was shown to 
stain viable T. brucei parasites with a bright red fluorescence, more intense than that of its 
analogue ethidium bromide (Cox et al., 1984). Our microscopy experiments confirmed 
these findings. When in vitro-cultured wild type trypanosomes were incubated at 37°C 
with micromolar concentrations of this phenanthridine (10-50 mM), the fluorophore was 
absorbed by the cells, staining with a stable fluorescence the nucleus and, to a lesser extent, 
the kinetoplast (Figure 4.15, left panels). Propidium also dispersed inside the cytoplasm, 
revealing the shape of the whole cell. For in vitro parasites, long times of incubation 
(greater than 1 hour) were needed to obtain the internalisation of sufficient dye in order to 
give a relatively good signal-to-noise ratio, indicating a slow mechanism of uptake for this 
fluorophore. 
4.2.4.2  Fluorescence in ex-vivo viable trypanosomes 
Using prolonged incubation times (1-2 hours), in ex-vivo specimens, propidium iodide 
brightly stained trypanosomes, leaving the erythrocytes non-fluorescent. Interestingly, 
when parasites grown in rodents were treated ex-vivo following the same protocol used for 
in vitro cells, their corresponding fluorescence intensity appeared much higher (Figure 
4.15, right panels), even though their general fluorescent pattern was identical. A 
significant fraction of wild type trypanosomes in infected rat blood samples was killed by 
this phenanthridine after 2 hours of incubation, the cells appearing to be lysed by the dye 
(given at 10 or 50 mM). At this time point, the same concentration of the fluorophore did 
not kill in vitro cells. The high trypanocidal activity of propidium on wild type cells was 
confirmed by our Alamar Blue data: for this compound we measured an IC50 of 30.26 ± 
7.66 nM (mean of three experiments ± standard deviation). 
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The different levels of propidium absorption by in vitro and ex-vivo trypanosomes could be 
due to the fact that cells from rodents might be more fragile than those grown in culture, 
resulting in their being more permeable to the fluorophore. However, ex-vivo parasites 
incubated up to 1 hour with propidium iodide appeared normal and actively motile in the 
sample. We may also hypothesize a mechanism of transport of this compound into 
trypanosomes, subject to down-regulation in in vitro-grown cells compared to in vivo-
grown parasites, as occurs with uptake of DB75 by the P2/TbAT1 transporter (Chapter 6). 
Uptake experiments carried out in our laboratory showed that pentamidine can partially 
inhibit ehidium bromide internalisation (Chris Ward, personal communication), suggesting 
a competition for the same surface binding sites. It is possible that propidium, being an 
analogue of ethidium, is transported by similar permeases into trypanosomes. Co-treatment 
of ex-vivo wild type trypanosomes with propidium (1 mM) and P2-substrates DB75  
(10 mM) or adenosine (25 mM), however, did not reveal significant differences in 
fluorescence development as compared to cells treated with propidium alone (data not 
shown). This result excluded a primary role of the P2 transporter in the uptake of the 
phenanthridine. Future fluorescence experiments on mutant strains lacking specific 
pentamidine transporters could reveal if they are involved in the uptake of propidium 
iodide and give some indications regarding how it crosses the parasite’s membrane. 
When viewed at low magnification, the trypanosome’s cytosol appeared homogeneously 
stained by propidium iodide (Figure 4.15). However, when cells were examined at high 
magnification (100× objective) the cytoplasmic emission showed a punctate distribution 
(Figure 4.16). These fluorescent granules could correspond to the inclusion bodies already 
observed in trypanosomes treated with other phenanthridines (Ormerod, 1951; Taylor, 
1960). The inclusion bodies were described as cytoplasmic granules mainly composed of 
ribonulceic acids and proteins, hence a target for propidium iodide, which is a known 
strong RNA-binding compound. 
Since propidium was capable of labelling viable parasites in blood samples, its staining 
properties were assessed for lower dye concentration and shorter times of incubation. 
These experiments were carried out in order to identify a protocol more suitable for field 
diagnostic purposes, for which reagent availability and sample processing time are of 
fundamental importance. Microscopy showed that in ex-vivo samples treated at 37°C, 
concentrations of the fluorophore as low as 5 mM could stain live trypanosomes in 10-15 
minutes, although the emission was not bright (Figure 4.17). Propidum internalisation was 
dose- and time- dependent: when 0.5 mM of the fluorophore were used, at least 30 minutes  Federica Giordani, 2010    Chapter 4, 114 
 
Figure 4.16 – Propidium iodide-stained trypanosome viewed at high magnification. 
Aliquots of rat blood infected with T. b. brucei w.t. parasites were incubated ex-vivo with  
10 m m m mM propidium iodide for 1 h at 37°C. The wet thin sm ear was viewed under the RHOD 
filter of the Zeiss Axioplan microscope. 
RHOD 68 ms exposure; 100× objective. *: kinetoplast; ►: nucleus. Bar: 10 m m m mM. 
 
Figure 4.17 – Propidium iodide fluorescence development within ex-vivo trypanosomes. 
Rat blood samples infected with T. b. brucei w.t. parasites were incubated with different 
concentrations of propidium iodide at 37° C. At the  indicated time points thin wet smears 
were prepared and viewed under the RHOD filter of the Zeiss Axioplan microscope. 
RHOD 68 ms exposure; 40× objective.   *: kinetoplast; ►: nucleus. Bar: 10 m m m mM. 
were needed to obtain a discrete staining of trypanosomes, while this time decreased to 15-
20 minutes when 1 mM was applied. If incubation was carried out at room temperature, 
fluorescence development was significantly reduced, possibly due to a lower fluidity of the 
plasma membrane. During these experiments using wet films, white blood cells labelled by 
the dye were never observed. This suggested the hypothesis that propidum entered 
trypanosomes using specific transporters that were not present on leukocytes’ surface. Federica Giordani, 2010    Chapter 4, 115 
 
Figure 4.18 – Fixed thin blood smears stained with propidium iodide. 
(A) Blood smear air-dried and fixed in methanol before staining with 5 m m m mM of propidium. 
(B) Blood smear air-dried and stained with 5 m m m mM of propidium without methanol fixation. 
Both specimens were covered with a coverslip and immediately viewed under the RHOD 
filter of the Zeiss Axioplan microscope. Specimen examination was carried out within few 
hours from their preparation using murine blood infected with T. b. brucei w.t.. Note that the 
nuclei of trypanosomes on the top right and at the bottom of panel B appear swollen. 
RHOD 68 ms exposure; 40× objective. →: white blood cell; *: kinetoplast; ►: nucleus. 
Bar: 10 m m m mM. 
4.2.4.3  Fluorescence in fixed thin blood smears 
Propidium iodide yielded very bright fluorescence in fixed infected thin blood films. In 
these specimens, where the barrier represented by intact membranes was eliminated, 
application of 5 mM of the fluorophore gave an immediate red fluorescence inside 
trypanosomes and nucleated blood cells (Figure 4.18 A). The nucleus and kinetoplast of 
parasites were brightly labelled as well as other nucleic acids present in the sample. A 
faster and simpler preparation of the specimens was assessed: air-dried smears were 
immediately stained with the fluorophore without previous fixation in methanol. In these 
specimens trypanosomes were brightly fluorescent, but the shape of the cells could appear 
deformed and damaged, often showing an enlarged nucleus (Figure 4.18 B). When used to 
stain old, fixed specimens (kept in a box for several weeks) propidium iodide 
homogeneously stained the whole cell body of parasites (Figure 4.25 A). 
4.2.4.4  Compatibility with the LED Cytoscience SMR microscope 
Another interesting feature of propidium iodide was its compatibility with the LED 
Cytoscience SMR fluorescent microscope. Using this instrument, parasites in thin smears 
and stained with 5 mM of the fluorophore appeared orange-red, easily distinguishable from 
the red blood cells, green on the background (as already mentioned previously, no images 
were produced since a suitable camera was not available). Federica Giordani, 2010    Chapter 4, 116 
4.2.5 Acridine orange 
None of the novel and known fluorescent dyes described above possessed all of the 
characteristics an ideal probe for trypanosome detection must have (fast labelling, high 
yield, specificity, photochemical stability, affordability). The widely used fluorophore 
acridine orange, instead, appeared to have most of these qualities, as confirmed by our 
experiments. 
4.2.5.1  Fluorescence in in vitro viable trypanosomes 
Acridine orange quickly permeated the parasite’s membrane, yielding a bright green 
fluorescence upon FITC excitation (Figure 4.19). A concentration as low as 1 mM of this 
compound was sufficient for obtaining a bright signal within 1 minute of incubation. The 
temperature of treatment did not affect dye penetration inside the cells, indicating passive 
diffusion (Figure 4.19). Treatment with the fluorophore revealed the nucleus and the 
kinetoplast of trypanosomes, but it also produced a cytoplasmic diffuse green fluorescence, 
which greatly facilitated detection of parasites in the specimen. These characteristics made 
acridine the best fluorescent probe for trypanosomes tested during the project. 
Nevertheless, its use in the arsenical drug resistance test (Stewart et al., 2005) was not 
possible, since this fluorophore crosses the plasma membrane non-specifically and our 
experiments showed that its internalisation was completely unaffected by the presence 
(wild type line) or absence (tbat1
-/- line) of the P2/TbAT1 transporter on the parasites’ 
surface (Figure 4.19). After only 15 minutes of incubation with the dye (1 mM, 37°C), a 
few cells from in vitro culture started to show some aberrations (i.e. fragmentation of the 
nucleus, abnormal shape), a probable consequence of the genotoxicity of acridine orange. 
In attempt to detect the acidocalcisomes, a known intracellular target of acridine orange, 
stained parasites were examined at high magnification. Due to the high fluorescent 
emission of the dye upon FITC filter excitation, however, visualization of these organelles 
proved difficult and only some of them emerged from the diffuse cytoplasmic green 
fluorescence (Figure 4.20). A brighter vacuole, situated at the posterior of the cell, and 
believed to be the lysosome, based on its intracellular position (Shimamura et al., 2001), 
was evidenced using both FITC and RHOD filter set. This vesicular structure, 
distinguishable from the others by its more intense emission, did not appear in previously 
published epifluorescence micrographs of T. evansi (Mendoza et al., 2002) and procyclic 
trypomastigotes of T. brucei (Docampo and Moreno, 1999) treated with acridine orange,  Federica Giordani, 2010    Chapter 4, 117 
 
Figure 4.19 – In vitro wild type and tbat1
-/- trypanosomes treated with acridine orange at 
different temperatures. 
Aliquots of T. b. brucei w.t. cells from culture were incubated with 1 m m m mM acridine orange at 
4° C, room temperature or 37° C for 1 minute. Wet fil ms were viewed under the FITC filter of 
the Zeiss Axioplan microscope. Fluorescence intensity of labelled parasites was not 
affected by different incubation temperatures or by the absence of the P2 amino-purine 
transporter (tbat1
-/- line) on the cell surface. 
FITC 68 ms exposure; 40× objective. *: kinetoplast; ►: nucleus. Bar: 10 m m m mM. 
 
 
Figure 4.20 – Acridine orange-stained trypanosome viewed at high magnification. 
T. b. brucei w.t. trypanosomes from culture were incubated with 5 m m m mM acridine orange at 
37° C for 15 minutes and embedded in 1% agarose befo re viewing at ×1,000 total 
magnification. For fluorescence the FITC and RHOD filters of the Zeiss Axioplan microscope 
were used. 
FITC 5 ms exposure, RHOD 68 ms exposure; 100× objective. →: acidocalcisomes;     
►: lysosome. Bar: 10 m m m mM. 
although differences in sample preparation and cell line used do not allow direct 
comparison with our work. 
4.2.5.2  Fluorescence in ex-vivo trypanosomes 
Acridine orange has already been successfully used to selectively stain parasites, including 
trypanosomes, among blood cells (Kawamoto, 1991; Bailey and Smith, 1992; Delacollette Federica Giordani, 2010    Chapter 4, 118 
and Van der Stuyft, 1994; Adeoye and Nga, 2007). During our fluorescence experiments 
on infected rat blood, we were able to label viable T. b. brucei with a bright green 
fluorescence, using a very low concentration of the dye (5 mM) (Figure 4.21). Vital 
staining of parasites was extremely fast (1 minute was sufficient to obtain a bright signal) 
and red blood cells remained largely unlabelled (although some appeared to fluoresce 
faintly). Labelling of live trypanosomes in a blood samples could be easily carried out by 
directly adding few microliters of acridine orange solution directly to the drop of blood 
before the preparation of the wet film. This procedure, already illustrated for malaria 
parasites (Metzger and Nkeyi, 1995), had many advantages, being extremely fast (there 
was no need to air-dry or fix the specimen) and allowing easy discrimination of parasites 
due to their motility among blood cells. 
Direct application of acridine orange (5 mM) to dried, fixed blood smears, was equally 
effective (Figure 4.22 A). In these specimens trypanosomes were instantaneously stained 
by the dye. The kinetoplast and the nucleus of parasites appeared very bright, but the entire 
cell shape of the parasites was also revealed upon FITC excitation. Other nucleated cells in 
the specimen showed high emission. In an attempt to simplify sample preparation, we also 
stained a thin air-dried smear with the same dose of acridine orange, eliminating the 
methanol fixation step (as previously shown for propidium iodide). In this case the 
trypanosomes’ nucleus and kinetoplast also appeared brightly fluorescent, but the 
cytoplasm remained unstained (Figure 4.22 B). The samples used during these experiments 
were prepared on the same day as the test. When acridine orange was used to label few 
weeks old thin blood films, the fluorescence inside trypanosomes appeared more evenly 
distributed, and no organelles could be distinguished (as already observed for blood smears 
stained with propidium iodide, Section 4.2.4.3). 
4.2.5.3  Compatibility with the LED Cytoscience SMR microscope 
The LED Cytoscience SMR microscope was designed to excite green fluorescent 
compounds such as acridine orange (Jones et al., 2007) and the efficacy of the instrument 
in visualising malaria parasites labelled with this fluorophore has already been proven 
(Jones et al., 2005 and 2007). Similarly, acridine orange-stained T. b. brucei could be 
readily identified under the LED source of the Cytoscience microscope, appearing highly 
fluorescent over a black background (no images are available). Federica Giordani, 2010    Chapter 4, 119 
 
Figure 4.21 – Wet thin blood smear stained with acridine orange. 
Murine blood infected with T. b. brucei w.t. was incubated with 5 m m m mM acridine orange at r.t. 
for 1 minute. An aliquot of the sample was then used to prepare the wet smear which was 
viewed under the FITC filter of the Zeiss Axioplan microscope. Note that the position of 
motile trypanosomes changed during acquisition of fluorescence and bright field images. 
FITC 60 ms exposure; 40× objective. Bar: 10 m m m mM. 
 
Figure 4.22 – Fixed thin blood smears stained with acridine orange. 
(A) Blood smear air-dried and methanol-fixed before staining with 5 m m m mM of acridine orange. 
(B) Blood smear air-dried and stained with 5 m m m mM of acridine orange without methanol 
fixation. Both specimens were prepared using murine blood infected with T. b. brucei w.t. 
parasites. After staining, slides were covered with a coverslip and immediately viewed 
under the FITC filter of the Zeiss Axioplan microscope. Specimens examination was carried 
out within few hours from their preparation. 
FITC 68 ms exposure; 40× objective. →: white blood cell. *: kinetoplast; ►: nucleus. 
Bar: 10 m m m mM. 
4.2.6 Fluorescent staining of thick blood smears 
The fluorescent properties of the dyes tested during this project were mainly studied using 
thin blood films (whether wet or fixed). However, although thin specimens are still used in 
the field due to their straightforward preparation, their examination suffers a very low 
sensitivity (Chappuis et al., 2005). Preparation of Giemsa-stained thick films is usually 
preferred for diagnosis, decreasing the detection limit from 10,000 to 5,000 cells/ml (Louis 
et al., 2001; Chappuis et al., 2005). Hence, in order to be a useful tool for the diagnosis of  Federica Giordani, 2010    Chapter 4, 120 
 
Figure 4.23 – Air-dried thick blood smears stained with acridine orange or propidium iodide. 
The thick smears infected with T. b. brucei were left to air-dry and kept unfixed until staining 
with 5 m m m mM of acridine orange (A) or propidium iodide (B): 30 m m m ml of either dye solutions were 
applied to the smear and covered with a coverslip. Acridine orange was excited using the 
FITC filter of the Zeiss Axioplan microscope, while propidium iodide was excited using the 
RHOD filter set. 
FITC and RHOD 68 ms exposure; 100× objective. →: white blood cell; ♦: trypanosome.  
Bar: 10 m m m mM. 
trypanosomiasis, fluorescence microscopy has to be easily applied to thick blood 
preparations as well as thin films. Since acridine orange and propidium iodide had proven 
very efficacious in staining trypanosomes, these two fluorophores were used to assess the 
feasibility of different staining protocols for fluorescent labelling of infected thick blood 
films (see Section 2.5.3 for preparation of these specimens). 
The first protocol evaluated involved direct staining of air-dried thick smears. To prepare 
the samples, a drop of either dye (30 ml of a 5 mM solution) was put onto a dry, unfixed 
thick film, and covered with a coverslip. This resulted in a partial solubilisation and 
haemolysis of the sample, which was unevenly spread on the microscope slide surface. 
Fluorescence from these samples was relatively unfocused, with a high background 
probably being due to the unbound dye (Figure 4.23). White blood cells showed bright 
fluorescence, while trypanosomes had only low emission. If the fluorophores were applied 
to the thick smear and allowed to air-dry without applying a coverslip, examination of the 
specimen revealed the presence of crystals, high background and no specific fluorescence. 
A different protocol included a dehaemoglobinisation step to eliminate the red blood cells 
from the film before staining, as is performed for the preparation of malaria specimens for 
fluorescence microscopy (Sodeman, 1970; Caramello et al., 1993). Air-dried thick smears 
were soaked in distilled water for 5 minutes, left to dry and then fixed in cold methanol for 
2 minutes. After evaporation of the fixative, samples were stained, as previously described, Federica Giordani, 2010    Chapter 4, 121 
 
Figure 4.24 – Thick blood smears stained with acridine orange or propidium iodide before 
air-drying. 
To prepare the specimens, a drop of T. b. brucei-infected blood (20 m m m ml) at high parasitaemia 
was put on a slide and mixed with a drop of dye (20 m m m mM). After spreading, the thick smears 
were left to air-dry and, then, viewed under the 100× objective of the Zeiss Axioplan 
microscope without addition of any coverslip. Samples stained with acridine orange (A) 
were excited under the FITC filer set, while those stained with propidium iodide (B) were 
excited using the RHOD filer set. Note that the blood samples used for staining with either 
fluorophore had the same high parasitaemia (1×10
6 cells/ml), but propidium iodide could 
stain only few, probably damaged, trypanosomes in the specimens. 
FITC 68 ms exposure; RHOD 30 ms exposure; 100× objective. →: white blood cell;    
♦: trypanosome. Bar: 10 m m m mM. 
with 30 ml of 5 mM acridine orange or propidium iodide and a coverslip was applied. 
Despite the additional processing steps, however, these samples did not show any 
improvement compared to those directly stained without the treatment in distilled water 
and methanol (data not shown). 
The thickness of this kind of blood preparation evidently did not allow the solution of the 
fluorophore to distribute evenly among the layers of dried blood cells and, therefore, reach 
all parasites at a sufficient concentration for brilliant staining. It might be possible to obtain 
better specimens by exposing them to the fluorophore solution for longer times, but this 
would cause a further delay for the diagnostic result. An easier and faster method could be 
the direct addition of the dye solution to the drop of blood just after its collection and 
before the preparation of the thick film. To verify the efficacy of this procedure, solutions 
of acridine orange or propidium iodide (20 mM) were mixed with the drop of blood on the 
microscope slide before spreading the sample in a circle with the corner of another slide 
and leave it to air-dry at room temperature. Using this method, samples stained with the 
cell-permeable acridine orange resulted in a better quality than those stained after the thick 
film had already been dried (Figure 4.24 A): trypanosomes showed a higher fluorescence, 
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also lower and the image more focused. Propidum iodide, however, did not stain 
trypanosomes or other nucleated cells in these specimens, leading to a general red 
background. It is probable that the time needed for the smear to dry (several minutes) was 
not sufficient for this dye to permeate the cells and only trypanosomes with damaged 
membranes internalised the fluorophore becoming highly fluorescent (Figure 4.24 B). 
Of all the protocols used, direct application of acridine orange to the drop of blood before 
preparation of the thick film appeared to be the best technique, both for its straightforward 
procedure and the quality of the fluorescence. To allow even higher levels of trypanosome 
staining, it could also be possible to collect the blood in a small tube, in which incubation 
with the fluorophore could proceed for longer times, followed by preparation of the thick 
smear (this was the protocol most used to stain infected blood samples during this project, 
see Section 2.5.3.2). 
When considering the use of fluorescently stained thick blood smears for diagnosis, 
another important aspect to consider is the necessity of having a microscope equipped with 
a high magnification, oil-immersion objective to examine the samples. Even though 
fluorescent parasites could also be detected in the thick specimen using the 40× objective, 
in the field high magnification objectives (100×) are used in order to identify, with 
confidence, trypanosomes in thick smears, where they usually appear deformed. The 
current LED Cytoscience microscope, however, has only a single, fixed 40× objective 
fitted, not suited to view thick smears. Future prototypes will have to take into account this 
issue and include higher magnification objectives in their design. 
4.2.7 Double stain with Giemsa and fluorophores 
The introduction of LED fluorescence microscopes in health care facilities of HAT 
endemic countries would be intended not only as a substitute to traditional parasitological 
techniques, but also as a complementary tool. The combination of both light and 
fluorescence microscopy could offer a simple way of improving accuracy of 
parasitological examination, by offering the possibility to re-check dubious specimens for 
diagnostic confirmation. This would be particularly useful for fixed samples, whether thin 
or thick Giemsa-stained blood films. For this reason, it would be ideal that each specimen 
could be easily examined using both techniques. Therefore, the possibility of double 
staining Giemsa-treated thin blood samples with acridine orange or propidium iodide, a 
procedure shown to be feasible for some fluorescent dyes (Guy et al., 2007), was assessed. Federica Giordani, 2010    Chapter 4, 123 
 
Figure 4.25 – Thin blood smears stained with propidum iodide alone or double-stained with 
Giemsa and the fluorophore. 
(A) Blood smear labelled with 50 m m m ml of 5 m m m mM propidium iodide.  
(B) Giemsa-stained blood smear (5% Giemsa solution) subsequently stained with 5 m m m mM of 
propidium iodide. Murine blood infected with T. b. brucei w.t. (1×10
6 cells/ml) was used to 
prepare the thin films, which were left to air-dry and kept in a slide box for several weeks 
before staining. Both specimens were viewed under the same experimental conditions, 
using the RHOD filter of the Zeiss Axioplan microscope. 
RHOD 68 ms exposure; 40× objective. The arrow in panel B indicates a trypanosome. Bar: 10 m m m mM. 
Thin infected blood smears, stained with a 5% Giemsa solution (Section 2.5.3.3), were 
subsequently treated with 5 mM of either fluorophore and viewed under the fluorescence 
microscope. In these specimens, however, neither trypanosomes nor white blood cells 
acquired fluorescence (Figure 4.25 B for the specimen stained with propidium), a result 
probably due to the fact that the binding sites targeted by the fluorophores (i.e. nucleic 
acids) were already occupied by the Giemsa stain. 
An alternative protocol could involve sequential staining of the same specimen, by 
introducing a destaining step of the Giemsa solution before the addition of the fluorophore. 
To destain Giemsa-labeled specimens we soaked thin films in a solution of 90% ethanol 
and 1.5% HCl for 30 minutes (Suzuki et al., 1991). The samples were, then, stained with  
5 mM of acridine orange or propidium iodide and immediately examined under 
fluorescence microscopy. The destaining procedure proved capable of eliminating enough 
Giemsa dye in order to allow both fluorophores to label parasites, but the emission was not 
as brilliant as in samples directly stained for florescence microscopy. Moreover, the 
background was relatively high and this hampered quick detection of parasites. 
Simultaneous labelling of the same specimen with a fluorophore and the histological 
Giemsa stain would offer the advantage of complementing bright field and fluorescence 
microscopy. However, the incompatibility of the dyes used usually hampers this approach, Federica Giordani, 2010    Chapter 4, 124 
as observed for association of propidium iodide and acridine orange with Giemsa. In the 
future, it will be important to verify other combinations of staining agents or, eventually, to 
define a straightforward and efficient destaining protocol, in order to improve the overall 
diagnostic performance and accuracy of microscopy. Federica Giordani, 2010    Chapter 4, 125 
4.3 Discussion 
4.3.1 New fluorophores for the arsenical drug resistance test 
The arsenical drug resistance test was developed as a quick, simple assay to identify 
trypanosome strains resistant to diamidines and arsenical drugs (Stewart et al., 2005). As 
for other diagnostic techniques, its introduction in poor-income endemic countries is 
mainly hampered by the need for expensive, sophisticated fluorescence microscopes, but 
the use of cheaper LED-driven instruments could make this technique more easily 
affordable. We showed the feasibility of performing the test in association with a 
prototypical UV LED-illuminated microscope (Chapter 3), although the detailed conditions 
of the test still need optimisation. 
The original assay developed by Stewart and collaborators used UV fluorescent diamidines 
as substrates (Stewart et al., 2005). However, UV LED light sources for fluorescence 
microscopy are not yet widely available as compared to LEDs for excitation of green-
emitting fluorophores. The LED Cytoscience SMR microscope, for example, works in this 
spectral region (lEX=472 nm, lEM>500 nm). We were, therefore, interested in identifying 
new compounds to use as substrates for the test but with longer excitation wavelengths 
than those of the originally used UV fluorescent compounds. The series of five green 
fluorescent pentamidine analogues synthesised in Prof. D. W. Boykin’s laboratory 
appeared to be interesting for this purpose, since they carried the P2/TbAT1 recognition 
motif and had longer excitation wavelengths than that of their parental compound DB75 
(Table 4.1). The Alamar blue data confirmed a dependence on this transporter for uptake 
into trypanosomes (Table 4.4). DB1680 appeared to rely less on this mechanism of uptake, 
but we failed to prove a possible involvement of an endocytic mechanism of 
internalisation. Passive diffusion through the membrane could represent another route of 
entry for DB1680: the polar nature given by the dicationic structure of the DB compounds 
is thought to hamper the interaction with the lipid layer, but the presence of multiple 
aromatic rings in the molecule linker could increase its lipophilicity and allow a faster 
diffusion. Although the other four compounds of the series lost some trypanocidal activity 
in the absence of an active P2 transporter, we were not able to identify clear differences in 
fluorescence development in treated trypanosome strains expressing, or not expressing, the 
P2 amino-purine transporter (Figure 4.11). The main problem with these diamidines, 
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short incubation times (within 15 minutes). The low emission was probably caused by the 
intrinsic low yields of the compounds, but also by the use of an inappropriate detection 
system, since the standard FITC filter only partially matched the spectral region in which 
the green diamidines fluoresced. Due to their excitation maxima being too short, the five 
dyes were also incompatible with the LED Cytoscience SMR microscope. The use of 
another LED source with a shorter excitation wavelength (~420 nm) fitted into this 
instrument, however, could allow the detection of the diamidines’ green fluorescence. 
The five green fluorescent molecules were capable of specifically staining trypanosomes in 
blood samples (Figure 4.9), a characteristic that could make them possible fluorescent 
markers for trypanosomes, if appropriate filter sets and LED sources could lead to higher 
yields from the compounds. 
4.3.2 Intracellular distribution of the five pentamidine analogues 
The study of the fluorescent properties of the pentamidine analogues revealed interesting 
staining features which raised new questions about their intracellular targets and 
mechanism of trypanotoxicity. As with other diamidines (Mathis et al., 2007) these 
compounds were good DNA binders: melting temperatures measured for DB1464, 
DB1680 and DB1692 bound to a poly(dA)·poly(dT) oligomer were 9.4, 15.0 and 17.0 °C 
respectively (these data were kindly provided by Prof. D. W. Boykin). However, during 
our experiments none of the five compounds apparently labelled the nucleus of 
trypanosomes, while all of them brightly stained the kinetoplast DNA (kDNA). This result 
was unexpected, since nuclear DNA, which is surrounded by a porous membrane, should 
be more accessible to fluorophores than the kinetoplast, which is enclosed inside the 
mitochondrial membrane. It is probable that most diamidines reach the kDNA before other 
intracellular targets because the mitochondrial membrane potential acts as a potent driving 
force (de Koning, 2008). However, during our experiments, visible fluorescence inside the 
nucleus did not develop even after long incubation times (up to 8 h) (Figure 4.4). A 
possible explanation for the lack of signal development from inside the nucleus is that the 
pentamidine analogues did enter the organelle to reach the chromosomal DNA, but an 
unknown phenomenon caused quenching of their emission. Another possibility could be a 
shift in fluorescence of the compounds bound to nuclear DNA that could not be detected 
using our standard filter sets. Further investigations will be needed to understand these 
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Another interesting feature concerning the staining pattern of the green fluorescent 
compounds was their accumulation in a series of cytoplasmic corpuscles, as already 
observed for other diamidines (Mathis et al., 2006). As previously discussed with regard to 
DB75 fluorescent pattern (Chapter 3), the identity of these corpuscles is still unclear and 
needs to be investigated in more details, especially to understand if they localise within the 
mitochondrion or correspond to cytoplasmic vesicles. The causes of the red fluorescence 
shift observed under the RHOD filter (Figure 4.8) are also unknown: it could be caused by 
peculiar environmental conditions inside organelles or by binding to cytoplasmic 
macromolecules. Mathis and colleagues were of the opinion that it was acidocalcisomes 
that accumulated diamidines, an identification based on the similarity to the fluorescent 
pattern of acridine orange in trypanosomes and its abolition following pre-treatment with 
compounds which inhibit acidification of intracellular organelles (Mathis et al., 2006 and 
2007). Some observations made during our experiments with the green fluorescent 
diamidines were consistent with this theory, although a definitive identification could not 
be made. The posterior fluorescent spots observed after DB1680 treatment (Figure 4.8), 
and initially believed to be endosomes, for example, overlapped the area occupied by the 
acidocalcisomes labelled, during another experiment, with acridine orange (Figure 4.20). 
The identification of these cytoplasmic vesicles, stained by the fluorophores, as 
acidocalcisomes would offer an explanation for the fluorescence bathochromic shift (i.e. 
red emission) observed for all the compounds of the series: these organelles have an acidic 
pH and contain phosphates, both of which can interact with the compounds and influence 
their fluorescence spectra. Similarly, the brighter fluorescent spot labelled by DB1692 and 
visible under the RHOD filter after 1 hour of incubation (Figure 4.8) could be identified 
with the lysosome, another acidic organelle located at the posterior of the cell. The 
corpuscles observed following T. b. brucei treatment with the green fluorescent 
diamidines, using the FITC channel, generally appeared more similar to those visualised 
during our experiments with DB75 (Section 3.2.7) than to the acidocalcisomes evidenced 
by Mathis and collaborators (Mathis et al., 2006 and 2007). Unlike the myriad of vesicles 
that became visible in 2 or 4 hours incubation (depending on the diamidine used) described 
by these authors, the green fluorescent pentamidine analogues we tested were observed in 
only a limited number of corpuscles, which were stained within 1 hour of incubation. The 
use of different fluorophores and experimental conditions (in particular, different filter 
sets) could explain the discrepancies between our results and those published by Mathis 
and collaborators, but future studies will be necessary to clarify the intracellular 
distribution of these compounds. Federica Giordani, 2010    Chapter 4, 128 
4.3.3 Phenanthridines and acridine orange as fluorescent probes 
for trypanosomes 
By being both fluorescent in the range of the available LED Cytoscience SMR microscope 
and trypanocidal (which may imply specific internalisation into parasites), phenanthridines 
appeared to be promising compounds for our project. Fluorescence of isometamidium 
inside trypanosomes, however, was found to be too low to be considered of any utility for 
fluorescence diagnostics (Figure 4.13). Moreover, this phenanthridine preferentially 
accumulated inside the kinetoplast and did not allow determination of parasites shape in 
the sample. The staining properties of ethidium bromide and its analogue propidium iodide 
proved more interesting. Both compounds could stain viable trypanosomes in blood 
samples, revealing the whole cells shape (Figures 4.12 and 4.15). Propidium iodide, in 
particular, produced a brilliant and stable emission once bound to trypanosomes’ nucleic 
acids. This compound is supposed to be a membrane-impermeant molecule, which is 
generally considered unable to enter intact cells (Foglieni et al., 2001). However, 
propidium was clearly able to permeate trypanosomes in blood samples at a relatively fast 
rate, which depended on the concentration of the compound and on the temperature of 
incubation (Figure 4.17). Internalisation of this phenanthridine appeared to be enhanced 
when cells were treated at 37°C rather than at room temperature, indicating a probable 
transport-mediated uptake. This hypothesis was supported by indications, obtained in our 
laboratory, of transporter involvement in the internalisation of the propidium structural 
analogue ethidium bromide (Chris Ward, personal communication). Future studies on this 
subject could reveal how these trypanocidal drugs enter the parasites. In fixed specimens, 
where the integrity of the membranes was lost, the staining properties of propidium iodide 
and ethidium bromide were excellent (Figures 4.14 and 4.18), although staining of other 
nucleated cells in the specimens was evident. 
Acridine orange, an analogue of phenanthridine, was the fluorophore with the best 
characteristics among those tested. As propidium iodide, it was able to stain trypanosomes 
instantaneously in fixed blood samples at very low concentrations (Figure 4.22). This 
fluorophore could also enter viable parasites quickly, probably due to its lipophilic nature 
(Figure 4.21). Acridine orange has the advantage of being less expensive than propidium 
iodide (~£80 for 1 g for acridine, ~£90 for 100 mg for propidium from Molecular Probes, 
Invitrogen) and very low concentrations are needed for microscopy. Since phenanthridines 
are intercalating agents and, therefore, potential mutagens and carcinogens, the fact that 
very low concentrations can be used not only reduces the costs, but also the risks Federica Giordani, 2010    Chapter 4, 129 
associated with the handling of the fluorophore. The fluorescent properties of acridine 
orange have already been exploited for the diagnosis of HAT in the quantitative buffy coat 
test (Bailey and Smith, 1992), which is very sensitive but also too expensive and 
sophisticated to be widely applied in poor rural settings. The use of this fluorophore to 
label trypanosomes in microscopy specimens is relatively straightforward and definitively 
faster than the currently used Giemsa stain. We showed how the dye could be directly 
applied to dry but also wet thin blood smear, further decreasing the time needed for 
specimen preparation (since there was no need to dry or fix the sample). This also 
facilitated the identification of labelled trypanosomes by their fast movement among blood 
cells. Acridine orange stained live parasites in medium with a bright, stable fluorescence 
(Figure 4.19), and we would expect it to stain parasites in human fluids other than blood, 
such as lymph node aspirate or cerebrospinal fluid, equally well. The simple addition of a 
drop of dye to a wet film prepared with these human samples could enable a faster 
detection of trypanosomes, normally identified only by their active wriggling in unstained 
samples (Chappuis et al., 2005). However, the application of aspecific, membrane-
permeant fluorophores, such as acridine orange, might be problematic for CSF samples, 
where the high white blood cell count, usually associated with HAT infection, could 
interefere with parasite visualisation. Moreover, other co-infecting microorganisms present 
in the sample (in particular blood) may be stained aswell, thus complicating diagnosis. 
These aspects will need to be verified by future experiments. Direct application of acridine 
orange during the preparation of thick smears (Section 4.2.6) proved to be a fast and 
simple procedure to label trypanosomes in these specimens. Since the entire parasite cell 
was stained, trypanosomes could be identified even if their shape was slightly deformed in 
these preparations. 
Due to its ideal fluorescent characteristics, acridine orange has been independently chosen 
by FIND (Foundation for Innovative New Diagnostics) to develop new fluorescence-based 
diagnostics for trypanosomiasis (http://www.finddiagnostics.org/). 
4.3.4 Practical considerations on the use of the LED Cytoscience 
SMR microscope 
The LED Cytoscience SMR microscope (Figure 1.8) excited acridine orange and 
propidium iodide yielding bright fluorescence. The instrument proved easy to use and 
could be positioned in a dim dark room. However, when utilising the instrument we 
noticed some defects, which will need to be considered when developing new prototypes Federica Giordani, 2010    Chapter 4, 130 
for field use. First, the presence of a single eyepiece could result in eye fatigue after hours 
of microscopy, as already pointed out (Hänscheid, 2008). A fake, blind eyepiece positioned 
in the place of the one missing could easily solve this issue, by allowing the microscopist 
to keep the unused eye open during slide observation. A second problem was represented 
by the fact that the stage could not be moved. This obliged the microscopist to manually 
move the slide horizontally, with consequent loss of time and difficulties in 
homogeneously screening the specimen. The introduction of a cross-table to clamp slides 
and move them on the stage would make the microscope more practical, with only a minor 
loss in compactness. A third aspect to be mentioned was the presence on the instrument of 
a single, low magnification, 40× objective. This was ideal to quickly screen thin film, but 
not to view thick smears, for which a high magnification 100× objective is commonly 
used. In the field, thick specimens are usually preferred to thin ones because of their higher 
sensitivity (Chappuis et al., 2005). Fitting an appropriate, high magnification objective 
(100× or 60×) in microscopes designed for the field will, therefore, have to be considered 
in future prototypes.  
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5.1 Introduction 
One aspect of this research project involved the direct synthesis of potential fluorescent 
probes for African trypanosomes. In designing the new molecules, it was decided to couple 
fluorescent moieties to a parasite surface transporter’s substrate, in order to ensure fast and 
specific internalisation into parasites. This strategy had already been attempted by previous 
work by Azema and collaborators (Azema et al., 2004), who designed fluorescent 
substrates of the glucose transporter family by linking a dansyl chloride group (which is 
fluorescent) to hexoses. These fluorophores, however, seemed to enter into trypanosomes 
without interacting with the transporters, probably due to their lipophilic nature, which 
allowed them to diffuse through the plasma membrane. 
Nutrient uptake routes represent useful pathways to carry toxins and other compounds into 
parasites. Internalisation of the fluorescent diamidines described in Chapters 3 and 4 was 
assured by the activity of other classes of trypanosome transporters, including the amino-
purine transporter P2/TbAT1, and the high and low affinity pentamidine transporters 
(HAPT and LAPT). To deliver fluorescent groups into trypanosomes, we chose to exploit a 
different class of parasite carriers: the amino acid transporters. Trypanosomatids possess a 
large family of specific and generic amino acids transporters (Barrett and Gilbert, 2006; 
Jackson, 2007), since these parasites are auxotrophic for the essential amino acids of 
humans (Berriman et al., 2005). The high affinity of these carriers could assure the 
concentration of the designed substrates against their concentration gradient. Moreover, 
addition of hydrophobic aromatic substituents, typical of fluorogenic groups, to polar 
amino acids was expected to lead to products still hydrophilic enough to preclude passive 
diffusion through the membrane, as happened for the hexose analogues mentioned above 
(Azema et al., 2004). Obviously, amino acid transporters, as glucose transporters, are not 
exclusive to trypanosomes. However, differences in affinity and rate of activity between 
parasite and human carriers might ensure specific internalisation into parasites (a 
phenomenon difficult to predict in advance), as observed for the sugar derivatives designed 
by Azema and colleagues (Azema et al., 2004). 
To generate fluorescent amino acid conjugates, different aromatic substituents were linked 
to the side-chain of various amino acids. Fluorophores included UV fluorescent groups 
such as dansyl chloride (λEX=337 nm, λEM=492 nm) and 2-(bromomethyl)naphthalene 
(λEX=274 nm, λEM=334 nm). Among them, dansyl chloride was considered of particular 
interest. This compound [5-(dimethylamino)naphthalene-1-sulfonyl chloride], is a Federica Giordani, 2010    Chapter 5, 133 
naphthalene-based, lipophilic fluorophore, nonfluorescent until it reacts with amines. It is 
generally used for amino acid and protein covalent labelling (Chersi et al., 1997; 
Gonçalves, 2009), but sugars too are often fluorescently tagged with this organic probe 
(Hermetter et al., 2001; Azema et al., 2004). 
The work was carried out under the supervision of Dr. A. Sutherland in the Chemistry 
Department of the University of Glasgow. Purity and characterisation of the compounds 
generated were verified by IR, 
1H NMR/
13C NMR spectroscopy and mass spectrometry 
analyses. Optical activity was also determined. Full chemical characterisation and detailed 
synthetic procedures are presented in Section 5.2.4, while general experimental details are 
in Section 2.8. The biological and fluorescent properties of the amino acid derivatives 
obtained were, successively, assessed on in vitro, wild type trypanosomes. Federica Giordani, 2010    Chapter 5, 134 
5.2 Results 
5.2.1 Synthesis of a dichlorobenzyl tyrosine derivative 
The first compound synthesised was a tyrosine analogue (Tyr(Cl2-Bzl)-OH, named FG10) 
(Figure 5.1). This compound was chosen for the presence in its molecular structure of two 
aromatic rings (one from the lateral chain of the amino acid, the other from a condensed 
dichlorobenzyl alcohol moiety), and, therefore, likely to have fluorescent properties. 
Another reason for this choice was the possibility of obtaining the product from a 
commercially available starting material ([Boc-O-(2,6-dichlorobenzyl)-L-tyrosine], or Boc-
Tyr(Cl2-Bzl)-OH, from Sigma-Aldrich) through a single, standard reaction. This offered an 
opportunity to gain some initial experience in the chemistry laboratory. 
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Figure 5.1 – Synthesis of Tyr(Cl2-Bzl)-OH (FG10) from Boc-Tyr(Cl2-Bzl)-OH. 
The single reaction involved the deprotection of the amino group of the commercially 
available tyrosine analogue. 
The tyrosine derivative FG10 was produced with good yield (83%) by removing the 
protective t-Boc residue from the amino group of tyrosine, following a standard procedure. 
5.2.2 Synthesis of a 2-methylnaphthalene serine derivative 
A second compound was obtained by linking a 2-methylnaphthalene substituent (the 
fluorophore) to the side-chain of the amino acid L-serine, following a two step procedure 
(Figure 5.2). Alkylation of 2-(bromomethyl)naphthalene to the hydroxyl group of N-Boc-
serine (Sigma-Aldrich) gave the desired intermediate product (FG60, 46% yield). A 
previous attempt to perform this reaction using the methyl ester of serine as starting 
material, instead, did not give the expected product. In this case, the addition of the 
aromatic electrophile 2-(bromomethyl)naphthalene generated a mixture of two unknown 
compounds, one of which contained a methyl ester. This mixture was treated with 6 M HCl 
under reflux conditions in an effort to hydrolyse the ester. However, this proved 
unsuccessful, completely decomposing the molecules. Federica Giordani, 2010    Chapter 5, 135 
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Figure 5.2 – Synthesis of the 2-methylnaphthalene serine derivative FG70. 
Synthesis involved alkylation of an analogue of the amino acid serine (amino group 
protected by a t-Boc residue) with 2-(bromomethyl)naphthalene, to give the intermediate 
compound FG60, and subsequent deprotection of the amino group of the amino acid to 
generate the final product. 
The second reaction of the synthetic pathway involved treatment with TFA to release the 
protecting t-Boc group from the amino group of serine, generating the final product (FG70) 
with 100% yield. 
5.2.3 Synthesis of a dansyl chloride lysine derivative 
The synthesis of a dansyl chloride derivative was then attempted. This molecule was 
considered quite promising since the addition of a dansyl substituent to primary amino 
groups is known to give a stable blue or blue-green fluorescence to the product. A first 
attempt to obtain a serine derivative through condensation of dansyl chloride with the side-
chain of this amino acid failed, probably due to an intramolecular rearrangement that led to 
the unprotected carboxyl group of serine to attack the S-O bond, resulting in the 
elimination of the adduct (data not shown). 
We then decided to change starting material, using the amino acid lysine, and to protect its 
carboxyl group at the outset. The long side-chain of this amino acid represented a steric 
barrier to possible intramolecular rearrangement and its nitrogen was expected to form a 
stronger chemical bond with the sulfur of the dansyl chloride than the oxygen of serine. 
Following this approach we were able to obtain the final product (FG400) in five steps 
(Figure 5.3). Each reaction was carried out at first on a small scale and, if it proved 
successful, a larger scale reaction was set up. A modified lysine (Boc-Lys(Cbz)-OH, 
Sigma-Aldrich), with the amino group protected by a t-Boc residue and the lateral chain 
blocked by a carbobenzyloxy (Cbz) group, was used as starting material. Synthesis started 
by blocking the free carboxylic acid of lysine by addition of an ethyl group, following a 
standard procedure (the compound obtained was named FG90). Successively, the side-
chain of the amino acid was deprotected using a hydrogenation reaction, to expose the 
amino group for the subsequent condensation with the fluorophore. Conditions applied for 
this reaction were the same as those published by Bergeron and collaborators (Bergeron et. Federica Giordani, 2010    Chapter 5, 136 
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Figure 5.3 – Synthesis of the dansyl chloride lysine derivative FG400. 
The carboxyl group of the starting material (a lysine molecule with both amino groups 
blocked) was initially protected by an ethyl residue to generate FG90. The amine of the side-
chain of lysine was, then, exposed (in the compound FG100) for the subsequent fusion with 
the dansyl chloride group (the joined product was named FG200). Both the carboxyl and 
amino group of the amino acid were, successively, deprotected to give the final product 
FG400. 
al., 1997). The product (FG100) was obtained using an acid environment and Pd/C as 
catalyst and it was purified by filtration through Celite
® as a Cl
-NH3
+ salt. Interestingly, the 
use of the acid reagent (HCl 1 N) helped the removal of the Cbz-protecting group without 
taking the t-Boc group off. The next step was the condensation of the lysine derivative with 
dansyl chloride. For this reaction, a procedure published by Ceroni and collaborators was 
followed with some modifications (Ceroni et al., 2002). Two equivalents of NEt3 were 
needed to first eliminate the Cl
-NH3
+ salt and then to act as a reagent. The product FG200 
was obtained with a 57% yield after purification by flash silica gel chromatography. 
Standard procedures were followed in the last two reactions to deprotect the amino and 
carboxylic groups of lysine, to generate the final product FG400. 
1H NMR spectroscopy 
(Figure 5.4), mass spectrometry (Figure 5.5) and IR spectra (Figure 5.6) of the dansyl 
chloride derivative are shown below. Federica Giordani, 2010    Chapter 5, 137 
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Figure 5.4 – 400 MHz 
1H-NMR spectrum of the dansyl chloride lysine derivative FG400 
(sample dissolved in CD3OD). 
Peaks generated by the different hydrogens of the molecule are indicated by arrows and 
symbols. 
 
 
Figure 5.5 – Electron impact positive (EI
+) mass spectrum of FG400. 
The peak identifying the compound is indicated by an asterisk. The mass shown in the 
spectrum (MW 334.1) corresponds to the mass of the molecule (MW 379.5) after elimination 
of its carboxylic group (occurred during the application of this mass spectrometry 
technique). Federica Giordani, 2010    Chapter 5, 138 
 
Figure 5.6 – IR spectrum of FG400. 
The main functional groups are indicated underneath the corresponding absorption peaks. 
5.2.4 Experimental details 
(2S)-2-Amino-3-[4-(2,6-dichlorobenzyloxy)phenyl]propionic acid (FG10) 
O
CO2H
NH2
Cl
Cl
 
Trifluoroacetic acid (3 ml) was added to a solution of Boc-Tyr(Cl2-Bzl)-OH (1.00 g, 2.27 
mmol) in DCM (10 ml). The solution was left stirring overnight at room temperature and 
then the solvent was evaporated in vacuo. Starting material, TFA salt and impurities were 
eliminated by extraction with EtOAc and H2O (4 × 50 ml) and the combined aqueous 
phases were finally dried to give the product (FG10) as a white powder (0.64 g, 83%). mp: 
204-206°C (lit. 200-203°C; Yamashiro and Li, 1973); [a]D
23 –18.2 (c 1.0, MeOH); 
nmax(KBr)/cm
-1: 3442 (NH), 2990 (CH), 1665 (CO), 1521, 1243, 1023; dH (400 MHz, 
CD3OD): 3.01 (1H, dd, J 14.6, 8.5 Hz, 3-HH), 3.26-3.28 (1H, m, 3-HH), 3.86 (1H, dd, J 
8.5, 4.5 Hz, 2-H), 5.28 (2H, s, CH2O), 7.03 (2H, d, J 8.8 Hz, 2 × Ar-H), 7.26 (2H, d, J 8.8 
Hz, 2 × Ar-H), 7.34-7.38 (1H, m, 1 × Ar-H), 7.44-7.46 (2H, m, 2 × Ar-H); dC (100 MHz, 
CD3OD): 37.3 (CH2), 57.1 (CH), 66.2 (CH2), 116.3 (CH), 129.3 (ArC), 129.8 (2 × ArCH), 
131.7 (2 × ArCH), 132.1 (2 × ArCH), 133.6 (ArC), 138.1 (2 × ArC), 159.8 (ArC), 173.2 Federica Giordani, 2010    Chapter 5, 139 
(CO); LRMS (FAB
+): 340.2 ([MH]
+, 99%), 294.2 (24), 265.1 (17), 176.8 (15), 159.9 (60); 
HRMS calcd for C16H16
35Cl2NO3 340.0507, found 340.0510. 
(2S)-2-(tert-Butoxycarbonylamino)-3-(naphthalen-2-ylmethoxy)propionic acid (FG60) 
CO2H
O
NHBoc
 
A solution of N-(tert-butoxycarbonyl)-L-serine (0.50 g, 2.44 mmol) in DMF (10 ml) was 
prepared at 4°C under argon conditions. After slow addition of 60% NaH powder (0.23 g, 
5.37 mmol), the solution was left stirring for 0.5 h and then 2-(bromomethyl)naphthalene 
(0.59 g, 2.68 mmol) was added. The mixture was left stirring for another hour at 4°C and, 
finally, overnight at room temperature. The addition of a saturated aqueous solution of 
NaCl (30 ml) gave a precipitate that was filtered and the filtrate was extracted with diethyl 
ether (3 × 25 ml). HCl was added to the aqueous layer until pH 2 was reached and the 
solution was immediately extracted with EtOAc (3 × 25 ml). The collected organic phases 
were dried over MgSO4 and the solvent was evaporated in vacuo. The obtained residue 
was purified by flash column chromatography on silica gel, using a gradient of petroleum 
ether/ethyl acetate as eluent to give the product as a brown oil (0.39 g, 46%). [a]D
25 +20.7 
(c 1.0, CHCl3); nmax(neat)/cm
-1: 3439 (NH), 2979 (CH), 1685 (CO), 1508, 1163, 818, 754; 
dH (400 MHz, CDCl3): 1.37 (9H, s, 3 × CH3), 3.67 (1H, dd, J 9.2, 3.2 Hz, 3-HH), 3.90 (1H, 
dd, J 9.2, 3.2 Hz, 3-HH), 4.42-4.44 (1H, m, 2-H), 4.61 (2H, s, CH2O), 5.37 (1H, d, J 8.4 
Hz, NH), 7.32-7.34 (1H, m, Ar-H), 7.37-7.42 (2H, m, 2 × Ar-H), 7.65 (1H, br s, Ar-H), 
7.73-7.74 (3H, m, 3 × Ar-H); dC (100 MHz, CDCl3): 28.3 (3 × CH3), 53.8 (CH), 69.7 
(CH2), 73.6 (CH2), 80.4 (C), 125.6 (ArCH), 126.1 (ArCH), 126.2 (ArCH), 126.7 (ArCH), 
127.7 (ArCH), 127.9 (ArCH), 128.4 (ArCH), 133.1 (ArC), 133.2 (ArC), 134.7 (ArC), 
155.8 (C), 175.2 (C); LRMS (CI
+): 346.3 ([MH]
+, 5%), 290.2 (56), 272.2 (10), 141.2 (99), 
132.1 (10); HRMS calcd for C19H24 NO5 346.1654, found 346.1658. 
(2S)-2-Amino-3-(naphthalen-2-ylmethoxy)propionic acid (FG70) 
CO2H
O
NH2  Federica Giordani, 2010    Chapter 5, 140 
To a solution of FG60 (0.35 g, 1.02 mmol) in DCM (10 ml), the reagent trifluoroacetic 
acid (4 ml) was added and the solution was left stirring overnight at room temperature. 
Evaporation of the solvent gave the TFA salt product as an oil (0.32 g, 100%). 
nmax(neat)/cm
-1: 3420 (NH), 2925 (CH), 1675 (CO), 1509, 1203, 817; dH (400 MHz, 
DMSO-d6): 3.76-3.91 (2H, m, 3-H2), 3.96-3.97 (1H, m, 2-H), 4.61-4.76 (2H, m, CH2O), 
7.42-7.59 (4H, m, Ar-H), 7.82-8.02 (3H, m, Ar-H); dC (100 MHz, DMSO-d6): 54.2 (CH), 
59.4 (CH2), 72.5 (CH2), 25.4 (ArCH), 125.8 (ArCH), 126.0 (ArCH), 126.2 (ArCH), 127.6 
(ArCH), 127.7 (ArCH), 127.9 (ArCH), 133.5 (ArC), 134.5 (ArC), 140.0 (ArC), 169.5 
(CO); LRMS (FAB
+): 246.2 ([MH]
+, 9%), 142.2 (54), 102.7 (20), 81.0 (100), 59.4 (35); 
HRMS calcd for C14H16 NO3 246.1130, found 246.1114. 
Ethyl (2S)-6-(Benzyloxycarbonylamino)-2-(tert-butoxycarbonylamino)hexanoate (FG90) 
CO2Et CbzHN
NHBoc  
A stirred solution of Boc-Lys(Cbz)-OH (0.50 g, 1.32 mmol) in dry DCM (15 ml) was 
prepared under argon atmosphere. The reagent EDCI (0.40 g, 2.11 mmol), the catalyst 
DMAP (0.10 g) and dry ethanol (0.40 ml, 6.60 mmol) were sequentially added to the 
solution, which was allowed to stir at room temperature for 48 h. The mixture was, then, 
extracted with H2O (2 × 30 ml) and the collected organic phases were dried over MgSO4 
and, finally, concentrated in vacuo to give FG90 as an oil (0.54 g, 100%). [a]D
25 +2.0 (c 
1.0, CHCl3); nmax(neat)/cm
-1: 3339 (NH), 2936 (CH), 1712 (CO), 1525, 1251, 1167, 1026; 
dH (400 MHz, CDCl3): 1.29 (3H, t, J 7.2 Hz, CH3-CH2), 1.38-1.45 (11H, m, 3 × CH3, 4-
H2), 1.50-1.57 (2H, m, 3-H2), 1.60-1.69 (1H, m, 5-HH), 1.79-1.81 (1H, m, 5-HH), 3.17-
3.22 (2H, q, J 6.8 Hz, 6-H2), 4.17-4.22 (2H, m, OCH2-CH3), 4.24-4.29 (1H, m, 2-H), 5.03 
(½H, br m, NH), 5.10 (2H, s, CH2), 5.18-5.20 (½H, m, NH), 6.49-6.50 (½H, m, NH), 7.31-
7.37 (5H, m, Ar-H), 8.22-8.24 (½H, m, NH); dC (100 MHz, CDCl3): 14.2 (CH3), 22.4 
(CH2), 28.3 (3 × CH3), 29.4 (CH2), 32.4 (CH2), 40.6 (CH2), 53.3 (CH), 61.3 (CH2), 66.6 
(CH2), 79.8 (C), 128.1 (ArCH), 128.2 (3 × ArCH), 128.5 (ArCH), 136.6 (C), 155.6 (C), 
156.5 (C) 172.8 (C); LRMS (CI
+): 409.5 ([MH]
+, 12%), 353.5 (37), 309.5 (73), 245.3 (55), 
123.2 (98); HRMS calcd for C21H33N2O6 409.2339, found 409.2340. Federica Giordani, 2010    Chapter 5, 141 
Ethyl (2S)-6-Amino-2-(tert-butoxycarbonylamino)hexanoate (FG100) 
CO2Et H2N
NHBoc  
1 N HCl (1.30 ml) was added to a stirred solution of FG90 (0.51 g, 1.25 mmol) in EtOH 
(20 ml). After addition of 0.05 g of Pd/C 10%, H2 at atmospheric pressure was introduced 
and the mixture was left stirring for 3 h before further catalyst (0.02 g) was added. The 
solution was stirred at room temperature under H2 atmosphere overnight. The black 
suspension was then filtered through Celite
® and washed with EtOH (3 × 25 ml). The 
filtrate was, finally, dried in vacuo to give FG100 as an oil (0.38 g, 100%). [a]D
24 +2.3 (c 
1.0, CHCl3); nmax(neat)/cm
-1: 3413 (NH), 2979 (CH), 1701 (CO), 1523, 1369, 1166, 1025; 
dH (400 MHz, CDCl3): 1.21 (3H, t, J 7.0 Hz, CH3-CH2); 1.37 (10H, br s, 9 × CH3, 1 × 4-
HH), 1.51-1.74 (5H, m, 3-H2, 4-HH, 5-H2), 2.87-2.96 (2H, m, 6-H2), 4.09-4.19 (3H, m, 
OCH2-CH3, 2-H), 5.22 (½H, br d, J 7.2 Hz, NH), 6.52 (½H, d, J 7.2 Hz, NH), 7.52 (2H, br 
s, NH2); dC (100 MHz, CDCl3): 14.2 (CH3), 22.6 (CH2), 27.6 (CH2), 28.4 (3 × CH3), 32.1 
(CH2), 39.8 (CH2), 53.4 (CH), 61.4 (CH2), 79.8 (C), 155.6 (C), 172.7 (C); LRMS (CI
+): 
275.3 ([MH]
+, 100%), 219.2 (77), 175.2 (33), 156.2 (12), 123.2 (23); HRMS calcd for 
C13H27N2O4 275.1971, found 275.1974. 
Ethyl (2S)-2-(tert-Butoxycarbonylamino)-6-(5-dimethylaminonaphthalene-1-
sulfonylamino)hexanoate (FG200) 
CO2Et
H
N
S
O
O
N
NHBoc
 
NEt3 (0.40 ml, 2.84 mmol) was added to a stirred solution of FG100 (0.37 g, 1.35 mmol) in 
DCM anhydrous (10 ml) under argon atmosphere. Dansyl chloride (0.36 g, 1.35 mmol), 
previously suspended in dry DCM (10 ml), was added dropwise to the solution, which was 
left stirring overnight at room temperature. After removal of the solvent under reduced 
pressure, the yellow-brown residue was resuspended in DCM and washed with H2O (30 
ml), saturated aqueous Na2CO3 solution (30 ml) and again with H2O (3 × 30 ml). The 
organic layer was, then, dried over Na2SO4 and concentrated in vacuo. The yellow-brown 
oil was resuspended in a small amount of DCM, purified by silica gel column Federica Giordani, 2010    Chapter 5, 142 
chromatography using a gradient of DCM : MeOH (from 100% : 0% to 95% : 5%) and 
finally dried in vacuo to give the product as a yellow oil (0.39 g, 57%). [a]D
25 +9.6 (c 1.0, 
CHCl3); nmax(neat)/cm
-1: 3362 (NH), 2939 (CH), 1710 (CO), 1458, 1367, 1321, 1145, 
1092, 791; dH (400 MHz, CDCl3): 1.17-1.24 (5H, m, 4-H2, CH3-CH2), 1.28-1.45 (12H, m, 
3-H2, 3 × CH3), 1.50-1.59 (1H, m, 5-H2), 2.81 (8H, br s, 6-H2, 2 × N-CH3), 4.06-4.11 (3H, 
m, OCH2-CH3, 2-H), 5.17 (1H, d, J 8.4 Hz, NHBoc), 5.73 (1H, br t, J 5.8 Hz, SO2-NH), 
7.11 (1H, d, J 7.4 Hz, Ar-H), 7.43-7.49 (2H, m, 2 × Ar-H), 8.18 (1H, d, J 7.4 Hz, Ar-H), 
8.31 (1H, d, J 8.8 Hz, Ar-H), 8.47 (1H, d, J 8.8 Hz, Ar-H); dC (100 MHz, CDCl3): 14.2 
(CH3), 22.2 (CH2), 28.4 (3 × CH3), 29.0 (CH2), 32.3 (CH2), 43.0 (CH2), 45.5 (2 × CH3), 
53.1 (CH), 61.4 (CH2), 80.0 (C), 115.2 (ArCH), 118.7 (ArCH), 123.2 (ArCH), 128.4 
(ArCH), 129.6 (ArC), 129.7 (ArCH), 129.9 (ArC), 130.5 (ArCH), 134.6 (ArC), 152.1 
(ArC), 155.5 (C), 172.7 (C); LRMS (FAB
+): 530.2 ([MNa]
+, 100%), 507.2 (100), 452.2 
(53), 408.2 (39), 317.2 (13), 170.8 (99), 59.4 (38); HRMS calcd for C25H37N3O6NaS 
530.2301, found 530.2317. 
(2S)-2-(tert-Butoxycarbonylamino)-6-(5-dimethylaminonaphthalene-1-
sulfonylamino)hexanoic acid (FG300) 
CO2H
NHBoc
H
N
S
O
O
N
 
FG200 (0.20 g, 0.39 mmol) was dissolved in MeOH (10 ml) and the solution was cooled to 
4ºC. LiOH·H2O (0.03 g, 0.59 mmol) dissolved in H2O (5 ml) was added dropwise to the 
mixture and the reaction was, then, warmed to room temperature and allowed to stir 
overnight. The reaction mixture was dried under reduced pressure and the resulting residue 
was resuspended in H2O. After acidification to pH 2 by addition of 2 M HCl, the mixture 
was extracted with EtOAc (3 × 25 ml) and the organic layer was dried over MgSO4 and 
concentrated in vacuo to give FG300 as a yellow viscous oil (0.20 g, 100%). [a]D
25 +4.7 (c 
1.0, CHCl3); nmax(neat)/cm
-1: 3370 (NH), 2937 (CH), 1695 (CO), 1509, 1316, 1161, 1062; 
dH (400 MHz, CDCl3): 1.18-1.34 (13H, m, 3-H2, 4-H2, 3 × CH3), 1.40-1.58 (2H, m, 5-
CH2), 2.80 (8H, br s, 6-H2, 2 × N-CH3), 4.11-4.12 (1H, m, 2-H), 5.17-5.19 (1H, br d, J 6 
Hz, NHBoc), 5.39 (1H, br s, SO2-NH), 7.10 (1H, d, J 7.2 Hz, Ar-H), 7.40-7.46 (2H, m, 2 × 
Ar-H), 8.13-8.14 (1H, m, Ar-H), 8.22-8.24 (1H, m, Ar-H), 8.43 (1H, d, J 8.8 Hz, Ar-H); dC Federica Giordani, 2010    Chapter 5, 143 
(100 MHz, CDCl3): 22.2 (CH2), 28.4 (3 × CH3), 28.9 (CH2), 31.8 (CH2), 42.8 (CH2), 45.5 
(2 × CH3), 53.1 (CH), 80.2 (C), 115.4 (ArCH), 119.2 (ArCH), 123.4 (ArCH), 128.4 
(ArCH), 129.5 (ArCH), 129.6 (ArC), 129.7 (ArC), 130.2 (ArCH), 134.8 (ArC), 151.5 
(ArC), 155.8 (C), 176.5 (C); LRMS (FAB
+): 502.2 ([MNa]
+, 49%), 479.2 (39), 424.2 (35), 
170.9 (100), 168.9 (37), 86.0 (17); HRMS calcd for C23H33N3O6NaS 502.1988, found 
502.1973. 
(S)-2-Amino-6-(5-dimethylamino-naphthalene-1-sulfonylamino)-hexanoic acid (FG400) 
CO2H
NH2
H
N
S
O
O
N
 
FG300 (0.08 g, 0.16 mmol) was dissolved in DCM (10 ml) at room temperature. After 
addition of TFA (1 ml) the solution was allowed to stir overnight. The reaction mixture 
was then concentrated in vacuo to give FG400 as a yellow viscous oil (0.08 g, 100%). 
[a]D
26 +6.8 (c 1.0, MeOH); nmax(neat)/cm
-1: 3422 (NH), 2940 (CH), 1677 (CO), 1202, 
1141, 796; dH (400 MHz, CD3OD): 1.39-1.52 (4H, m, 3-H2, 4-H2), 1.76-1.89 (2H, m, 5-
H2), 2.89 (2H, t, J 5.8, 6-H2), 3.20 (6H, s, 2 × N-CH3), 3.87 (1H, br t, J 6.4 Hz, 2-H), 7.69-
7.76 (3H, m, Ar-H), 8.30 (1H, d, J 7.2 Hz, Ar-H), 8.57 (1H, d, J 8.4 Hz, Ar-H), 8.65 (1H, 
d, J 8.4 Hz, Ar-H); dC (100 MHz, CD3OD): 23.0 (CH2), 30.3 (CH2), 31.0 (CH2), 43.4 
(CH2), 46.5 (2 × CH3), 53.8 (CH), 117.9 (ArCH), 123.2 (ArCH), 125.6 (ArCH), 129.0 
(ArCH), 129.7 (ArCH), 129.9 (C), 130.5 (ArCH), 130.9 (C), 137.6 (C), 149.0 (C), 171.8 
(CO); LRMS (EI
+): 334.1 ([M-COOH]
+, 2%), 306.1 (6), 278.1 (10), 171.1 (64), 154.0 (9), 
95.0 (12), 69 (100), 45 (68); HRMS calcd for C17H24N3O2S 334.1589, found 334.1583. 
5.2.5 Biological evaluation 
5.2.5.1  Fluorescence spectra 
Once the synthesis was completed, the biological properties of the three amino acid 
derivatives were evaluated. The fluorescence excitation and emission spectra of the 
compounds were measured using solutions of the molecules in distilled water (Section 
2.6). Pre-scan of FG10 and FG70 (0.5 to 10 mM) revealed that both molecules absorbed  Federica Giordani, 2010    Chapter 5, 144 
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Figure 5.7 – Fluorescence spectra of FG400. 
The spectra were measured using a 10 m m m mM solution of the compound in dH2O. 
EX; excitation spectrum; EM: emission spectrum. 
UV radiation, but no relevant emission peaks could be identified in the visible region of the 
spectrum, thus preventing more accurate spectra measurements (data not shown). For the 
lysine derivative FG400, instead, we could measure an excitation wavelength maximum of 
333 nm and emission of 520 nm (Figure 5.7). Another absorption peak in the UV region, 
with maximum at 247 nm was identified. Fluorescence intensity in aqueous solution was 
weak (see, for comparison, the spectra of DB75 shown in Figure 4.6). Both the large 
Stokes shift (i.e. distance between excitation and emission maxima) and the low yield 
found for our dansyl chloride conjugate were in agreement with the data reported for this 
class of fluorophores (the Molecular Probes Handbook, available online at the website 
http://probes.invitrogen.com/handbook/, indicates for dansyl sulfonamides an absorptivity 
as weak as e ~4,000 cm
-1M
-1 at 330-340 nm and a low quantum yield). 
5.2.5.2  Trypanotoxicity 
The Alamar Blue assay (Section 2.4) was performed to obtain some indication concerning 
interaction of the synthesised molecules with trypanosomes: trypanotoxicity could be 
expressed after entry of the compounds into the cell, a requirement for their use as 
fluorescent probes. The results, however, did not give any information on this subject, 
showing that none of the amino acid derivatives had any trypanocidal activity up to  
100 mM (Figure 5.8). Treatment with the three compounds did not appear to alter the 
normal cell motility and morphology. 
5.2.5.3  Fluorescence microscopy 
To directly visualise the ability of the amino acid derivatives to stain live cells, treated in 
vitro wild type trypanosomes were viewed under the standard filter sets of the Zeiss  Federica Giordani, 2010    Chapter 5, 145 
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Figure 5.8 – Sensitivity of T. b. brucei w.t. S427 to the three amino acid derivatives. 
The data shown are from a representative Alamar Blue experiment. Pentamidine was used 
as positive control. For each curve, the lowest concentration data point is the “no drug” 
negative control. Error bars represent the standard deviation of the two replicates. 
Fluorescence is in arbitrary units. 
Axioplan fluorescence microscope. Parasites incubated for up to 2 hours with 100 mM 
FG10 and FG70 did not show any fluorescence emission when excited using DAPI or 
FITC channels. This confirmed the findings obtained with the spectra measurements, 
which showed no emission in the visible region for these conjugates. 
The dansyl chloride lysine derivative FG400, instead, appeared to accumulate into 
trypanosomes and labelled the cells after only 15 minutes of incubation, when given at  
100 mM (Figure 5.9). A blue, faint emission could be detected using the DAPI filter set: the 
entire cell was stained and some more intense spots were visible in its posterior region. A 
slightly better signal was obtained with the FITC channel. The use of this filter to excite 
the fluorophore allowed evidence of the entire shape of the parasites, including the 
flagellum, and various bright corpuscles spread throughout the whole cell body. The use of 
50 mM FG400 gave similar results, but a further decrease to 10 mM proved insufficient for 
trypanosome labelling. Dye emission (especially upon DAPI excitation) seemed to 
diminish at long incubation times (from 1 hour). The cause of this phenomenon is still 
unknown; it is possible that the activity of intracellular enzymes determined the release of 
the nonfluorescent dansyl residue from the amino acid. As already mentioned, FG400 had 
a large Stokes shift (λEX=333 nm, λEM=520 nm), which did not match any of the standard 
filter sets fitted on the Zeiss microscope (DAPI: λEX=365 nm, λEM=445 nm; FITC: 
λEX=470 nm, λEM=519 nm). This factor could have contributed to the low emission 
observed during qualitative fluorescence microscopy, along with the intrinsic low yield of 
the dansyl conjugate. Following incubation of trypanosomes in blood samples (100 mM for Federica Giordani, 2010    Chapter 5, 146 
 
Figure 5.9 – Fluorescence imges of trypanosomes stained with FG400. 
Aliquots of T. b. brucei w.t parasites from culture were incubated with 100 m m m mM FG400 at 37° C 
for 15 minutes. Trypanosomes were, then, immobilised in 1% agarose and viewed under 
DAPI and FITC filters of the Zeiss Axioplan microscope. 
DAPI 33 ms exposure, FITC 60 ms exposure; 100× objective. Bar: 10 m m m mM. 
 
Figure 5.10 – Fluorescence images of trypanosomes stained with DB1919. 
The compound DB1919 was kindly provided by Prof. D. W. Boykin (Georgia State University, 
Atlanta). Aliquots of T. b. brucei w.t parasites from culture were incubated with 10 m m m mM of the 
compound at 37°C for 1 hour. Trypanosomes were, the n, immobilised in 1% agarose and 
viewed under DAPI and FITC filter of the Zeiss Axioplan microscope. 
DAPI 33 ms exposure, FITC 60 ms exposure; 100× objective. Bar: 10 m m m mM. 
up to 2 h) no fluorescent parasites were observed, possibly due to some quenching 
phenomenon happening inside this complex matrix. 
The fluorescence pattern of FG400 was similar to that of another dansyl chloride derivative 
(DB1919) synthesised in Prof. D. W. Boykin’s laboratory and kindly provided us to test 
for our project. In this compound, the dansyl chloride group was linked to an amidino 
moiety (the recognition motif of the P2 amino-purine transporter), instead of the lateral 
chain of an amino acid, as in FG400. Treatment of in vitro wild type cells with 10 mM of 
this compound also yielded a faint fluorescence under both DAPI and FITC filter sets 
(Figure 5.10). At this dose, the emission started to be detectable after 15 minutes of 
incubation. The use of lower concentrations (1 or 5 mM) of the fluorophore or shorter times 
of incubation were not sufficient to obtain a recordable signal. A bright fluorescent spot 
positioned in the posterior of the cell (similar to that observed inside trypanosomes stained 
with the dansyl lysine derivative) was clearly evident under DAPI and FITC filter, but for 
this molecule we were not able to see other cytoplasmic corpuscles. The brighter spot 
labelled by both dansyl conjugates could be generated by compound internalised by Federica Giordani, 2010    Chapter 5, 147 
endocytosis and accumulated inside endosomes. Further studies will be needed to verify 
this hypothesis. As observed for FG400, also DB1919 fluorescence in infected blood 
samples was extremely low, close to background levels (data not shown). Federica Giordani, 2010    Chapter 5, 148 
5.3 Discussion 
In this chapter, the synthesis and biological evaluation of three amino acid derivatives, 
designed as possible fluorescent probes for trypanosomes, is described. This phase of the 
project offered me the opportunity to learn the work carried out in an organic chemistry 
laboratory and to participate directly in the initial development (from its creation to its 
testing) of new chemical agents. 
The synthetic strategy adopted involved the fusion of fluorogenic groups to the side-chain 
of amino acids. The intention was to exploit these biomolecules as “haptophore” 
(anchorer) moieties, able to rapidly convey the fluorophores into trypanosomes by means 
of surface amino acid transporters activity. This approach was similar to that used in the 
field of drug development to introduce toxins into parasites by linking them to substrates of 
specific trypanosome membrane transporters (Baliani et al., 2005; Barrett and Gilbert, 
2006; Chollet et al., 2009). Although the complexity of the synthetic pathway increased 
from the first to the last of the three compounds synthesised (a single reaction to generate 
FG10, two for FG70, five for FG400), a basic strategy was followed for all of them: (1) 
potentially reactive groups of the amino acid were protected or deprotected in preparation 
for the reaction of alkylation; (2) the fluorogenic moiety was fused with the side-chain of 
the amino acid; (3) the groups still blocked were deprotected, to release the final amino 
acid derivative. 
Of the three amino acid conjugates synthesised, the dansyl chloride lysine derivative 
FG400 was the only one that showed a detectable signal in the visible region of the 
spectrum (λEM=520 nm). The blue-green fluorescence of this compound was visible in in 
vitro trypanosomes treated with the fluorophore (Figure 5.9). However, fluorescence was 
generally low, even when the compound was used at a relatively high dose (100 mM). The 
emission of dansyl chloride derivates is known to be weak in aqueous solution and 
environment-sensitive. Both of these factors could have contributed to the low and 
unstable emission observed. Moreover the compound would need specific filters to be 
optimally excited and detected (λEX~340 nm, λEM>520 nm), while standard DAPI and 
FITC channels only partially overlapped the spectra of this conjugate. No fluorescent 
signal could be detected in treated infected blood samples, possibly due to some quenching 
event which occurred in these specimens. The lack of fluorescence in ex-vivo samples did 
not allow a check for specific labelling of trypanosomes as compared to other mammalian 
cells present in the blood film. Federica Giordani, 2010    Chapter 5, 149 
No indication regarding the mechanism of entry of FG400 into trypanosomes was 
obtained. We expected the molecule to be internalised through the activity of specific 
amino acid transporters, but other routes could not be excluded. Addition of substituents to 
the core amino acid structure could affect the function and stereochemistry of the 
“haptophore”, thus preventing recognition by binding sites of specific transporters. Among 
other routes, endocytosis could have contributed to the uptake of FG400. The presence of 
fluorescent corpuscles in the region where endosomes are normally localised (Figure 5.9) 
suggested this hypothesis, but these corpuscles and the other smaller bright spots (spread 
throughout the whole cell length), observed in treated parasites, could equally represent 
secondary sites of accumulation following transporter uptake. 
The synthesised tyrosine (FG10) and serine (FG70) conjugates did not show any 
interesting fluorescent properties. Although we could measure excitation peaks in the UV 
region of the spectrum for both compounds, no visible emission was evidenced by 
spectrometry or qualitative fluorescence microscopy for any of them. No increase of 
autofluorescence in cells treated with the tyrosine derivative FG10 was observed. Tyrosine 
is a fluorescent amino acid (λEM=300 nm), responsible for the intrinsic fluorescence of 
cells and tissues together with the other aromatic amino acids tryptophan and 
phenylalanine and molecules such as NADH and FAD (Petty, 2007). Evidently, the 
experimental conditions adopted and the low yields of this amino acid (e ~1,405 cm
-1M
-1 at 
274 nm) did not allow detection of increased emission in treated cells. 
To conclude, the overall fluorescence of the three amino acid derivatives proved too low to 
be considered of real interest for use in field fluorescence diagnostics of trypanosomiasis, 
but in the future new, more effective fluorogenic derivatives for parasite labelling could be 
synthesised following the same approach adopted here. 
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6.1 Introduction 
6.1.1 The P2 amino-purine transporter and its substrates 
The P2 amino-purine transporter is a membrane carrier found only in Trypanosoma brucei 
(Carter and Fairlamb, 1993; Mäser et al., 1999). The protein is encoded by a single copy 
gene named TbAT1, which is located in the subtelomeric region of chromosome V (Lanteri 
et al., 2006; Stewart et al., 2010). The physiological substrates of this carrier are adenosine 
and adenine, which the parasite needs to scavenge from the human host, since it lacks the 
pathway for purine synthesis de novo (Geiser et al., 2005). The importance of this 
transporter lies in its primary role in the uptake of various toxic compounds, including 
diamidine and melaminophenyl arsenical trypanocidal drugs, which share the same 
recognition motif that the P2 transporter uses to interact with its physiological ligands 
(Carter and Fairlamb, 1993; Barrett and Fairlamb, 1999; de Koning, 2008). Loss of activity 
of this transporter can cause the development of drug resistance, especially for those drugs 
(diminazene, DB75) that rely nearly exclusively on its activity for their uptake into 
trypanosomes (de Koning et al., 2004; Lanteri et al., 2006). On the other hand, the 
presence in T. brucei of other related low affinity transporters partially compensate for loss 
of P2 activity in tbat1
-/- cells (which lacks both alleles of the TbAT1 gene) and derived 
lines, allowing lower but significant internalisation of drugs such as pentamidine and 
melarsoprol into parasites (de Koning, 2001b; Matovu et al., 2003). 
All of the fluorescent diamidines tested during this project were substrates of the P2 
amino-purine transporter. As already mentioned, DB75 is internalised mainly through this 
route (Lanteri et al., 2006) and this substrate specificity has been exploited to develop the 
arsenical drug resistance fluorescence test (Stewart et al., 2005; Chapter 3). Similarly, 
DAPI relies on the P2 transporter for uptake into trypanosomes, but this compound has 
also significant affinity for the high affinity pentamidine transporter (HAPT) (Bridges et 
al., 2007). Not surprisingly, the Alamar Blue data on drug sensitivity indicated that the five 
green fluorescent diamidines synthesised in Prof. D. W. Boykin’s laboratory was mediated 
by P2 activity, although other transporters appeared to play a role in their accumulation, as 
shown by fluorescence images of the tbat1
-/- cell line incubated with these compounds 
(Chapter 4). 
Since a significant part of this project had focused on studying the ability of different 
compounds to enter via the P2 carrier, either alone or as one of several transporters, it was Federica Giordani, 2010    Chapter 6, 152 
of interest to investigate important aspects of the activity of this carrier under different 
conditions. 
6.1.2 Regulation of the P2 transporter expression 
Extensive study has elucidated the substrate specificity and kinetics of the P2 transporter 
(Carter and Fairlamb, 1993; Barrett and Fairlamb, 1999; Mäser et al., 1999; de Koning, 
2001a; de Koning et al., 2004; Lanteri et al., 2006; Collar et al., 2009) and various efforts 
have been made in order to exploit this knowledge to target toxic compounds into 
trypanosomes through this route (Tye et al., 1998; Stewart et al., 2004; Baliani et al., 2005; 
Barrett and Gilbert, 2006; Chollet et al., 2009; Landfear, 2009). However, very little is 
known about the localisation of this carrier within the parasite or about the regulatory 
mechanisms of its expression under different environmental conditions. It is known that P2 
activity is dependent on the life cycle stage of T. b. brucei, being expressed in bloodstream 
forms but not in procyclics (de Koning, 2001a). Moreover, several strands of evidence 
obtained in our laboratory indicate that P2 activity is down-regulated in bloodstream cells 
grown in culture compared to its expression levels in parasites from in vivo models. Uptake 
of radiolabelled adenosine into T. b. brucei cells through this transporter route was found 
to be much lower in cells from culture than in cells from rat (Pui Ee Wong, University of 
Glasgow, unpublished; Figure 6.1). 
Other uptake assays showed that trypanosomes grown in vivo and subsequently transferred 
to broth culture gradually down-regulated the adenosine P2-mediated transport activity; 
levels similar to continuously in vitro-grown parasites were reached after 8 hours (Pui Ee 
Wong, unpublished). This phenomenon could be a response of parasites to the rich in vitro 
environment, where nutrients are easily available in the medium and high transporter 
expression would be energetically unfavourable. Other data obtained by Pui Ee Wong in 
our laboratory demonstrated that the expression of the P2 transporter was higher in 
trypanosomes which had reached high parasitaemia levels compared to those that had 
reached only low blood parasitaemia (Pui Ee Wong, unpublished). This observation could 
be another indication that high levels of P2 expression help protozoan parasites to better 
compete for nutrients (in this case, purines) inside their host. 
Understanding how trypanosomes regulate the expression of this transporter in response to 
changes in their environment and life cycle stage is important, especially when considering 
the crucial role of P2 in the internalisation of various trypanocidal compounds. The  Federica Giordani, 2010    Chapter 6, 153 
 
Figure 6.1 – Adenosine uptake in trypanosomes grown either in tissue culture or harvested 
from rat blood. 
T. b. brucei S427 w.t. cells from culture (in vitro cells, blue ■) were directly used for the 
assay after washing in CBSS, while parasites grown in rats (in vivo cells, red ▲) were 
separated from blood cells by elution over a DE52 column and washed in CBSS before use. 
Uptake of [
3H]adenosine (10 nM) was measured in the presence of increasing 
concentrations of unlabeled adenosine after 30 sec incubation. Data were fitted to a sigmoid 
curve using the nonlinear regression equation of GraphPad Prism 5.0 software package. 
Data and graph were kindly provided by Pui Ee Wong (University of Glasgow, unpublished), 
and are included here to provide context for work conducted as part of this thesis. 
observation that P2 expression is linked to the level of parasitaemia could have 
pharmacokinetic implications for drug development, considering that in humans T. b. 
gambiense usually gives rise to very low parasitaemia levels while concentration of T. b. 
rhodesiense in human hosts is normally quite high. Furthermore, investigations with 
compounds whose entry into trypanosomes has some dependency on P2 may be influenced 
by the expression levels of this carrier. For example, during this project, it emerged that 
various fluorophores (especially DB75 and propidium iodide) yielded a brighter 
fluorescence emission in ex-vivo stained trypanosomes (blood films) than cells derived 
from in vitro culture, treated under the same experimental conditions (Chapters 3 and 4). 
This difference may be due to the in vitro down-regulation of the P2 transporter in the case 
of DB75, but a similar mechanism, involving other transporters, could also be valid for 
propidium iodide. The use of trypanosomes grown in rodent blood for testing of 
fluorophores was, thus, not only justified by the fact that these blood samples better mimic 
the human specimens used for diagnosis than cultured parasites, but also by the 
observation that the staining properties of ex-vivo trypanosomes could prove different than 
those of cells cultivated in vitro. 
The biological mechanisms that trypanosomes use to regulate the levels of the P2 
transporter are not known. Various phenomena could be involved in this process, including 
different levels of transcription of the TbAT1 gene, instability of the mRNA, post-
transcriptional modifications or compartmentalisation of the protein. Here, the Federica Giordani, 2010    Chapter 6, 154 
construction, by genetic engineering, of a fluorescently tagged P2 transporter, aimed to 
localise the carrier in trypanosomes under various environmental conditions, is described. 
6.1.3 TbAT1 fluorescent tagging 
Previous attempts to generate antibodies against the P2 transporter protein to assess its 
intracellular localisation failed (Richard Burchmore, personal communication). We, 
therefore, decided to study P2 expression and cell distribution by constructing a reporter 
system, in which the TbAT1 gene was expressed together with a fluorescent protein. For 
tagging, we chose the monomeric red fluorescent protein mCherry (λEX=587 nm, λEM=610 
nm). This fluorophore was derived, by sequential mutations, from mRFP1 (Campbell, et 
al., 2002), the monomeric mutant of the Discosoma sp. reef coral tetrameric DsRed protein 
(Shaner et al., 2004). The mCherry protein is reported to have high photostability, high 
pH-stability and a good maturation rate (measured as the time needed to reach its full 
fluorescence) (Shaner et al., 2004 and 2005) and it has already been successfully expressed 
in various organisms (Snaith et al., 2005; Pisharath et al., 2007; Pradel et al., 2007). To 
ensure that the fluorescent tag itself did not interfere with the biological function of the 
target transporter, two constructs were prepared: one with the gene encoding for the red 
fluorescent protein linked to the C-terminus of TbAT1 (TbAT1::mCherry, C-t construct) 
and one with the mCherry gene linked to its N-terminus (mCherry::TbAT1, N-t construct). 
The tetracycline-responsive expression vector pHD676 (Biebinger et al., 1997) was chosen 
for cloning. The decision to use an inducible system was made in order to obtain a tight 
control on transcription, minimising the risk of over-expression of the exogenous genes, 
which could lead to mislocalization of the encoded protein. The two fusion constructs 
(TbAT1::mCherry and mCherry::TbAT1) were designed to be inserted within pHD676 as 
HindIII-BamHI fragments, with insert downstream of a procyclic acidic repetitive protein 
(PARP) promoter, containing tetracycline operator sequences (Wirtz and Clayton, 1995; 
Figure 6.3 A). When transfected into a cell line genetically modified to express a 
tetracycline repressor (bloodstream form strain 449), the transcription of the exogenous 
genes was expected to be repressed until addition to the medium of the inducer 
tetracycline. This antibiotic, by binding the repressor, released it from the operator. A 
separate constitutive promoter drove transcription of the hygromycin selectable marker 
(Biebinger et al., 1997). pHD676 was designed to integrate, once linearised, into the 
trypanosome’s genome within the non-transcribed intergenic spacers of the rRNA repeat 
region, with an orientation opposite to that of rRNA gene transcription (Wirtz and Clayton, Federica Giordani, 2010    Chapter 6, 155 
1995). Both constructs (N-t and C-t) were also transfected into the tbat1
-/- line lacking the 
endogenous P2 transporter (Matovu et al., 2003), where they were expected to work in a 
constitutive way. Federica Giordani, 2010    Chapter 6, 156 
6.2 Results 
6.2.1 Preparation of the TbAT1-mCherry recombinant constructs 
6.2.1.1  Amplification of TbAT1 and mCherry ORF 
The TbAT1 ORF was amplified from gDNA extracted from T. b. brucei S427 wild type by 
using the high proofreading enzyme KOD Hot Start DNA polymerase (Novagen) (Section 
2.7.2.1). Two different sets of primers, containing the appropriate restriction sites for 
subsequent cloning, were designed for its amplification (Table 2.2): MB407 and MB408 
for the N-t sequence (mCherry ORF upstream TbAT1), MB411 and MB412 for the C-t 
(mCherry downstream the TbAT1 sequence). The gene for the mCherry fluorescent protein 
was amplified, using the same high fidelity enzyme, from vector p2664 (Kelly et al., 
2007), developed in Dr. M. Carrington’s laboratory (University of Cambridge). Another 
two sets of primers flanking the mCherry ORF were designed for its amplification (Table 
2.2): MB405 and 406 for the N-t construct, MB409 and MB410 for the C-t. A pair of 
glycine residues was introduced as a linker between the TbAT1 and mCherry sequences in 
order to provide flexibility to the fused protein. 
6.2.1.2  Sequence analysis 
Sequencing of the PCR products showed that both of the TbAT1 amplicons (for N-t and C-t 
constructs) had the correct sequence (data not shown). The mCherry N-t product sequence 
also proved correct. The mCherry amplicon for C-t tagging, however, possessed a single 
point mutation at base 64 of its ORF, where the change from a cytosine to an adenine 
corresponded to an amino acid change from a histidine to an asparagine (Figure 6.2). 
Another discrepancy between our mCherry protein sequence (for both N-t and C-t tagging) 
and that published by Shaner and collaborators (Shaner et al., 2004) was the presence in 
our products of an asparagine instead of an aspartic acid at position 8. This Asp
8 residue 
was encoded by the gene sequence in p2664 used as template for mCherry amplification, 
and therefore was not the product of a mutation event. Restriction sites introduced for 
cloning proved correct for all of the amplicons. Federica Giordani, 2010    Chapter 6, 157 
 
Figure 6.2 –Amino acid sequence alignment of mCherry PCR products for N-t and C-t 
tagging. 
mCherry ORF was amplified from vector p2664 (Kelly et al., 2007). Discrepancies between 
our products and the published mCherry sequence (Shaner et al., 2004) are shaded in red. 
The first amino acid change (Asp
8→Asn) is at position 8 of both N-t and C-t products; the 
second mutation (His
22→Asn) is at position 22 of the C-t product. Additional residues 
introduced by PCR amplification upstream and downstream the mCherry ORF, containing 
the restriction sites and the stop codon (-), are shaded in grey. 
6.2.1.3  Cloning into the expression vector pHD676 
The TbAT1 and mCherry genes were first linked together in a pGEM-T Easy plasmid 
(Promega) and, then, the whole HindIII-BamHI fragment containing the fused ORF 
(TbAT1::mCherry or mCherry::TbAT1) was excised and inserted into the expression vector 
pHD676 (Biebinger et al., 1997) to generate either the N-t (pMB-G94) or C-t (pMB-G95) 
final expression constructs (see Figure 2.1 for a schematic representation of the preparation 
of the constructs and Figure 6.3 A for the vectors maps). Interestingly, the bacterial pellet 
transformed with the C-t vector was pink, while the N-t transformants had a normal 
yellowish colour. Insertion of the TbAT1 and mCherry genes inside pHD676 was assessed 
by restriction digest analysis (Figure 6.3 B). The use of HindIII-BamHI enzymes released 
the correct 2148 bp fragment containing the fused TbAT1 and mCherry sequences. Double 
HindIII-ApaI digest released the expected 754 bp fragment (containing mCherry) from 
pMB-G94 and a 1405 bp fragment (containing TbAT1) from pMB-G95. Digest with ApaI-
BamHI gave the correct 1394 bp band (TbAT1) in pMB-G94 and 743 bp band (mCherry) 
in pMB-G95. Sequencing of the vectors confirmed the correctness of the insertion for both 
N-t and C-t HindIII-BamHI fragments. 
mCherry C-t    (1) GGPMATSGMVSKGEENNMAIIKEFMRFKVNMEGSVNGHEFEIEGEGEGRP 
mCherry N-t    (1) HKLMATSGMVSKGEENNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRP 
 
mCherry C-t   (51) YEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSF 
mCherry N-t   (51) YEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSF 
 
mCherry C-t  (101) PEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQ 
mCherry N-t  (101) PEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQ 
 
mCherry C-t  (151) KKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPV 
mCherry N-t  (151) KKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPV 
 
mCherry C-t  (201) QLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKGSGTA- 
mCherry N-t  (201) QLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKGSGTAG 
 
mCherry C-t  (250) GS- 
mCherry N-t  (251) GGP Federica Giordani, 2010    Chapter 6, 158 
 
 
Figure 6.3 – Maps of pMB-G94 and pMB-G95 and their restriction profiles. 
(A) The two constructs pMB-G94 and pMB-G95 were derived from pDH676 by insertion of 
TbAT1-mCherry fused ORFs (TbAT1::mCherry or mCherry::TbAT1) as HindIII-BamHI 
fragment downstream of a tetracycline-inducible PARP promoter, containing the 
tetracycline operator sequence. The hygromycin phosphotransferase gene (HYG) for 
hygromycin resistance was under control of a different constitutive rRNA promoter. 
Regulatory 5’ and 3’ actin (ACT) and PARP untranslated regions (5’ or 3’ UTR) are indicated. 
Stable integration in the rRNA intergenic region was obtained after linearization at the 
unique NotI site. 
(B) Restriction digest products of the two vectors, run on a 1% agarose gel (1 kb ladder, 
Promega). The uncut vector pMB-G95 was loaded as positive control. 
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6.2.2 Transfection and PCR screening of clones 
Bloodstream form T. brucei strain 449 (Biebinger et al., 1997) and the tbat1
-/- strain 
(Matovu et al., 2003) were transfected with 10 mg of either linearised vector pMB-G94 or 
pMB-G95 (Section 2.7.5). Clones were obtained for both cell lines after selection with 5 
mg/ml hygromycin. All transfectant lines grew well in culture in the presence of the 
selective drug, duplicating at a similar rate as the parental lines. 
To check for the presence of the vectors inside transfectants a PCR analysis was 
performed. A fragment spanning TbAT1 and mCherry domains was amplified from gDNA 
extracted from the clones (Section 2.7.2.2). Primers MB363 (annealing inside the mCherry 
ORF) and MB182 (annealing inside the TbAT1 ORF) were used for amplification of the  
N-t construct (expected product size of 1302 bp), and MB181 (annealing inside the TbAT1 
ORF) and MB410 (annealing at the 3’ of the mCherry ORF) were used for the C-t 
construct (expected product size of 1455 bp) (Table 2.3 for primer sequences). Various 
transfectants, derived from both 449 and tbat1
-/- cell lines, showed the expected band 
following PCR amplification (Figure 6.4). Four of them were chosen for subsequent 
molecular and biological assays (these clones are indicated with asterisks in Figure 6.4): 
two 449-derived lines transfected with pMB-G94 or pMB-G95 (449 Cl.4 N-t, 449 Cl.7 C-t, 
respectively) and two tbat1
-/--derived lines transfected with either vector (tbat1
-/- Cl.6 N-t, 
tbat1
-/- Cl.9 C-t). Some clones did not yield any product. Nevertheless, absence of an 
amplified fragment for these lines could be due to limiting quantities of gDNA template 
rather than to unsuccessful transfection, since all of the clones grew well under drug 
pressure. Amplification of the endogenous actin gene, however, gave clear bands for all 
clones, indicating the presence of DNA template in all samples. 
Although PCR analysis confirmed the presence of the constructs inside some of the 
transfectants, these results could not distinguish between their presence as stable gDNA 
integrated copies or as transient episomes. Bloodstream form trypanosomes, however, 
generally fail to maintain episomal plasmids, especially when compared to procyclic form 
(Patnaik et al., 1993; Burkard et al., 2007); hence, it was assumed DNA was integrated. Federica Giordani, 2010    Chapter 6, 160 
 
Figure 6.4 – PCR screening of transgenic bloodstream form cell lines. 
Genomic DNA from clones obtained after transfection of the 449 and tbat1
-/- lines with either 
pMB-G94 (N-t clones, panel A) or pMB-G95 (C-t clones, panel B) was extracted using the 
DNeasy
® Blood and Tissue Kit (Qiagen). A fragment spanning the fused TbAT1 and mCherry 
sequences was amplified using specific primers (Table 2.3). The expected band size for the 
N-t fragment was 1302 bp, for the C-t 1455 bp. Amplicons were run on a 1% agarose gel (1 
kb ladder, Promega). Numbers at the top of the gel indicate different clones: (A) 449 clones 
1,2,3,4 were obtained after transfection of 449 line with pMB-G94; tbat1
-/- clones 6,7,8,9 were 
obtained after transfection of tbat1
-/- line with pMB-G94. (B) 449 clones 2,4,7,9 were obtained 
after transfection of 449 line with pMB-G95; tbat1
-/- clones 1,2,9,12 were obtained after 
transfection of tbat1
-/- line with pMB-G95. Actin (ACT, expected band size 455 bp) 
amplification was used to verify presence of gDNA template in the PCR samples. Clones 
chosen for successive biological assays are indicated with an asterisk. 
+: positive control (purified plasmid); -: negative control (no gDNA). Federica Giordani, 2010    Chapter 6, 161 
6.2.3 Southern blot 
Southern blot hybridization (Section 2.7.6) was used to determine correct and stable 
integration of the constructs within the non-transcribed rRNA spacer of the trypanosome’s 
genome, in the reverse orientation relative to endogenous rRNA genes transcription. The 
ORFs of both TbAT1 and mCherry were used as probes. Two clones (449 Cl.7 C-t and 449 
Cl.4 N-t) were selected for study. At the same time, the gDNA of the parental line 449 was 
also analysed to determine the restriction pattern of the endogenous copy of the TbAT1 
gene. 
6.2.3.1   Clone 449 Cl.7 C-t 
The gDNA of clone 449 Cl.7 C-t and its parental line 449 were digested with seven 
different restriction enzymes and probed with the TbAT1 ORF. Southern analysis of the 
449 line identified the position of the endogenous copy of the TbAT1 gene (Figure 6.5). All 
band sizes corresponded to the expected restriction pattern of the TbAT1 genomic region 
(24 kb total length) annotated for T. brucei in GeneDB (http://www.genedb.org/Homepage), 
except for StuI. The expected band for this enzyme was 6.7 kb, while the fragment in our 
blot had a size of ~3.7 kb, possibly due to heterogeneity between the published 927 strain 
genome and that of 427 strain used during our experiments. The sizes of the bands for the 
other enzymes were: PstI: 6.8 kb; HindIII: 13.9 kb; BglII: no bands; NcoI: 3.5 and 3.9 kb; 
XhoI: 2.7 kb; SpeI: 8.7 kb. 
In the derived clone 449 Cl.7 C-t, insertion of the vector pMB-G95 (containing the 
exogenous TbAT1 copy) yielded additional bands (Figure 6.5). To determine the 
correctness of integration, the size of these bands was compared to the published restriction 
maps of the rRNA locus (Biebinger et al., 1996 and 1997), schematically reproduced in 
Figure 6.6 together with the restriction pattern of the two transfected vectors. In addition to 
the endogenous 6.8 kb band, PstI digestion yielded an extra-band of the expected size (8 
kb). Digestion with HindIII, StuI and BglII yielded two additional bands instead of the 
single one expected. An explanation for this result is the possible insertion of two copies of 
the vector in two separated rRNA spacers with different restriction polymorphisms, a 
known characteristic of this genomic region that complicates analysis (Biebinger et al., 
1996). Nevertheless, insertion in other regions of the genome for one or both constructs 
can not be excluded. If this hypothesis was right we would expect a similar double band 
pattern also for PstI, NcoI and XhoI, but this was not observed. HindIII digestion produced  Federica Giordani, 2010    Chapter 6, 162 
 
Figure 6.5 – Southern blot analysis of line 449 and derived clone 449 Cl. 7 C-t, hybridized 
with TbAT1 probe. 
gDNA of both cell lines was digested with seven different enzymes and hybridized with a 
probe constituted by the whole TbAT1 ORF to verify integration in the rRNA non-transcribed 
spacer. Asterisks denote the extra bands hybridized in the derived clone compared to the 
parental line. 
1: PstI; 2: HindIII; 3: StuI; 4: BglII; 5: NcoI; 6: XhoI; 7: SpeI. 
a band of ~9 kb and another that could correspond to the expected 12.3 kb, but the exact 
size of this band was difficult to determine, being beyond the range of the molecular 
weight ladder used. The expected band size after StuI digestion was of 5.7 kb, as found, 
while the slightly bigger band (~5.9 kb) could derive from a polymorphic restriction site in 
another rRNA spacer. The size of the bands yielded following BglII digestion (~8.8 and 
9.7 kb) could not be explained using the mapped sites, and other polymorphic BglII 
restriction sequences must be present in our line, if the vector targeted the rRNA spacer. 
NcoI digestion generated an expected band of 0.9 kb and another one of ~1.6 kb expanding 
outside the vector length, as the band (~8.5 kb) generated by XhoI digestion (no restriction 
map of the rRNA locus was available for these two enzyme). TbAT1 probing following 
SpeI digestion yielded the correct vector-internal 3.2 kb fragment. Overall we can conclude 
that the vector had integrated into the T. brucei genome, but that this integration had not 
been targeted to the precise location anticipated, or else polymorphisms between the  Federica Giordani, 2010    Chapter 6, 163 
 
Figure 6.6 – Restriction digest map of vectors pMB-G94 and pMB-G95 and of the rRNA locus 
of T. b. brucei. 
(A) Schematic representation of the two vectors used for transfection (pMB-G94 and pMB-
G95) linearised at the unique NotI site. Underneath each construct are illustrated the 
restriction fragments resulting from their digestion with the seven enzymes used for 
Southern blotting (PstI, HindIII, StuI, BglII, NcoI, XhoI, SpeI). 
(B) Restriction map of the the rRNA locus of T. b. brucei S427 (adapted from Biebinger et al., 
1996 and 1997), with the size of the fragments expected by digest of this locus with PstI, 
HindIII, StuI and BglII indicated underneath (restriction map of this locus for NcoI, XhoI, SpeI 
was not available). 
Restriction sites that vary between loci are in brackets. Black boxes represent the rRNA 
genes. The striped box indicates the site of vector integration. Arrows indicate the direction 
of transcription. B: BglII; H: HindIII; P: PstI; S: StuI. Federica Giordani, 2010    Chapter 6, 164 
 
Figure 6.7 – Southern blot analysis of line 449 and derived clone 449 Cl.7 C-t, hybridized 
with mCherry probe. 
gDNA of both cell lines was digested with seven different enzymes and hybridized with a 
probe constituted by the mCherry ORF to verify integration in the rRNA non-transcribed 
spacer. 
1: PstI; 2: HindIII; 3: StuI; 4: BglII; 5: NcoI; 6: XhoI; 7: SpeI. 
non-transcribed intergenic spacers in the ribosomal locus of 427 genome (the strain from 
which b.f. 449 derives) affected restriction patterns. 
After probing with TbAT1, the two membranes were stripped (Section 2.7.6.4) and re-
probed with the mCherry ORF. As expected, hybridization of the gDNA from the parental 
line (449) yielded no bands (Figure 6.7). In the derived clone 449 Cl.7 C-t, PstI, HindIII, 
BglII, XhoI and SpeI digestion yielded the same bands detected using the TbAT1 probe (8 
kb for PstI, 9.0 and 12.3 kb for HindIII, 8.8 kb and 9.7 for BglII, 8.5 kb for XhoI and 3.2 kb 
for SpeI) (Figure 6.7). StuI digestion showed the correct 2.4 kb band. The other very small 
band expected after digestion with this enzyme (0.3 kb) had gone off the end of the gel and 
does not appear in the blot shown in Figure 6.7. NcoI digestion yielded the expected 1.8 kb 
band. Federica Giordani, 2010    Chapter 6, 165 
6.2.3.2  Clone 449 Cl.4 N-t 
As for the C-t clone, the Southern blot of the N-t clone (449 Cl.4 N-t) showed additional 
bands compared to the parental 449 line (Figure 6.8), indicative of integration of the vector 
into the parasite genome (the digestion pattern for the parental line has already been shown 
in Figure 6.5). For this clone each enzyme yielded a single extra band pattern compared to 
the 449 line, suggesting a single insertion event. The size of some of the bands expanding 
beyond the length of the vector, and expected to be identical to the bands obtained for the 
C-t clone (Figure 6.6), actually differed from these. Hence, integration of the constructs 
inside the genome of the two clones appeared to be at two different sites. In 449 Cl.4 N-t 
PstI digestion should have yielded an additional band of 8 kb identical to that of the C-t 
clone, but in the N-t clone a band with a slightly bigger size (~8.5 kb) was observed. 
HindIII yielded an extra band, slightly smaller than that generated by the endogenous 
TbAT1 copy (13.9 kb), but bigger than the band of 12.3 kb found in the C-t clone. XhoI 
digestion, instead, yielded a band of 8.5 kb identical to the C-t clone. Digestion with either 
StuI, NcoI or SpeI were expected to generate bands contained within the length of the 
vector and all of these enzymes yielded correct band sizes:the StuI band was 3.8 kb,the 
NcoI band was 2.0 kb and the SpeI band was 3.2 kb. The second band yielded by NcoI 
digestion (a faintly detectable 2.4 kb band) must be due to a site just downstream the site of 
integration, as inferred also for the C-t clone. Finally, BglII digestion generated a high 
molecular weight band of ~14 kb. 
The use of the mCherry probe confirmed the presence of the sequence of the fluorescent 
protein within the clone 449 Cl.4 N-t, although the bands appeared faint in this particular 
blot (Figure 6.8). Bands obtained after digestion with PstI, HindIII, BglII, XhoI and SpeI 
were identical, as expected, to the bands obtained after hybridization with the TbAT1 probe 
(PstI and XhoI 8.5 kb, HindIII 13.5 kb, BglII 14 kb, SpeI 3.2 kb). StuI digestion generated 
an expected 4.3 kb band, but the small 0.3 kb band and the other expected 3.8 kb band 
were not detectable on the blot (the first one had probably run out of the gel and the second 
could have resulted too faint to be detectable). NcoI digestion yielded the expected 2.4 kb 
band. 
Summarising, Southern blot hybridization confirmed the presence of the exogenous TbAT1 
and mCherry fused ORF in the genome of both analysed clones. Integration of pMB-G94 
and pMB-G95 in the genome of the two clones seemed to have occurred at two different 
loci, none of which could be unequivocally identified with the rRNA spacers. Federica Giordani, 2010    Chapter 6, 166 
 
Figure 6.8 – Southern blot analysis of clone 449 Cl.4 N-t, hybridized with TbAT1 and 
mCherry probes. 
gDNA of both cell lines was digested with seven different enzymes and hybridized with a 
probe constituted by the TbAT1 (left) or mCherry (right) ORF to verify integration in the 
rRNA non-transcribed spacer. Asterisks denote the extra bands hybridized in the derived 
clone compared to the parental line. 
1: PstI; 2: HindIII; 3: StuI; 4: BglII; 5: NcoI; 6: XhoI; 7: SpeI. 
6.2.4 Western blot 
Southern analysis confirmed the presence of the fused TbAT1-mCherry reporter constructs 
inside the genome of the clones, but we had no indication concerning their correct 
transcription and translation. Integration in a silent region of the genome or rearrangements 
of the vectors during transfection were not ruled out by DNA analysis. Therefore, to study 
the expression of the constructs, a Western blot was performed (Section 2.7.10). 
To detect the protein formed by the fusion of TbAT1-mCherry sequences a DsRed 
monoclonal antibody (Clontech Laboratories), which also recognised the mCherry protein, 
was used. This was confirmed by the positive control, represented by a cytosolic fusion Federica Giordani, 2010    Chapter 6, 167 
protein containing the mCherry sequence and expressed in Leishmania mexicana (kindly 
provided by Elmarie Myburgh, University of Glasgow) (Figure 6.9). Unfortunately, our 
experiments failed to detect the TbAT1-mCherry fusion protein (predicted protein size was 
78 kDa: 27 kDa for the mCherry protein and 51 kDa for the P2 transporter). Instead, the 
mCherry antibody always bound to a 175 kDa protein, particularly abundant in the aqueous 
fraction but also detectable in the total protein extract of the clones analysed (Figure 6.9). 
This high molecular weight protein was not specific for our transfectants, since it was also 
detected in the parental line 449 (and in the other parental line tbat1
-/-, data not shown). 
 
Figure 6.9 – Western blot analysis of cell extracts from clone 449 Cl.4 N-t and 449 Cl.7 C-t. 
After growth in the presence of the inducer tetracycline, cells were lysed for differential 
extraction of proteins (Section 2.7.7). Total protein extract (T), enriched aqueous (A) and 
organic (O) protein fractions were prepared for both clones and probed with the DsRed 
monoclonal antibody (1:250) and the goat anti-mouse secondary antibody (1:2,000). The 
positive control (+) is represented by the total cell lysate from a Leishmania mexicana line 
expressing a cytosolic fusion protein containing mCherry (kindly provided by Elmarie 
Myburgh, University of Glasgow). Total cell lysate from the parental line 449, probed with 
the same antibody, is shown on the right. 
There are a number of potential reasons for the inability to detect our fusion protein. First, 
low levels of expression of the construct in the clones could have yielded only low 
amounts of protein (too low to generate a signal in the blot). The unknown mechanism 
involved in P2 down-regulation in vitro could have played a role in this phenomenon. For 
this reason, total cell lysate from clones grown in vivo (where P2 is not down-regulated) 
was analysed following the same procedure as for in vitro cells, but these samples also 
failed to show the expected protein (data not shown). Extraction of membrane proteins can 
be difficult; hence the organic fractions (where the fusion protein was expected to be 
present) were extracted using the non-ionic detergent Triton X-114, resulting in very 
viscous samples: this hampered both loading and running of the fractions; a smeared 
signal, stuck inside the well of the polyacrylamide gel of 449 Cl.7 C-t clone (Figure 6.9, Federica Giordani, 2010    Chapter 6, 168 
449 Cl.7 C-t clone, lane O) could derive from a protein sample that did not run properly 
inside the gel. 
Western blot analysis, therefore, was inconclusive and failed to demonstrate successful 
expression of the fusion protein in T. brucei, although a low abundant membrane protein 
might escape detection using these procedures. 
6.2.5 Drug sensitivity 
Since Western blot analysis failed to demonstrate the successful expression of the TbAT1-
mCherry reporter protein, we performed some biological assays as another means to assess 
functional expression. To determine whether the exogenous TbAT1 copy was functionally 
expressed inside the cells, the Alamar Blue assay was performed (Section 2.4). The test 
allows determination of bloodstream form trypanosome drug sensitivity, which reveals 
differences depending on the expression of the TbAT1 transporter in the cells. Four drugs 
were tested: DB75 and diminazene, two diamidines principally dependent on the P2 
transporter for their uptake into parasites (Lanteri et al., 2006; de Koning et al., 2004), 
pentamidine, another diamidine only partially dependent on P2 activity (de Koning, 
2001a), and suramin, a molecule thought to enter the cells by receptor-mediated 
endocytosis without any interaction with the P2 transporter (Fairlamb, 2003). IC50 (half 
maximal inhibitory concentration) values for the 449-derived lines were measured in the 
absence of tetracycline, or after addition of the inducer at 1 mg/ml, 48 h before performing 
the test, in order to obtain complete induction of reporter expression (Wirtz and Clayton, 
1995). All transfectant lines were cultivated in the presence or absence (removal was 
carried out 48 h before the test) of hygromycin, before and during the assay, to monitor 
possible interaction of this antibiotic with the other drugs or eventual effects on cell growth. 
IC50 values showed that addition of hygromycin to the medium did not interfere with the 
activity of the four drugs (Table 6.1), but slightly decreased the cell growth rate of the 
transfectants compared to the parental line (which was grown in absence of antibiotics). 
Therefore, to compare the effects of the various drugs on the tested cell lines, only data 
obtained with clones grown in medium without hygromycin were considered in this discussion. 
For all of the transformants it was evident that a significant increase in sensitivity to P2-
transported drugs (DB75 and diminazene) was induced compared to the parental line 
(Table 6.1 and Figure 6.10), suggesting active expression of the exogenous copy (or Federica Giordani, 2010    Chapter 6, 169 
copies) of TbAT1. For clone 449 Cl.4 N-t (Figure 6.10 A), the IC50 value following DB75 
treatment was 11.6-fold lower than the value measured for the parental line 449 in the 
presence of tetracycline, and 2.6-fold lower in case of diminazene treatment. Both 
differences were statistically significant (P <0.01) by the Student’s t-test. Increase of 
sensitivity of the clone compared to the 449 line was much smaller following pentamidine 
(1.2-fold) and suramin (1.4-fold) incubation. Although the data measured for clone 449 
Cl.4 N-t incubated with suramin was found significantly lower (P <0.01) than that of line 
449, in the presence of tetracycline, this result was not confirmed by any of the other 
transformants analysed. The causes of the slightly higher sensitivity to suramin of clone 
449 Cl.4 N-t compared to its parental line could be ascribed to a slightly lower growth rate 
of the clone, or to some other mutational event which could have increased its sensitivity to 
the drug (especially in the presence of tetracycline). An absence of the inducer tetracycline 
in the medium resulted in IC50 values being very similar between the clone and its parental 
line, indicating a successful regulation of the system. 
Clone 449 Cl.7 C-t (Figure 6.10 C) was also significantly more sensitive to DB75 (6.7-fold 
lower IC50, P <0.01 by the t-test) and diminazene (5.7-fold lower IC50, P <0.001) 
compared to line 449, in the presence of tetracycline. The clone was only 1.3-fold more 
sensitive to pentamidine than 449 and did not show any significant difference with the 
parental line after suramin treatment. This clone transfected with the C-t construct 
appeared to have a worse regulation compared to clone 449 Cl.4 N-t and, even in the 
absence of tetracycline, it still maintained higher sensitivity towards DB75 (P <0.01), 
diminazene (P <0.001) and pentamidine (P <0.05) than 449 line. This result could be 
explained by lessened control at the tetracycline-responsive site, or by different levels of 
transcription between rRNA spacers or other possible integration sites. Variability between  
phenotypes of different clones is a common phenomenon and it has already been observed 
in bloodstream transfectants (Biebinger et al., 1996). 
For tbat1
-/--derived lines (Figure 6.10 B and D), the absence of the endogenous P2 
background resulted in more significant differences between transfectant and parental IC50 
values. tbat1
-/- Cl.6 N-t was 85.2-fold more sensitive to DB75 treatment than tbat1
-/- cell 
line (P <0.001) and 14.5-fold to diminazene (P <0.01). Clone tbat1
-/- Cl.9 C-t showed a 
similar trend, resulting in its being 117.1-fold more sensitive to DB75 and 27.2 to 
diminazene than tbat1
-/- (P <0.001 in both cases). Differences between transfectants and 
parental line drastically diminished following pentamidine treatment and disappeared 
following suramin incubation for both tbat1
-/--derived clones. 
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In conclusion, the drug sensitivity data were consistent with successful and inducible 
expression of the reporter gene. Furthermore, it appeared that both N-terminal and C-
terminal fusions were functional, which indicated neither terminus played a role in the 
transport process of the P2 permease. 
6.2.6 Fluorescence microscopy 
The Alamar Blue results indicated that the exogenous copy of the TbAT1 gene was actively 
expressed and functional, but these data did not give any indications concerning the 
expression of the fused mCherry protein. To assess expression of the genetically encoded 
fluorescent protein inside trypanosomes all of the clones were analysed by fluorescence 
microscopy. The microscopy study was also expected to reveal the subcellular distribution 
of the fused protein and, therefore, of the P2 amino-purine transporter, which represented 
the final aim of this work. 
6.2.6.1  Fluorescence of clones grown in vitro 
In vitro transfectants were viewed under the Zeiss Axioplan fluorescence microscope using 
the DsRed filter (λEX=545 nm, λEM=605 nm), which matched the recommended 
wavelengths for the mCherry protein (Shaner et al., 2005). For 449-derived clones, 
construct expression was induced with tetracycline (1 mg/ml) 48 h before viewing. Initial 
screening of live in vitro parasites revealed a very low and hardly detectable fluorescence 
for all of the clones. Nevertheless, fluorescence levels of the transfectants appeared higher 
compared to the autofluorescence shown by parental 449 and tbat1
-/- lines (no images were 
acquired, since fast cell movement hampered the exposure to the camera for prolonged times). 
Due to this low fluorescence of the clones, long times of exposure were necessary in order 
to acquire images and, therefore, cells needed to be fixed. Various fixatives were tested. 
Immersion in MeOH overnight did not give clear samples for microscopy and the use of 
2.5% glutaraldehyde was found responsible to induce a high autofluorescence in both 
clones and parental lines upon DsRed filter excitation (see Sections 2.5.2.3 and 2.5.2.4 for 
fixation procedures). The induction of autofluorescence by glutaraldehyde is a problem 
known in the literature and, apparently, is due to formation of cross-links of the fixative 
with the ε-amino groups of lysine residues on proteins (Collins and Goldsmith, 1981; 
Choromanski, 1984). The fact that glutaraldehyde had been successfully used in our 
laboratory for fixation of T. b. gambiense cells (stib 386 and Eliane) for fluorescence Federica Giordani, 2010    Chapter 6, 173 
microscopy studies (Paul Capewell, University of Glasgow, personal communication) 
could be due to their different composition in the external protein coat compared to the 
427-derived strains used here (for example, different VSGs might be expressed). For our 
experiments, fixation in 3% formaldehyde (Section 2.5.2.5) provided the best samples for 
microscopy, without inducing cell autofluorescence, and was, therefore, used to fix the 
clones and parental lines under study for image acquisition. Fixed trypanosomes were 
viewed immediately or the day after fixation, since a deterioration of the samples was 
observed within a week after their preparation. 
Images acquired using long exposure times for the camera (1.8 s) allowed capture of the 
low fluorescence from trypanosomes (Figure 6.11). All transfectants examined had a 
relative higher emission compared to their parental lines, for which only a very low 
autofluorescence could be detected. Quantitative measurement of the percentage of 
fluorescence intensity for one of the clones analysed (449 Cl.4 N-t) revealed that its 
emission was just double the autofluorescence of the 449 line (Figure 6.12). However, it is 
also noteworthy that the threshold used for quantification of cells fluorescence had to be 
changed for the parental 449 line in order to exclude its high background. Due to the even 
lower emission of tbat1
-/--derived clones, it was not possible to obtain fluorescence 
measurements for these lines. 
Comparison of the fluorescence micrographs of transfectants and their parental lines 
(Figure 6.11) showed that, in general, tbat1
-/--derived clones had a lower fluorescence than 
449-derived cells and clones expressing the C-t construct yielded a lower emission than the 
corresponding parasites transfected with the N-t vector. Nevertheless, each transfectant line 
had internal variability and fluorescence levels varied among cells from the same clone. 
The difference in fluorescence emission of the various transfectants compared to their 
parental lines suggested expression of the fluorescent mCherry protein, albeit at very low 
levels. Moreover, each clone’s fluorescence appeared to be associated with the plasma 
membrane, as expected for the transmembrane transporter protein P2. The signal showed a 
patchy distribution throughout the whole cell body, but was not present in the flagellum. 
The clones transfected with the C-t construct (derived from both 449 and tbat1
-/- lines) 
often demonstrated one (or more) large and bright fluorescent spot(s), in a region between 
the nucleus and the flagellar pocket. Since the endomembrane system is located in this area 
of the cell (Field et al., 2007), it could be possible that these fluorescent dots identified 
with mature or intermediate forms of the fusion protein accumulated inside vesicles, before 
their transport to the plasma membrane. The P2 transporter might, then, be redistributed to Federica Giordani, 2010    Chapter 6, 174 
 
Figure 6.11 – Fluorescence images of four in vitro-grown clones expressing the P2 
transporter fused with the mCherry fluorescent protein. 
Strain 449-derived clones were induced with 1 m m m mg/ml tetracycline 48 h before microscopy 
examination. After fixation in formaldehyde all cells were excited under the DsRed filter of 
the Zeiss Axioplan microscope. Parental cell lines (449 and tbat1
-/-) were processed as their 
derived clones in order to compare their autofluorescence level. Acquired fluorescent 
images (centre) were deconvolved (right) using the iterative restoration program of Volocity 
Imaging software (Improvision). Bright field images counterstained with DAPI, to identify the 
position of the nucleus and the kinetoplast, are shown on the left. 
DsRed 1.8 s exposure; 100× objective. Bar: 10 m m m mm. Federica Giordani, 2010    Chapter 6, 175 
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Figure 6.12 – Percentage of fluorescence intensity measured for clone 449 Cl.4 N-t. 
Emission of the clone is compared to the autofluorescence measured for its parental 449 
line under the same experimental conditions. Samples of both cell lines were fixed in 
formaldehyde. Clone 449 Cl.4 N-t was incubated with 1 m m m mg/ml tetracycline, 48 h before 
microscopy, to induce expression of the fusion protein mCherry::TbAT1. Fluorescence 
intensity of 100 cells for each line was measured using the Volocity software quantitation 
package (Improvision) upon DsRed filter excitation of the Zeiss Axioplan microscope. 
the cell surface from these cytosolic stocks, following specific external stimuli, a 
phenomenon already observed for other protozoan membrane proteins such as the proteins 
associated with differentiation of T. brucei (Dean et al., 2009) and the polyamine 
transporter TcPOT1.1 of T. cruzi (Hasne et al., 2010). Nevertheless, the fact that this 
pattern was much less frequent inside N-t clones supported the hypothesis that the C-t 
tagging of the P2 transporter interfered with its distribution to the targeted cell membrane, 
leading to the accumulation of the fusion protein inside an intermediate vesicle. 
6.2.6.2  Fluorescence of clones grown in vivo 
The low fluorescence of in vitro transfectants could have been caused by unsuccessful 
transcription of the constructs containing the fused TbAT1-mCherry sequence. 
Trypanosomes, however, are known to regulate gene expression mainly at the post-
transcriptional level, rather than by modulating transcriptional activity (Berberof et al., 
1995). Other downstream regulatory mechanisms (such as mRNA stability or protein 
folding and distribution), could have contributed to the low levels of fluorescence. Various 
uptake assays carried out in our laboratory demonstrated a significant down-regulation of 
the P2 transporter activity in in vitro cells compared to parasites grown in rodents (Section 
6.1.2). Therefore, the fluorescence of in vivo-grown transfectants was studied, in order to 
exclude possible endogenous down-regulation mechanisms interfering with our construct 
expression. Federica Giordani, 2010    Chapter 6, 176 
 
Figure 6.13 – Fluorescence images of two C-t clones expressing the TbAT1::mCherry fusion 
protein and grown in mice. 
Water containing doxycycline (200 m m m mg/ml) in a 5% sucrose solution was given to mice 
infected with 449-derived clone in order to induce the transcription of the transfected C-t 
construct (Wirtz et al., 1998). Tail prick samples were obtained 3 days post-infection, while 
the blood smears were prepared 4 days post-infection (Section 2.3 for procedures). All 
samples were viewed under the DsRed filter of the Zeiss Axioplan microscope. 
DsRed 1.0 s exposure; 100× objective. Bar: 10 m m m mm. 
Two clones transfected with the C-t construct (449 Cl.7 C-t and tbat1
-/- Cl.9 C-t) were 
injected into ICR mice by Dr. P.E. Wong. To induce the expression of the system in the 
449-derived clone, 200 mg/ml doxycycline (a water soluble form of tetracycline) were 
added to the drinking water of the mouse infected with this transfectant line (Wirtz et al., 
1998; Krieger et al., 2000). Both clones were able to infect mice, but while the tbat1
-/--
derived line reached a very high parasitaemia four days post-infection, the 449-derived 
clone remained at a low concentration. Fluorescence intensity of parasites in blood samples 
(Figure 6.13) was, however, very similar to their fluorescence observed in in vitro-grown 
trypanosomes (Figure 6.11). The tbat1
-/-- derived clone, especially, had an extremely faint 
emission, which hampered image acquisition. In the 449 Cl.7 C-t line, the fluorescent dot 
already observed in formaldehyde-fixed cells, was clearly visible in the posterior part of 
the cell. The low levels of fluorescence obtained for both in vitro and in vivo transfectants 
indicated that they could be more likely ascribed to the chosen expression system rather 
than to other parasitic regulatory mechanisms. Federica Giordani, 2010    Chapter 6, 177 
6.3 Discussion 
The main aim of this molecular biology project was to tag the P2 amino-purine transporter 
with a fluorescent protein, in order to localise it inside trypanosomes by fluorescence 
microscopy. Two tetracycline-inducible constructs were built by linking the red fluorescent 
protein mCherry either at the N-terminus or C-terminus of the TbAT1 gene, which encodes 
the transporter. Constructs were transfected into bloodstream form 449 (a transgenic line 
expressing the tetracycline repressor) (Biebinger et al., 1997) and into the tbat1
-/- line, 
which lacks both alleles of the TbAT1 gene (Matovu et al., 2003) and in which we 
expected to have a constitutive expression of the constructs. Unfortunately, microscopy 
experiments showed very low fluorescence intensity yields for all of the transfectant lines, 
thus making them unsuitable for more thorough localisation studies. 
The lack of bright fluorescence emission of the mCherry protein could be ascribed to 
various factors. First of all, the change of the amino acid at position 22 (His
22→Asn) of the 
mCherry protein for C-t tagging (Figure 6.2) could have altered the phenotype of the 
mature protein, since this residue was one of the mutations introduced during its generation 
(Shaner et al., 2004). This hypothesis, though, was not supported by fluorescence 
microscopy (Figure 6.11), which showed equally low levels of emission for the C-t and the 
N-t construct (which did not have this mutation). Despite being indicated as another critical 
residue (Shaner et al., 2004), the other amino acid change at position 8 (Asp
8→Asn) of 
both N-t and C-t mCherry products, was not expected to affect the phenotype of the mature 
fluorescent protein, since this particular mutation was also present in the sequence of other 
mCherry proteins successfully used to build fusion constructs (Elmarie Myburgh, 
University of Glasgow, personal communication). 
Another possible explanation for our result could be the use of an unsuitable expression 
system. Vector pHD676 was chosen in order to control the transcription of the fused 
TbAT1-mCherry protein, avoiding the problems of mislocalisation and assembly into non-
physiological complexes often encountered with over-expressed tagged proteins (Shen et 
al., 2001; Shahi et al., 2002). The use of this vector, however, could have been responsible 
for low levels of fused protein, affecting the overall fluorescence signal. The PARP 
promoter, which drives the expression of the exogenous constructs in pHD676, is known to 
be down-regulated in bloodstream forms once integrated within the rRNA spacer or in 
other genomic sites, and this could have contributed to low expression (Biebinger et al., 
1996). Nevertheless, in trypanosomes gene expression is mostly regulated at the post-Federica Giordani, 2010    Chapter 6, 178 
transcriptional level, rather than by modulation of transcription (Berberof et al., 1995). The 
choice of another vector containing different untranslated regulatory regions (UTR) 
encoding for trans-splicing and polyadenylation signals (such as VSG 3’UTR), could have 
a significant impact on the levels and stability of the transcribed mRNA and therefore, on 
the overall expression of the exogenous genes. Instability of the two fused proteins could 
be another possible cause for the low fluorescence shown by our clones. The presence of 
the tagged P2 transporter could have prevented correct folding of the mCherry protein to 
its mature form, disrupting its fluorescent properties. 
Despite unsatisfactory fluorescence intensity emission shown by the clones, various data 
indicated that the phenotype of transfectants differed from that of the parental lines. The 
additional copy(ies) of the TbAT1 gene introduced by transfection appeared to be actively 
expressed, as shown by the Alamar Blue data (Table 6.1). Hence, it was reasonable to 
expect that the whole construct (mCherry::TbAT1 or TbAT1::mCherry) was correctly 
transcribed and translated, although the precise targeted genomic region remained unclear 
for the clones analysed (Section 6.2.3). However, we could not detect the mCherry protein 
inside cell lysates (Figure 6.9), indicating that the protein was not produced or that its 
levels inside parasites were under detection limits of the Western analysis performed. The 
fused mCherry protein yielded very low fluorescence emission, but direct comparison by 
fluorescence microscopy with the parental lines revealed, for all of the clones, a higher 
signal than the autofluorescence of cell lines 449 and tbat1
-/- (Figure 6.11). The emission 
observed in fixed transfectants, moreover, showed a staining pattern at the cell periphery, 
consistent with a membrane distribution. If this signal was indeed derived from the 
mCherry-tagged transporter, we can conclude that the P2 carrier localises all along the 
trypanosome cell body, in a patchy pattern, and it is not present in the flagellum of the 
cells. In various clones (especially transfectants containing the C-t construct) one, or more, 
large, fluorescent spots were detected in the posterior part of the cell, in an area between 
nucleus and kinetoplast. These fluorescent dots could correspond to immature forms of the 
protein contained inside cell compartments, such as vesicles of the Golgi apparatus or the 
endoplasmic reticulum; alternatively, they could represent unprocessed proteins not 
correctly expressed. Another option would be that these spots represent stocks of the 
mature form of the P2 transporter, accumulated inside vesicles, ready to be redistributed to 
the cell surface, in response to changes in the parasite’s external environment. This 
mechanism had already been observed for other parasitic membrane proteins, whose 
distribution was found to shift from an area corresponding to (or adjacent to) the flagellar 
pocket, to the cell surface, as a result of thermal (Dean et al., 2009) or metabolic (Hasne et Federica Giordani, 2010    Chapter 6, 179 
al., 2010) stimuli. The presence of sequestered stocks of P2 in the clones analysed during 
this work would be in agreement with the fact that these cells were in vitro-grown 
parasites, which, as mentioned above (Section 6.1.2), show a relatively low P2 activity. 
Nevertheless, three observations contrasted with this model: (1) the spots evidenced by 
fluorescence microscopy were mainly observed in parasites transfected with the C-t 
construct, suggesting a defective expression of this vector (for example, an eventual signal 
associated to the C-terminus of TbAT1 and directing the transporter to the membrane could 
have been disturbed by the tag protein); (2) the fluorescent inclusions appeared not only in 
in vitro parasites but also in in vivo cells, in which the P2 transporter is expected to be 
highly expressed on the cell surface; (3) the spots appeared generally closer to the nucleus 
than to the flagellar pocket, therefore strengthening the hypothesis of an immature form of 
the protein stuck in some early vesicle of the endosomal system. A series of studies carried 
out on Leishmania species demonstrated that these parasitic protozoa cope with purine 
starvation by upregulating nucleoside transporter proteins at a post-transcriptional level, 
primarily by enhancing translation, without modifying protein turnover (Carter et al., 2010; 
Ortiz et al., 2010). A similar control mechanism of expression can not be ruled out for the 
P2 transporter of T. brucei, but further study will be required to verify this hypothesis. 
The fluorescent tagging approach used during this project to build a fluorescent P2 amino-
purine transporter, has left a series of questions, making it difficult to draw solid 
conclusions. It would be interesting to study the expression of the TbAT1-mCherry fused 
protein in a different over-expression vector, to try and enhance levels of expression, or to 
tag the transporter with a different fluorescent protein (such as the Green Fluorescent 
Protein) to rule out possible problems related to the specific tagging gene. Different 
approaches for protein detection could also be pursued. Previous work carried out in our 
laboratory already attempted, unsuccessfully, to generate and express a fusion construct 
containing a Myc-tagged TbAT1 sequence (Bridges, 2006). A more interesting approach 
would be to epitope-tag the TbAT1 gene at its endogenous chromosomal locus, in order to 
mimic more closely its expression regulation under physiological conditions (Shen et al., 
2001).  
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Accurate and early diagnosis of human African trypanosomiasis is paramount both for 
interrupting the progression of this deadly disease in the patient and for stopping the 
transmission cycle of the parasite. Nevertheless, the diagnostic tools available for use in 
HAT endemic countries remain inaccurate and inadequate, leading to misdiagnosis and 
under-detection. Despite the enormous progress made by the academic world in the field of 
molecular parasitology, this knowledge has only had a minor impact on the work of health 
personnel in rural areas of Africa (Brun and Balmer, 2006). Nowadays, the identification 
of T. b. gambiense infected individuals still relies on the activity of mobile teams, whose 
equipment consists in a thirty-year-old serological test (the CATT test), used to rapidly 
screen the population at risk, and on basic light microscopes, used to confirm the infection 
(Chappuis et al., 2005). The urgent need for better diagnostics which are cheap and robust, 
but also rapid and user-friendly is hindered both at the development stage, due to the 
perspective of low return on investment for commercial companies, but also during the 
phase of field application, because of the lack of resources and of trained personnel, the 
underdeveloped health care system and the remoteness of many endemic foci. The recent 
institution of public-private partnerships (above all the Foundation for Innovative New 
Diagnostics, FIND) aims at the identification and implementation of diagnostics for 
neglected diseases and is hopefully destined to change this state of affairs (Steverding, 
2006). 
Parasitological examination represents the weak point in the T. b. gambiense HAT 
diagnostic algorithm (Lutumba et al., 2005). Conventional light microscopy techniques are 
insensitive, time-consuming and inadequate for use in screening programmes. A series of 
new, highly sensitive and specific molecular diagnostic approaches are currently under 
study and, in the future, might replace the inefficient methods utilised today (Radwanska, 
2010). Although the introduction in the field of relatively sophisticated technologies (in 
particular PCR techniques) has been slow, their evolution into practical solutions offers 
concrete potential. The loop-mediated isotermal amplification (LAMP) reaction (Njiru et 
al., 2008b) and the lateral flow test (dipstick) (Deborggraeve et al., 2006) are two 
examples of these attempts to simplify diagnostics. 
The introduction of fluorescence technologies in HAT endemic countries is another option 
to improve the efficiency of the parasitological confirmation step. The advantages offered 
by fluorescence microscopy over conventional light microscopy in terms of increased 
sensitivity and gain in reading time have been reported in many studies on other tropical 
infectious diseases (Keiser et al., 2002; Steingart et al., 2006) and have been confirmed in Federica Giordani, 2010    Chapter 7, 182 
fields trials (Torrea et al., 2008). The use of fluorescence for diagnosis of trypanosomiasis 
is not new, as it has already been applied in the sensitive, but expensive, quantitative buffy 
coat assay (Bailey and Smith, 1992). The real innovation is represented by the 
development of new LED light sources suitable for fluorescence imaging, which allow the 
design of instruments that are more compact, energetically efficient and cheaper than 
conventional ones (Jones et al., 2005 and 2007). All of these characteristics make LED-
illuminated instruments ideal for use by mobile teams, and not exclusively of reference 
health centres. 
A preliminary evaluation of diverse fluorophores and staining protocols to use with LED 
fluorescence microscopes for trypanosomiasis diagnosis was the main aim of this project. 
Fluorescent staining of parasites with acridine orange proved to be a very straightforward 
and fast procedure for labelling trypanosomes in both fresh and fixed specimens. The 
emission of this fluorophore could be easily detected using the SMR LED microscope 
manifactured by Cytoscience, making their use immediately available for field testing. 
Also the diamidine DB75 appeared to be a very interesting probe for trypanosome 
diagnosis. Its utilisation as a vital dye or to stain fixed specimens proved particularly 
effective in blood samples and its excitation under a UV LED light source was excellent. 
Of note, the procedures followed for preparation of fluorescent specimens were extremely 
easy to perform and did not require specialist skills. Furthermore, the LED microsocopes 
used during this project proved to be user-friendly and efficient. Future work will have to 
validate the use of LED fluorescence microscopy on human samples and under field 
conditions, where researchers will have to pay particular attention on how to preserve 
reagent stability and how to create a dark/dim environment in which to perform 
microscopy (in case of outdoor use). 
The exploitation of surface transporters peculiar to trypanosomes appeared an useful and 
straightforward way to specifically target fluorophores to these parasites and improved 
compounds may be developed following this approach. In the future, then, the synthesis of 
more efficient and specific fluorescent molecular markers for trypanosomes may allow not 
just parasite detection, but also speciation (Radwanska et al., 2002c). Moreover, the use of 
fluorescent probes could be extremely useful for other aspects of disease management, as 
demonstrated by the arsenical drug resistance test developed in our laboratory (Stewart et 
al., 2005). Finally, the potential positive impact that fluorescence microscopy applications 
could have in the management of African animal trypanosomiasis, for which the diagnostic 
problems are very similar to those encountered for HAT, should not be underestimated. Federica Giordani, 2010    Chapter 7, 183 
Although the introduction of fluorescence microscopy in the field would bring significant 
advantages, potentially reducing the workload of microscopists and making HAT diagnosis 
more reliable, it will not be sufficient to detect all cases. This technique will not increase 
the theoretical detection limit of conventional light microscopy (Radwanska, 2010) and, 
due to the low parasite loads typical of this disease, a sample concentration step will still 
be required. Efforts have already been made to improve the format and the efficacy of the 
most sensitive concentration technique available, the mAECT (Büscher et al., 2009; 
Camara et al., 2010). In the future, microfluidics technologies might help in the separation 
and concentration of parasites from blood (Huang et al., 2004), making this procedure 
faster and more efficient. 
The crucial importance of the parasitological examination step originates from the 
necessity to confirm the result of serological tests (mainly the CATT test), which are ideal 
for mass screening, but not specific or sensitive enough to allow decisions for treatment 
(Chappuis et al., 2005). Various laboratories are, today, very active in the search for new 
serodiagnostic markers for HAT, with the aim of designing a more specific alternative to 
the CATT test, but an antigen detection test for trypanosomes, despite being highly 
advocated, has not been developed yet (Radwanska, 2010). Recent advances in genomics, 
proteomics and metabolomics may enable the identification of new trypanosome markers 
to exploit in serodiagnosis. Another very interesting application of these last two 
technologies is their use in the identification of specific host fingerprints, to utilise as 
indicators of disease (Agranoff et al., 2005; Wang et al., 2008). Surrogate biomarkers of 
infection are also under evaluation for trypanosomiasis staging, a very problematic step in 
HAT diagnosis, for which the only specific diagnostic test is currently represented by the 
detection of trypanosomes in the CSF (Lejon and Büscher, 2005). The design of a non-
invasive serological test, that does not require a dangerous and painful lumbar puncture to 
stage the disease, would be a great improvement in HAT field diagnostics (Lejon et al., 
2006). Moreover, this increasing number of informations will hopefully bring to the 
development of a serological test for T. b. rhodesiense, which is still lacking. 
During the last decade a coordinated and efficacious use of the, although limited, tools 
available (both diagnostic and therapeutic) has determined a decline in the number of HAT 
cases (Barrett, 2006). The introduction of new diagnostics and the amelioration of the tests 
already in use would certainly accelerate this process. The validation of better tools will 
also provide HAT health personnel of adequate instruments to face future challenges. In 
particular, the perspective of a decrease of HAT prevalence will require the use of always Federica Giordani, 2010    Chapter 7, 184 
more specific assays, while the foreseen overlap of T. b. gambiense and T. b. rhodesiense 
infections in Uganda will require tests able to differentiate between the two subspecies, in 
order to decide for appropriate treatment regimen. Together with significant improvements 
in patient management and disease control, availability of better diagnostics will also have 
positive effects on other aspects of HAT research and surveillance, such as patients 
recruitment for drug trials, epidemiological studies, evaluation of interventions and 
monitoring of drug resistance onset. Finally, simplification of diagnostic tests and 
procedures might help to move from expensive, active case-finding programs, carried out 
by specialised teams, towards a more incisive participation of the local health care system, 
improving the overall sustainability of HAT intervention policies (Checchi et al., 2006).     Appendices, 185 
Appendices 
Appendix A: HMI-9 medium (pH 7.4) 
Components (mg/L) 
Salts, etc  CaCl2  165 
   KCl  330 
   KNO3  0.076 
   MgSO4  98 
   NaCl  4,500 
   NaHCO3  3,020 
   NaH2PO4·H2O  125 
   Na2SeO3·5 H2O  0.017 
   Glucose  4,500 
   Phenol Red  15 
   HEPES  5,960 
  Bathocuproine sulfonate  28 
   Mercaptoethanol  15 
L-amino acids  Alanine  25 
   Arginine·HCl  84 
   Asparagine  25 
   Aspartic acid  30 
   Cysteine  182 
   Cystine  91 
   Glutamic acid  75 
   Glutamine  584 
   Glycine  30 
   Histidine·HCl·H2O  42 
   Isoleucine  105 
   Leucine  105 
   Lysine·HCl  146 
   Methionine  30 
   Phenylalanine  66 
   Proline  40 
   Serine  42 
   Threonine  95 
   Tryptophan  16 
   Tyrosine  104 
   Valine  94 
Vitamins, etc  B12  0.013 
   Biotin  0.013 
   D-Ca pantothenate  4 
   Choline chloride  4 
   Folic Acid  4 
   i-Inositol  7.2 
   Nicotinamide  4 
   Pyridoxal·HCl  4 
   Riboflavin  0.4 
   Thiamine·HCl  4 
Organic acids  Pyruvate·Na  114 
Purines, etc  Hypoxanthine  136 
   Thymidine (deoxy)  39 
Lipids & serum  Serum  10%     Appendices, 186 
Appendix B: general buffers and solutions 
CBSS buffer (pH 7.4) 
Hepes            25 mM 
NaCl            120 mM 
KCl            5.4 mM 
CaCl2            0.6 mM 
MgSO4·7 H2O         0.4 mM 
Na2HPO4          5.6 mM 
D-glucose          11.1 mM 
LB medium -Luria Bertani broth- (pH 7) 
LB powder (Sigma-Aldrich)      25 g 
dH2O            1 L 
LB agar  
Luria Agar (Sigma-Aldrich)      35 g 
dH2O            1 L 
PBS 
NaCl            137 mM 
KCl            2.7 mM 
Na2HPO4          10 mM 
KH2PO4          2 mM 
Phosphate buffer for Giemsa stain (pH 7.2) 
Na2HPO4          20 mM 
KH2PO4          4.4 mM 
PSG buffer (pH 8) 
Na2HPO4          56.9 mM 
NaH2PO4          3.9 mM 
NaCl            43.5 mM 
Glucose          60 mM 
TAE buffer (50×) (pH 8.5) 
Tris-acetate          2 M 
EDTA (pH 8.0)        50 mM 
TE buffer 
Tris-HCl (pH 8)        10 mM 
EDTA (pH 8)          1 mM     Appendices, 187 
Appendix C: buffers and solutions for Southern blot 
Denaturation solution 
NaCl            1.5 M 
NaOH           0.5 M 
Denhardt’s reagent (50×) 
Ficoll 400 (w/v)        1% 
Polyvinylpyrrolidone (w/v)      1% 
Bovine serum albumin (w/v)      1% 
Depurination solution 
HCl            0.25 M 
Lysis buffer for gDNA extraction 
Tris-HCl (pH 8)        10 mM 
EDTA           100 mM 
N-Lauroylsarcosine (w/v)      1% 
Proteinase K (added fresh)      100 mg 
Neutralising solution 
Tris-HCl (pH 7.4)        1 M 
NaCl            1.5 M 
Prehybridisation/hybridisation solution 
Formamide (v/v)        50% 
SSC            5× 
Denhardt’s reagent        10× 
SDS (w/v)          0.1% 
NaH2PO4 (pH 6.5)        20 mM 
EDTA (pH 8)          5 mM 
Herring sperm DNA (Promega)    200 mg/ml 
SSC (20×) (pH 7) 
NaCl            3 M 
Tri-sodium citrate        0.3 M 
Washing solution for membrane stripping 
SSC            0.1× 
SDS (w/v)          0.1% 
Tris-HCl (pH 7.6)        0.2 M     Appendices, 188 
Appendix D: buffers and solutions for protein extraction, SDS-
PAGE and Western blot 
Coomassie Brilliant Blue stain 
Coomassie Brilliant Blue (w/v)    0.1% 
Methanol (v/v)        45% 
Glacial acetic acid (v/v)      10% 
Laemmli buffer (2×) 
Tris-HCl (pH 6.8)        0.125 M 
Glycerol (v/v)         20% 
SDS (w/v)          4% 
b-mercaptoethanol (v/v)      10% 
Bromophenol blue (w/v)      0.003% 
Running buffer (5×) 
Tris-Base (pH 8.3)        0.125 M 
Glycine          0.96 M 
SDS (w/v)          0.5% 
Running gel (10%) 
Tris-HCl (pH 8.8)        0.38 M 
SDS (w/v)          0.1% 
Acryl/bis 30% (Amresco) (v/v)    10% 
Ammonium persulfate (w/v)      0.05% 
TEMED (v/v)         0.1% 
Stacking gel (3%) 
Tris-HCl (pH 6.8)        0.25 M 
SDS (w/v)          0.1% 
Acryl/bis 30% (Amresco) (v/v)    3% 
Ammonium persulfate (w/v)      0.05% 
TEMED (v/v)         0.1% 
STEN buffer 
Sucrose          250 mM 
Tris-HCl (pH 7.5)        25 mM 
EDTA           1 mM 
NaCl            150 mM 
Transfer buffer 
Tris-base (pH 8.3)        25 mM 
Glycine          0.7 M     References, 189 
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